CHAPTER FIVE

Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem

Laurent Verkoczy[1]

Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States
[1]Corresponding author: e-mail address: laurent.verkoczy@duke.edu

Contents

Abstract

A vaccine that can effectively prevent HIV-1 transmission remains paramount to ending the HIV pandemic, but to do so, will likely need to induce broadly neutralizing antibody (bnAb) responses. A major technical hurdle toward achieving this goal has been a shortage of animal models with the ability to systematically pinpoint roadblocks to bnAb induction and to rank vaccine strategies based on their ability to stimulate bnAb development. Over the past 6 years, immunoglobulin (Ig) knock-in (KI) technology has been leveraged to express bnAbs in mice, an approach that has enabled elucidation of various B-cell tolerance mechanisms limiting bnAb production and evaluation of strategies to circumvent such processes. From these studies, in conjunction with the wealth of information recently obtained regarding the evolutionary pathways and paratopes/ epitopes of multiple bnAbs, it has become clear that the very features of bnAbs desired for their function will be problematic to elicit by traditional vaccine paradigms, necessitating more iterative testing of new vaccine concepts. To meet this need, novel bnAb KI models have now been engineered to express either inferred prerearranged V(D)J exons (or unrearranged germline V, D, or J segments that can be assembled into functional rearranged V(D)J exons) encoding predecessors of mature bnAbs. One encouraging approach that has materialized from studies using such newer models is

sequential administration of immunogens designed to bind progressively more mature bnAb predecessors. In this review, insights into the regulation and induction of bnAbs based on the use of KI models will be discussed, as will new Ig KI approaches for higher-throughput production and/or altering expression of bnAbs in vivo, so as to further enable vaccine-guided bnAb induction studies.

1. OVERVIEW OF THE CURRENT STATE OF HIV VACCINE RESEARCH

1.1 Candidate Protective HIV-1 Responses

After more than 30 years of HIV vaccine research, the correlates of immune protection against HIV-1 remain ill defined. In terms of a protective role for T-cells, perhaps the strongest data supporting a critical need for this component during vaccination comes from a recent immunization study in non-human primates, using attenuated Simian immunodeficiency virus (SIV)-expressing rhesus cytomegalovirus (rhCMV) vectors (Hansen, Piatak, et al., 2013). In this study, rhCMV-vaccination cleared infection in approximately half of SIV-challenged macaques. Intriguingly, follow-up analyses established that the SIV-expressing rhCMV vector mediated atypical killing of SIV-infected CD4 T-cells, i.e., by CD8 T-cells that recognized either MHC class II or HLA E-restricted HIV antigens (Hansen, Sacha, et al., 2013). The variability in protection from challenge (and the associated viral control) afforded by this regimen was surprising, given the protective pattern normally observed for CD8 T-cell–mediated antiviral immunity is all-or-none, thus pointing to a strong host factor-influenced (immunogenetic or other) component for this effect. Nevertheless, the most interesting potential correlate emerging from these key studies is that while α-HIV CD8 CTL activity fails to control transmitted/founder (TF) virus escape during acute HIV infection (McMichael, Borrow, Tomaras, Goonetilleke, & Haynes, 2010), it can do so in the setting of SIV–rhCMV vaccination.

The largest major obstacle facing HIV-1 vaccine research, however, continues to be on the humoral side, namely, developing a vaccine approach capable of inducing a rapid and durable protective Ab response. While it is not known what spectrum of elicited functional antibodies could provide such protection, a key breakthrough for the field, right after two large phase III trials had failed, came when the RV144 trial results were reported in 2009. In this trial conducted in Thailand, the first statistically significant, albeit modest, reduction in HIV-1 acquisition were observed using a

regimen consisting of the combination of a replication-defective canarypox vector (ALVAC) prime and a recombinant gp120 protein (AIDSVAX) boost (Rerks-Ngarm et al., 2009). While vaccine efficacy approached 60% over the first year, it decreased over time and overall efficacy during the entire (3.5 year) trial period was 31%. An immune correlates follow-up study identified V2-specific IgG Abs that associated with decreased transmission risk (Haynes, Gilbert, et al., 2012). While the RV144 vaccine surprisingly induced no neutralization of HIV primary isolates, the vaccine regimen did induce V2 antibodies that bound HIV-infected CD4 T-cells and mediated antibody-dependent cellular cytotoxicity (ADCC). Thus, one potential correlate could be ADCC-mediated decrease in HIV acquisition (Haynes, Gilbert, et al., 2012; Tomaras et al., 2013).

As opposed to these seemingly more routinely induced, candidate protective Ab responses elicited by the RV144 trial, it is widely held (for reasons that will be discussed directly below) that the "holy grail" of HIV vaccinology, namely, induction of broadly neutralizing antibodies (bnAbs), is critical to achieve, as part of an HIV vaccine, for such a regimen to be *truly preventative*, and thus efficacious. However, to date, no immunization strategy can elicit such "difficult-to-induce" or "exceptional" Abs. A primary focus of this review is to discuss how humanized bnAb KI models, can enable more in-depth analysis of the challenges limiting the normally rare, but apparently desirable Ab traits that immunization will either have to select for, or generate, in order to confer bnAb function. More generally, this review will also cover how such KI models will help bridge a key technical gap in the field: the availability of more iterative, robust, and practical vaccine testing platforms.

1.2 The Case for bnAbs as Key Components of an Efficacious HIV Vaccine

Neutralizing antibodies (nAbs) are critical contributors to protective responses against most viral infections (Excler, Ake, Robb, Kim, & Plotkin, 2014; Plotkin, 2010). However, several features of HIV-1, namely the unusually dense glycosylation of its envelope (Env), its rapid integration into host cells, and its high mutation rate, collectively distinguish it from all other viruses for which successful nAb-eliciting vaccines have been made (Mascola & Haynes, 2013). Each of these features poses a unique, unprecedented challenge for developing an efficacious vaccine for HIV-1. The exceptional degree of glycosylation shields most relevant Env epitopes, rendering it highly refractory to recognition by conventional Abs, and thus allowing efficient escape (Wei et al., 2003). The rapid establishment of a

latently infected CD4$^+$ T-cell pool necessitates viral transmission be completely blocked. At the population level, mutability of Env requires a humoral response to be adept in dealing with extreme viral diversity. Given these stringent requirements, a truly protective HIV-1 vaccine will most likely need to induce a *rapid* recall response involving the aforementioned bnAbs, capable of neutralizing a *wide spectrum* of native HIV-1 strains, i.e., bearing highly occluded (heavily glycosylated) epitopes. Studies demonstrating absolute protection afforded by passive transfer (Hessell, Poignard, et al., 2009; Hessell, Rakasz, et al., 2009) or transduction (Balazs et al., 2012) of monoclonal bnAbs, prior to viral challenge, support this notion. Added rationale for pursuing a bnAb-based HIV vaccine approach has recently been provided by demonstration that a single injection of bnAbs protects from repeated weekly challenge, for up to 6 months (Gautam et al., 2016).

2. CHARACTERISTICS OF bnAbs ISOLATED DURING INFECTION AND THEIR ENV TARGETS: CLUES FOR VACCINE DESIGN

2.1 bnAb Rearrangements Differ Markedly From Those of Conventional Antibodies

Although an HIV-1 vaccine regimen has yet to be designed that is capable of inducing detectable plasma bnAb responses (Haynes, 2015), relatively recent findings that bnAbs do develop over years, in a subset of HIV-infected subjects (Gray et al., 2011; Hraber et al., 2014; Mikell et al., 2011; Simek et al., 2009; Tomaras et al., 2011) has provided renewed momentum for the HIV-1 vaccine field to devise new immunization formulations and strategies to induce them. Improved memory B-cell sorting/culturing techniques and high-throughput Ig cloning methodologies, combined with increased numbers of large cohorts of HIV-1-infected subjects from which longitudinal samples are available, have enabled the discovery and characterization of many new monoclonal bnAbs over the past few years, providing two key insights for HIV vaccine design. First, the discovery and elegant characterization of these new HIV-1 bnAbs has provided exquisitely detailed structural information regarding five distinct, but conserved, regions in the Env trimer in which their epitopes cluster (Burton & Hangartner, 2016; Burton & Mascola, 2015), thus providing a blueprint of the vulnerable regions a bnAb-eliciting vaccine can exploit. One of these five bnAb targets is in the gp41 subunit, the membrane proximal external region (MPER), while the other four are in the gp120 subunit: the coreceptor CD4-binding site (CD4bs) and three peptide/glycan epitope-rich regions, either centered

around the N160 glycosylation site in the stem of the V1/V2 loop (i.e., the trimer apex), around the N332 glycosylation site in the V3 variable loop (i.e., the high-mannose patch), or most recently, in the gp120/gp41 bridging interface.

The second major insight for HIV vaccine design is that bnAbs, despite their independent origins, share an intriguing set of traits, which are atypical of conventional Abs. Specifically, in addition to utilizing a restricted set of human V_H genes (Mascola & Haynes, 2013), all bnAbs isolated to date exhibit one or more of the following three unusual characteristics (Table 1): (i) poly-/autoreactivity, (ii) exceptionally long heavy chain (HC) complementarity-determining regions, i.e., HCDR3s, the critical antigen contact regions encoded by the V(D)J junctions of immunoglobulins (Ig), and (iii) high levels of V(D)J somatic hypermutation (SHM), the latter also frequently accompanied by otherwise extremely rare insertion or deletion events (indels), whose origins are poorly understood but thought to be associated with elevated SHM. Indeed, it is the atypical nature of these hallmark features that likely equips bnAbs with their protective functions, i.e., by allowing them to overcome particular structural barriers in Env. For instance, elongated HCDR3s likely play a role in countering glycan occlusion of bnAb epitopes by penetrating the glycan shield (Pejchal et al., 2010), polyreactivity may allow B-cell receptor (BCR) "heteroligation" to deal with unusually low surface density of Env trimers on HIV virions (Mouquet et al., 2010) or to better access lipid-occluded epitopes (Alam et al., 2009), and extensive SHM may provide structural flexibility to counter natural variation in otherwise relatively conserved bnAb-targeting regions (Burton & Hangartner, 2016; Klein et al., 2013; Kwong & Mascola, 2012; Mascola & Haynes, 2013; West et al., 2014).

It has now becoming increasingly clear that these same unusual bnAb traits also pose daunting immunologic obstacles to initiating and/or completing the maturation of bnAbs by vaccine strategies (reviewed in Haynes, Moody, et al., 2014; Verkoczy & Diaz, 2014; Verkoczy, Kelsoe, Moody, & Haynes, 2011). For example, long HCDR3s and in vitro polyreactivity are negatively correlated with function, specificity, and/or frequency of B-cells in the preimmune repertoire, due to difficulties in their immunoglublulin (Ig) HCs pairing to either surrogate or bona fide Ig light chains (LCs) and/or invoking central B-cell tolerance controls (Ivanov et al., 2005; Keenan et al., 2008; Meffre et al., 2001; Shiokawa et al., 1999; Wardemann et al., 2003). Furthermore, excess SHM generated during bnAb development during infection, if also required in the setting of vaccination,

Table 1 Distribution of **Atypical Characteristics** of HIV-1 bnAbs to Various Env Vaccine Targets

bnAb/bnAb Lineage	Env Region Specificity	Year Isolated	VH	VL	Poly-/Autoreactivity In Vitro[a]	"Tolerizing" Self-Reactivity In Vivo[b]	HCDR3 Length (Kabat AA)	SHM in V_HDJ_H (%)[c]	Indels[d] (Size–Location)
b12	CD4bs (HCDR3 loop)	1994	1–3	κ3–20	**Yes, SC**	No deletion	**18**	**21**	**NR**
HJ16	CD4bs (HCDR3 loop)	2010	3–30	κ4–1	**NR**	ND	**19**	**37**	**d1-HCDR2, i1-LFR3**
CH103–106	CD4bs (HCDR3 loop)	2013	4–59	λ3–1	**Yes, SC (not CH105); yes, PA**	Yes, for CH103 UCA (partial deletion, anergy, extensive LC/HC editing)	**13**	**20**	**d3-LCDR1 (CH103)**
CH98	CD4bs (HCDR3 loop)	2014	3–30	λ2–23	**Yes, SC and PA**	ND	**21**	**25 (nt)**	**d5-LFR1, d5-LCDR1, i8-LCDR3**
VRC13	CD4bs (HCDR3 loop)	2015	1–69	λ2–14	**NR**	ND	**21**	**52**	**i5-HCDR1**
VRC16	CD4bs (HCDR3 loop)	2015	3–23	κ1–39	**NR**	ND	**20**	**29**	**No**
VRC01–03	CD4bs (CD4 mimic via HCDR2)	2010	1–2	κ3–20	**No, SC; yes, PA**	No, based on VH1–2 + gl VRC01 LC KI model	**12–14**	**40–48**	**d2-LCDR1 (VRC01), i7-HFR3 (VRC03)**
NIH45, 46	CD4bs (CD4 mimic via HCDR2)	2011	1–2	κ3–20	**Yes, SC and PA**	ND	**16**	**41**	**d2-LCDR1**

Table 1 Distribution of **Atypical Characteristics** of HIV-1 bnAbs to Various Env Vaccine Targets—cont'd

bnAb/bnAb Lineage	Env Region Specificity	Year Isolated	VH	VL	Poly-/ Autoreactivity In Vitro	"Tolerizing" Self-Reactivity In Vivo	HCDR3 Length (Kabat AA)	SHM in V_HDJ_H (%)	Indels (Size–Location)
VRC-PG04,04b	CD4bs (CD4 mimic via HCDR2)	2011	1–2	κ3–20	**No, SC**	ND	14	44	**i1-HCDR1, i1-HCDR2, d3-LCDR1**
VRC-CH30–34	CD4bs (CD4 mimic via HCDR2)	2011	1–2	κ1–33	**No, SC; yes, PA**	ND	13	34–39	**i9-HCDR1**
3BNC60	CD4bs (CD4 mimic via HCDR2)	2011	1–2	κ1–33	**No, SC**	Yes, for germline-reverted 3BNC60 (partial deletion, anergy, extensive LC editing)	10	40	**i4-HFR3, d4-LCDR1**
3BNC117	CD4bs (CD4 mimic via HCDR2)	2011	1–2	κ1–33	**Yes, SC**	ND	10	36	**i4-HFR3, d4-LCDR1**
12A12, 12A21	CD4bs (CD4 mimic via HCDR2)	2011	1–2	κ1–33	**Yes, SC**	ND	13	38, 40	**No**
VRC-PG19, 20	CD4bs (CD4 mimic via HCDR2)	2013	1–2	λ2–14	**NR**	ND	11, 13	23, 24 (nt)	**d1-LCDR1 (VRC-PG19), d6-LCDR1 (VRC-PG20)**
VRC23	CD4bs (CD4 mimic via HCDR2)	2013	1–2	κ3–15	**NR**	ND	12	36	**No**

Table 1 Distribution of **Atypical Characteristics** of HIV-1 bnAbs to Various Env Vaccine Targets—cont'd

bnAb/bnAb Lineage	Env Region Specificity	Year Isolated	VH	VL	Poly-/ Autoreactivity In Vitro	"Tolerizing" Self-Reactivity In Vivo	HCDR3 Length (Kabat AA)	SHM in V_HDJ_H (%)	Indels (Size–Location)
VRC18	CD4bs (CD4 mimic via HCDR2)	2015	1–2	κ3–20	NR	ND	10	37	No
N6	CD4bs (CD4 mimic via HCDR2)	2016	1–2	κ1–33	No, SC & PA	ND	15	42	No
VRC27	CD4bs (CD4 mimic via HCDR2)	2016	1–2	κ1–33	NR	ND	14	40	No
DRVIA7	CD4bs (CD4 mimic via HCDR2)	2016	1–2	κ1–5	NR	ND	11	32	NR
8ANC131, 134	CD4bs (CD4 mimic via HCDR2)	2011	1–46	κ3–20	Yes, SC	ND	16	39, 40	d1–HCDR2, d1–LCDR1
1NC9, 1B2530	CD4bs (CD4 mimic via HCDR2)	2011	1–46	λ1–47	Yes, SC	ND	16	38, 41	No
CH235.12	CD4bs (CD4 mimic via HCDR2)	2014	1–46	κ3–15	No, SC and PA	ND	13	13 (nt)	NR

Table 1 Distribution of **Atypical Characteristics** of HIV-1 bnAbs to Various Env Vaccine Targets—cont'd

bnAb/bnAb Lineage	Env Region Specificity	Year Isolated	VH	VL	Poly-/ Autoreactivity In Vitro	"Tolerizing" Self-Reactivity In Vivo	HCDR3 Length (Kabat AA)	SHM in V_HDJ_H (%)	Indels (Size–Location)
179NC75	CD4bs (unliganded)	2015	3–21	λ3-1	NR	ND	24	36	No
2 F5	gp41 MPER	1993	2–5	κ1–13	Yes, SC and PA	Yes (profound central deletion, anergy, LC editing)	22	14	No
4E10	gp41 MPER	1994	1–69	κ3–20	Yes, SC and PA	Yes (profound central deletion, anergy, LC editing)	18	19	No
CAP206-CH12	gp41 MPER	2011	1–69	κ3–20	Yes, SC	ND	15	19	d1–HFR3
M66.6	gp41 MPER	2011	5–51	κ1–39	Yes, SC	ND	21	9	No
10E8	gp41 MPER	2012	3–15	λ3–19	No, SC; yes, PA	ND	20	27	No
DH512	gp41 MPER	2017	3–15	λ3–19	Yes, PA	ND	24	18	No
PG9	V1V2-glycan	2009	3–33	λ2–14	Yes, SC and PA	ND	28	17	i1–HFR1
PG16	V1V2-glycan	2009	3–33	λ2–14	No	ND	28	20	No
CH01–04	V1V2-glycan	2011	3–20	κ3–20	CH03 only, SC	ND	24	19–22	No

Table 1 Distribution of **Atypical Characteristics** of HIV-1 bnAbs to Various Env Vaccine Targets—cont'd

bnAb/bnAb Lineage	Env Region Specificity	Year Isolated	VH	VL	Poly-/ Autoreactivity In Vitro	"Tolerizing" Self-Reactivity In Vivo	HCDR3 Length (Kabat AA)	SHM in V_HDJ_H (%)	Indels (Size–Location)
PGT141–145	V1V2-glycan	2011	1–8	κ2–28	No, SC and PA	ND	31–32	28–30	di-HCDR3 (PGT145)
CAP256-VRC26	V1V2-glycan	2014	3–30	λ1–51	No, SC	ND	35–37	13–23	NR
PDGM1400	V1V2-glycan	2014	1–8	κ2–28	No, SC	ND	34	27 (nt)	No
2G12	V3-glycan	1994	3–21	κ1–5	No, SC and PA	ND	14	32	No
PGT125–131	V3-glycan	2011	4–39	λ2–8	Yes, SC and PA	ND	19	23–33	i6-HCRD2, d5-LCDR1
PGT121–123	V3-glycan	2011	4–59	λ3–21	No, SC and PA	No (for germline-reverted PGT121)	24	21–27	d7-LFR1; i3-LFR3
PGT135–137	V3-glycan	2011	4–39	κ3–15	NR	ND	18	25–29	i5-HCDR1 (PGT135–137), i1-LFR1 (PGT135), i1-HCDR2 (PGT136)
10–1074	V3-glycan	2012	4–59	λ3–3	NR	ND	24	21	d4-LFR1, i3-LFR3
VRC24	V3-glycan	2013	4–4	λ1–15	NR	ND	24	30	NR
DH270	V3-glycan	2017	1–2	λ2–23	NR	ND	20	6	No

Table 1 Distribution of **Atypical Characteristics** of HIV-1 bnAbs to Various Env Vaccine Targets—cont'd

bnAb/bnAb Lineage	Env Region Specificity	Year Isolated	VH	VL	Poly-/ Autoreactivity In Vitro	"Tolerizing" Self-Reactivity In Vivo	HCDR3 Length (Kabat AA)	SHM in V_HDJ_H (%)	Indels (Size–Location)
8ANC195	gp120–gp41 interface	2011	1–69	κ1–5	Yes, SC	ND	20	43	d1-HCDR1, i5-HCDR2, i1-LCDR1
3BC176	gp41–gp41 interface	2012	1–2	λ2–23	Yes, SC	ND	19	34	NR
35O22	gp120–gp41 interface	2014	1–18	λ2–14	No, SC	ND	14	44	i8-HFR3
PGT151–158	gp120–gp41 interface	2014	3–30	κ2–29	No, SC (PGT151, 152) NR (PGT153–158)	ND	26	26–31	NR
N123-VRC34.01	gp120–gp41 interface	2016	1–2	κ1–9	NR	ND	13	25	No

[a]SC, positive in standard clinical assays, i.e., HeP-2A IF staining for polyreactivity and/or in autoantigen ELISA/Athena panels; PA, protoarray analysis for >9400 host proteins.
[b]Based on data from human bnAb KI mouse models.
[c]Somatic hypermutation (SHM) data given in % amino acid changes, otherwise nucleotide (nt).
[d]d, deletion; i, insertion; size in aa; FR, framework region; CDR, complementary determining region.
ND = not determined, i.e., no bnAb KI mouse model made (thus far); NR = not reported.
As an example of nomenclature, d5-LFR1 is a deletion of 5-aa in light chain framework region 1, i3-HCDR1 is an insertion of 3-aa in heavy chain complementary determining region 1.

will invoke highly disfavored, protracted affinity maturation (AM) pathways (Batista & Neuberger, 1998; Haynes, Verkoczy, & Kelsoe, 2014; Kepler & Perelson, 1993; Sabouri et al., 2014) that seem impractical and/or unsafe for vaccination to induce.

2.2 Distribution of bnAb Traits Across Classes: Functional vs Immunological Implications for Vaccination

Despite the daunting set of challenges such unusual traits pose, and the emerging evidence these may all be problematic, to varying extents, for the completion of many (most) bnAb pathways, the potentially encouraging news is that matured bnAbs exhibit varying degrees of such features and/or combinations of them, depending on the bnAb "class" they belong in, i.e.,


Fig. 1 Varied penetrance of rare (but potentially desirable) traits in bnAbs to distinct Env regions. Shown is a schematic representation of the HIV prefusion trimer structure (Pancera et al., 2014), showing its gp120 and gp41 protomers. Below each of the major common regions targeted by bnAbs, the V2-glycan apex (*green*), V3 glycan high-mannose patch (*blue*), the CD4bs (*magenta*), the gp41 MPER (*orange*), and the gp120–gp41 bridging region (*red*), are listed prototype mAb bnAbs for that site, including ones (highlighted in color) for which bnAb KI models have been made (or are under construction). Next to each of the four better-characterized Env sites are the most penetrant functional trait in the corresponding bnAb class (in *blue boxes*), and above it (in *red letters*) is listed the major anticipated immunologic hurdle for vaccination to overcome.

which epitope clusters in Env they target (Table 1) (Fig. 1). For instance, while CD4bs "VRC01-class" bnAbs exceed 40% SHM levels (Mascola & Haynes, 2013), they have typical sized HCDR3s, and some, like VRC01, lack self-reactivity, both in vitro and in vivo (at least earlier in their development). On the other hand, bnAbs targeting the V2 apex or the high-mannose patch (despite all having long HCDR3s; Burton & Hangartner, 2016) or those directed to the MPER (despite all thus far exhibiting considerable self-reactivity; Verkoczy, Kelsoe, & Haynes, 2014), tend to accumulate fewer SHMs, relative to CD4bs-specific bnAbs (Bonsignori, Alam, et al., 2012; Sok et al., 2013; Verkoczy & Diaz, 2014). The fact that these traits are distributed somewhat differently for lineages targeting distinct sites in Env, suggests the roadblock(s) involved in their inefficient development/ maturation may be unique to bnAbs targeting different Env regions, and perhaps even individual lineages. Below, the distinct skewing of these signature traits based on bnAb class will be discussed, in terms of their functional importance relative to their perceived degree of difficulty to be induced by vaccination. Two bnAb classes in particular, those directed to the CD4bs, and those targeting the V3 high-mannose-targeting patch will be used as notable examples, since the greatest wealth of new precursor-targeting immunization strategies have been designed and tested in KI mice thus far, and thus are most relevant for purposes of discussion for the remainder of this review.

2.2.1 CD4bs-Directed bnAbs
CD4-bs-directed bnAbs can be divided into two subclasses, based on how their paratopes interact with CD4bs epitopes. The first group, "HCDR3-binders," bind primarily via contacts in their HCDR3s and includes the CH103 bnAb lineage, while a second group (CD4 mimics via HCDR2) a.k.a. "VRC01-class" bnAbs, which include 3BNC60 and VRC01 itself, bind predominantly via HCDR2 contacts, and utilize a canonical gene segment, V_H1-2 that acts as a structural mimic of CD4 (Scheid et al., 2011; Wu et al., 2010; Zhou et al., 2010).

With respect to the CD4 mimic (VRC01-like) bnAb subclass, these have typical HCDR3 regions, unlike most bnAbs, which bear unusually long (and hydrophobic or tyrosine sulfated) HCDR3s. However, these types of bnAbs are not free of carrying unusual Ab combining sites; namely, their LCs while variable, all contain an unusually short signature 5-amino acid (aa) CDRL3s, a feature that appears to be key for avoiding steric clashes with gp120 (Zhou et al., 2010, 2015, 2013). Given the rarity of LCs in the

repertoire with this signature, the frequency of VRC01 precursors in individual or Ig locus humanized has been found to be fairly limited (Jardine, Kulp, et al., 2016; Sok et al., 2016). Perhaps the most prohibitive aspect of VRC01-class bnAbs for vaccination, however, is their exceedingly high SHM levels, more than has been found for any other bnAb class to date (Table 1). While only a subset of these mutations are critical for bnAb function (Georgiev et al., 2014; Jardine, Sok, et al., 2016), SHM is nevertheless a largely random process, and AM occurs in nonlinear fashion. Thus, eliciting developmental pathways of VRC01-like Abs to maturation will need to induce substantially more mutations than this minimal set, which is still well above estimates of what typical vaccine regimens can induce. Finally, while tolerizing self-reactivity appears to be a universal and profound issue for all MPER Abs tested thus far, either in standard clinical autoantigen assays (Haynes, Moody, Verkoczy, Kelsoe, & Alam, 2005), host protein arrays (Liu et al., 2015; Yang et al., 2013), or those for which KI models have been made thus far (reviewed in Verkoczy et al., 2014; Zhang et al., 2016), it is encouraging that not all CD4bs are under such early, universal in vivo host controls. For example, a VRC01 HC + LC KI model exhibits normal B-cell development (Tian et al., 2016), although interestingly, a germline 3BNC60 HC + LC Ab KI model is under multiple tolerance controls (McGuire et al., 2016), despite having very similar immunogenetics (differing only in Vκ family LC usage); hence, this suggests LCs may be important in specifying tolerance induction for this bnAb class. Nevertheless, it remains to be seen if VRC01 is also under negative selection, but only later in its maturation, since most matured CD4 mimic bnAbs (including VRC01) avidly bind the conserved host antigen UBE3A ligase, which has been found to have significant overlap with both the VRC01 paratope and CD4 (Liu et al., 2015). The possibility of tolerance induction of VRC01 during AM, will be discussed further below, under the various vaccine studies reported in several independent VRC01 KI systems.

2.2.2 V3-Glycan (N332 Supersite) bnAbs

This class of bnAbs, including the PGT121 clonal family (Mouquet et al., 2012; Walker et al., 2011), and the recently reported DH270 lineage (Bonsignori et al., 2017), target the high-mannose patch around the N332 glycosylation site in the V3 loop near the apex of the Env trimer. The epitopes of this class of bnAbs are complex peptidoglycans (Garces et al., 2015, 2014; Mouquet et al., 2012; Walker et al., 2011), and induction of these types of bnAbs faces some of the same hurdles as those for other

bnAbs with elongated HCDR3s (i.e., MPER and V2-glycan-directed bnAbs), namely, the prohibitively low frequencies their precursors are predicted to be found in the human Ab repertoire, due to multiple pre-immunization issues, either with HC or SLC pairing (Ivanov et al., 2005; Martin et al., 2003; Vettermann & Jack, 2010; von Boehmer & Melchers, 2010), potential self-reactivity due to their surface expression at the pre-BCR stage (Keenan et al., 2008; Minegishi & Conley, 2001), or at the first tolerance checkpoint upon their expression as IgM$^+$ BCRs (Meffre et al., 2001; Shiokawa et al., 1999). However, the PGT121-clonal family 26-aa long HCDR3 is likely critical to penetrate through the glycan layer to interact with the underlying peptides (Pejchal et al., 2010). Other V3-glycan class bnAbs do not have as long (∼20-aa) HCDR3 regions (Table 1; Mascola & Haynes, 2013), including the PGT128 family and the related DH270 lineage; thus these bnAbs may not be as problematic immunologically. The PGT121 and PGT128 clonal family of bnAbs also have other peculiarities that may be difficult for vaccination to induce. In particular, PGT121 has LCs with a 3-aa insertion in framework 3 (LFR3), and PGT128 has a 6-aa insertion in its HCDR2; both events appear important for neutralization breadth/potency (Doores et al., 2015; Pejchal et al., 2011; Sok et al., 2013).

Encouragingly, SHM frequencies for the all V3 glycan bnAbs, although still well above average levels, are lower than most other bnAbs. Perhaps more importantly, intermediates of such bnAbs, for instance, those for PGT121, which already develop considerable breadth, have ∼10% SHM (Sok et al., 2013), thus more within ranges reasonable for vaccination. Most remarkably yet, DH270, although not as broad as PGT121, in addition to its relatively shorter HCDR3 noted above, also accumulates considerably less (∼6%) muta-tion (Bonsignori et al., 2017), and thus may represent a particularly feasible tar-get for more typical vaccination regimens to elicit. Finally, not much is yet known regarding self-reactivity of V3-glycan bnAbs and if tolerance control will be a concern for their maturation. In this regard, PGT121 exhibits no overt poly-/autoreactivity in vitro (Liu et al., 2015), and gl-PGT121 HC +LC KI mice exhibit normal development (Escolano et al., 2016), although as will be discussed further later on, it is not known if this knocked-in spec-ificity represents a true intermediate and/or if it bypassed a critical earlier developmental bottleneck. With the molecular elucidation of the complete DH270 lineage (i.e., from bona fide unmutated common ancestor (UCA) to bnAb), mice expressing either its UCA, or intermediates that have bypassed potential developmental bottlenecks, i.e., one with a G57R substitution, required for breadth in this lineage, are under construction (Alt, F., & Tian, M., personal communication), and thus should help clarify this question.

3. CURRENT GAPS IN HIV VACCINOLOGY

3.1 Current Gaps Are Not Just Knowledge-Based, but Also Technical: The Need for More Practical Animal Models

In addition to the RV144 trial results reported in 2009, in which the first statistically significant, albeit modest, reduction in HIV-1 acquisition by a vaccine regimen were observed (Rerks-Ngarm et al., 2009), the other major milestone in the HIV vaccine development field over the past few years has been the wealth of information obtained from identifying and characterizing the myriad of novel monoclonal bnAbs and their Env targets (Burton & Hangartner, 2016; Burton & Mascola, 2015). This burst in bnAb discovery has largely been enabled by major technological advances on the bnAb discovery side, which as noted above, has involved breakthroughs in memory B-cell sorting, culturing, and Ab cloning methodologies, as well as increased access to (and more comprehensive longitudinal sampling of) HIV-infected cohorts. Furthermore, on the bnAb characterization side, equally impressive advances in crystallography, protein modeling technologies, and bioinformatic analyses have allowed the elegant structural elucidation of the paratopes and epitopes of bnAbs from multiple classes, at near-atomic resolution. However, one area that has lagged behind considerably (until now), has been developing animal vaccine testing models capable of informing the field in an efficient yet relevant way. For such a model to do so, it would need possess a suitable balance of practicality and physiological relevance, allowing it to: (1) *conveniently* monitor human bnAb activation and maturation in vivo and (2) *iteratively* test the ability of new HIV vaccine regimens/concepts to induce and broaden nAb responses.

Access to such practical, yet physiologically relevant, animal models is arguably the largest technical hurdle facing the HIV vaccine field, for two reasons. *First*, there currently exist many more and increasingly sophisticated vaccine regimens and theoretical concepts, many/most which cannot be tested in more physiological settings, e.g., NHPs and/or vaccine trials, for logistic reasons, i.e., cost, number of experimental groups required. Furthermore, there is a major practical issue facing iterative testing of bnAb-inducing vaccines: that bnAb precursors are expected to be very low in such settings, thus presenting the hurdle of having high enough frequencies to allow for robust, convenient readouts, e.g., where serological analysis is possible (rather than recombinant Ab cloning). The alternative approach, testing such new vaccine approaches in WT small animal models does

overcome some of the logistic issues just mentioned, but has the same problem of practicality of readouts, and in addition, fails to meet a sufficient standard of physiological relevance, for many reasons that are now becoming more apparent (to be discussed further in Section 3.5). Perhaps the most problematic one is that no such small animal models offer a natural alternative that is truly physiologically relevant for studying the *human Ig* repertoire. Such concepts would thus benefit from having a more practical, yet still sufficiently physiological model, capable of bridging the gap between new theoretical concepts and more direct/rapid testing in a relevant setting. The *second reason* why not having access to practical (yet physiologically relevant) animal models poses a key technical hurdle for HIV vaccinology is that several key knowledge gaps in the basic B-cell immunology of HIV bnAb responses still exist, which in addition to the issues noted above for "bigger science" iterative vaccine testing, would also profit from such models. For instance, models with the added dimension of genetically malleability, i.e., where cell numbers, B-cell selection environment, and other key factors involved germinal center (GC) and memory B-cell formation can be readily manipulated, would be critical for such, more fundamental questions, in order to more precisely dissect the relevant factors specific to *individual* bnAbs, limiting and/are minimally required for their vaccine-induced maturation.

In the next three sections, specific knowledge gaps in HIV vaccinology most likely to benefit from improved animal models (having some of the features described above) will be reviewed. Then, in the last section, animal models traditionally used in the field will be compared to various new humanized Ig KI models, either recently generated or under development, which have been engineered to provide the best balance of practicality and physiologic relevance, in order to more feasibly study the atypical biology of bnAb development.

3.2 Are Certain "Unusual" bnAb Traits Functionally Needed, but Less Problematic for Vaccination to Elicit?

Given the daunting, yet not impenetrable, set of obstacles facing bnAb induction noted above, what are the most critical steps for developing a bnAb-eliciting vaccine? At least three major knowledge gaps need resolution. The first, which will be reviewed in this section (the others in ensuing sections), is to precisely understand the extent to which "unusual" bnAb traits (or combinations thereof) are required for neutralization breadth,

relative to being problematic for vaccination to induce. Importantly, because this knowledge is specifically needed for *individual* bnAbs, and in the setting of vaccination (rather than infection), more systematic examination across *multiple* bnAb lineages (representing distinct bnAb classes) is required, in order to obtain a *comprehensive* picture of all potential bnAb Env responses. Only then can it be truly ascertained if and which bnAb target(s) are more tractable to elicit. This series of endeavors could thus benefit tremendously from having more practical and physiologically relevant animal models, that allow development of either singular, or limited sets of bnAb lineages at a much higher resolution to be studied, than currently is possible, due to the rarity of B-cell clones expressing the very traits functionally required for developing bnAb activity.

Of the normally rare Ab-related traits that typify bnAbs, perhaps the one for which a more fundamental understanding is most needed (and would thus particularly benefit from studies in more practical, and genetically flexible animal models), is the exceptional SHM rates found in all bnAbs isolated thus far (excepting DH270; Table 1). As already noted in Section 1, the levels that bnAb VDJ's accumulate are remarkable (15%–52%) (Burton & Hangartner, 2016; Mascola & Haynes, 2013; Verkoczy & Diaz, 2014; West et al., 2014). Thus, especially critical to ascertain is how much of this SHM is actually required by vaccination to broaden nAb responses, and if this varies based on Env region that bnAbs target. In striking contrast to these exceptional levels in bnAbs, Abs from conventional antigen-activated B-cells, i.e., that *normally* undergo AM in GCs during *typical* secondary responses for producing high-affinity Abs (Eisen & Siskind, 1964), exhibit SHM frequencies that plateau at ∼6% (Batista & Neuberger, 1998). Levels above that tend to lower affinity (Batista & Neuberger, 1998; Kepler & Perelson, 1995; Zhang & Shakhnovich, 2010) and increase chances of creating pathogenic self-reactivity (Mietzner et al., 2008; Shlomchik et al., 1990; Tiller et al., 2007).

The need for these unusually high levels of SHM in bnAbs is currently unknown. However, all bnAbs, thus far, originate from subjects with prolonged HIV-1 infection, where bnAb-specific maturation issues, e.g., extensive host/virus coevolution (Doria-Rose et al., 2014; Liao, Lynch, et al., 2013) or potential purifying selection forces (Haynes, Verkoczy, et al., 2014; Sabouri et al., 2014; Verkoczy et al., 2013; Verkoczy & Diaz, 2014) could both generate high SHM associated with disfavored, highly convoluted AM pathways. On the other hand, it is also

possible that other, bnAb maturation "independent" confounding issues, i.e., irrelevant to bnAb formation, for example, those related to the chronic infection milieu like inflammation (Moir & Fauci, 2013) or B-cell dys-regulation (Levesque et al., 2009), may also contribute high "mutational noise." Additionally, while one study has argued such extreme SHM levels (>50% VDJ-aa mutation in some VRC01-like bnAbs; Table 1) confer to FRW regions the necessary flexibility to deal with viral diversity (Klein et al., 2013), in vitro mutagenesis studies show only 25%–30% of such high total SHM levels are functionally required (Georgiev et al., 2014). However, this latter report does not take into account the nonlinear acquisition of SHM accumulated during AM (Batista & Neuberger, 1998). Thus, what component of such SHM levels in bnAbs (far higher than in typical Ab responses), is actually needed for vaccination to induce their breath devel-opment, is a critical, yet completely unresolved issue.

Based on the initial in vitro mutation studies and accompanying consid-erations noted above, it is likely that at least some, and likely, considerable amounts of the high bnAb SHM rates are in fact required for their specific maturation process, and thus have direct relevance in the vaccine setting. Assuming this is so, the question then becomes: how much of the specific, yet convoluted AM is functionally driven, vs being host tolerance-induced? In this regard, at least three, nonmutually excusive, bnAb maturation-specific explanations exist for why such high SHM rates are seen (Kelsoe, Verkoczy, & Haynes, 2014; Verkoczy & Diaz, 2014) (Fig. 2). The first is that these mutations are necessary to modify germline Abs, so as to meet unusually stringent structural requirements (Fig. 2, Model "A"). In the case of HIV, due to extensive virus diversification resulting from the coevolu-tionary "arms race" between virus and host (Liao, Lynch, et al., 2013; Moore et al., 2012), such structural requirements might not only include high affinity, but also structural flexibility (Klein et al., 2013) to allow for restriction to core epitopes that are poorly recognized by naïve BCRs in the primary, germline Ab repertoire (Haynes, Kelsoe, Harrison, & Kepler, 2012; Hoot et al., 2013; Ota et al., 2012; Xiao et al., 2009), and/or to counter natural variation in otherwise relatively conserved bnAb-targeting regions (Kwong & Mascola, 2012).

The two other potential "vaccine-relevant" explanations for the unusual SHM levels bnAbs accumulate during prolonged infection, propose that tolerizing self-reactivity, now becoming relevant to limiting development of multiple bnAbs (Chen, Zhang, Hwang, et al., 2013; Doyle-Cooper et al., 2013; Finton et al., 2013; Haynes & Verkoczy, 2014; Liu et al., 2015;

Fig. 2 Potential "vaccine-relevant" mechanisms driving high SHM levels in bnAbs that develop during prolonged HIV-1 infection. In a "nontolerance" model (A), GC B-cells with no/minimal reactivity to mature Envs interact with founder/transmitted Envs and undergo extensive AM, driven by viral escape/Env diversification pressure, which demands difficult structural modifications to achieve both FRW flexibility and to accommodate finer variation in otherwise conserved Env epitopes. In models where HIV self-mimicry impacts SHM, i.e., (B) and (C), this could occur either as an indirect or direct result of tolerization. In a model where tolerizing self-reactivity indirectly impacts excess SHM (B), B-cells with bnAb epitopes that mimic host antigens (e.g., 2F5 ELDKWA minimal epitope) are clonally deleted in bone marrow development, creating "holes in the repertoire." In the absence of competition, weakly cross-reactive clones that already underwent non-Env-driven AM can then be recruited into additional, Env-driven AM pathways. Alternatively, in a model where self-tolerance directly drives excess SHM (C), B-cells that acquire both self and bnAb specificity via AM use additional rounds of SHM/selection to retain bnAb specificity, while removing tolerizing self-reactivity. In this model, the degree of additional selection/SHM would be proportional to how closely a particular bnAb epitope mimics self-antigen(s). Note that all three hypotheses are not mutually exclusive, and the combined mechanisms illustrated, could account for the especially tortuous pathways of certain bnAb lineages. *Figure reproduced with permission from Verkoczy, L., & Diaz, M. (2014). Autoreactivity in HIV-1 broadly neutralizing antibodies: Implications for their function and induction by vaccination.* Current Opinion in HIV and AIDS, 9*, 224.*

McGuire et al., 2016; Zhang et al., 2016), is the key driver (Fig. 2, Models B and C). One of the two hypotheses by which this occurs (Yang et al., 2013) (Fig. 2, Model B) is that due to mimicry of host antigens by many (or most) bnAb epitopes (Haynes, Moody, et al., 2005; Kelsoe et al., 2014), the potential bnAb pool of naïve B-cells (i.e., with germline (unmutated), BCRs capable of binding self-mimicking bnAb epitopes) are deleted in early development, thus never go on to be recruited into GCs and be driven by AM. In such a "holes in the B-cell repertoire" model, AM is not de novo, as the immune system is forced to work with what is available, and thus recruits weakly cross-reactive, previously mutated B-cell clones that eventually go on to generate bnAb via considerable additional AM. The other, distinct immune tolerance (and HIV mimicry)-based mechanism that has been proposed for driving high SHM levels in bnAbs isolated from infection (Verkoczy et al., 2013) (Fig. 2, Model C), is that peripheral tolerance considerably prolongs AM of bnAb$^+$ B-cells, when there exists close (but not complete overlap) in their reactivities for bnAb epitopes and the self-antigens they mimic. In this scenario, mutated, anergic mature bnAb$^+$ B-cells undergo antigen-driven, "conflicted" purifying selection that acts on V(D)J residues that remove self-reactivity while maintaining affinity for the bnAb epitope. Such a "tug-of-war" process would likely invoke multiple rounds of mutation/selection to decouple self-reactivity from functional (neutralization) specificity. Attempts at escaping negative selection would result in acquiring many additional mutations that not only remove self-reactivity, but also inadvertently remove bnAb specificity. This process often yields "affinity reversion" byproducts, which normally get deleted (Han, Zheng, Dal Porto, & Kelsoe, 1995; Pulendran, Kannourakis, Nouri, Smith, & Nossal, 1995; Shokat & Goodnow, 1995). However, in other cases (for reasons as-of-yet not understood), such as those reactive to protective and/or glycan-dependent epitopes, persist as anergic clones in mature B-cell compartments (Sabouri et al., 2014; Verkoczy et al., 2013), resulting in considerably more SHM, before the final desired "decoupled" end-product of this process is obtained. Additional evidence for this alternative peripheral tolerance process of "affinity reversion/dematuration," initially proposed as part of a model for GC reaction dynamics (Diaz & Klinman, 2000), has most directly been demonstrated in a well-controlled and elegant set of studies in HEL KI mice (Sabouri et al., 2014).

Regardless of what the relative contributions of AM-specific (tolerance and/or functional driven) or AM independent (i.e., chronic infection-related) issues mentioned above are in producing such high SHM in bnAbs after prolonged natural HIV-1 infection, this issue is nevertheless critical to resolve because if the minimal amount of SHM needed for bnAb generation

by vaccination can be defined and the level is considerably less than what occurs during infection, this would provide strong rationale to focus on devising vaccine strategies that "short-circuit," rather than recapitulate the evolutionary pathways deciphered during infection, in order to make prime/boost strategies feasible, and thus clinically translatable. Similarly, for the traits of elongated/hydrophobic HCDR3s and in vitro poly-/ autoreactivity, understanding their in vivo tolerizing effects across bnAb lineages against distinct Env regions is critical, in order to define their tractability as vaccine targets, because immunization strategies can either be directed to lineages with no self-reactivity, or alternatively, focus on modulating tolerance. Such modulation approaches could include regimens that employ appropriate combinations of higher avidity BCR cross-linking, stronger (and/or more specific) Toll-like receptor (TLR), and helper T-cell signals (Chaturvedi, Dorward, & Pierce, 2008; Cooke et al., 1994; Lau et al., 2005; Leadbetter et al., 2002; Marshak-Rothstein & Rifkin, 2007; Sekiguchi et al., 2002; Seo et al., 2002) or novel, more specific approaches such as checkpoint specific, or even molecule-targeting strategies that will be discussed further below, in Section 4.5.

3.3 Can HIV Vaccination Guide "Reasonable" Pathways to Breadth at Multiple Env Targets?

A second knowledge gap in developing a bnAb-eliciting vaccine, which could also benefit tremendously from having more practical and physiologically relevant animal models, is understanding whether vaccination can evolve more than one bnAb class/Env target to a degree of breadth that is sufficient for protection, yet feasible for AM to achieve. This would be critical to know because viral escape mutants develop in response to bnAbs targeting only a single region (Liao, Lynch, et al., 2013; Mascola & Haynes, 2013) and passively infused combinations of two, less-potent/broad bnAbs to distinct targets can synergize in conferring near-complete breadth (Bonsignori, Alam, et al., 2012; Bonsignori, Montefiori, et al., 2012; Doria-Rose et al., 2012; Mascola & Haynes, 2013). Taken together, these findings suggest an alternative bnAb-eliciting vaccine strategy, in which cumulative breadth is achieved by eliciting more modest breadth at two or more individual bnAb classes/targets, may not only be more reasonable "bar" for vaccine-guided AM to achieve, but may also reduce mutant escape frequency, and thus be at least equally, if not more efficacious. Achieving adequate cumulative breadth would likely also confer additional benefits, including overcoming expected individual Ab response diversity across

the vaccinated population, that could occur in the setting of responses to HIV vaccination, due to numerous factors, including immunogenetic variation, e.g., MHC class II haplotype restriction, or stochastic issues, for example, glycan epitope-targeting bnAbs requiring especially long HCDR3s (PGT121, PG9/16, VRC-26, etc.), resulting in naïve repertoire frequencies so infrequent (likely far lower than VRC01, which has been shown to be rare, i.e., between 1 in ~½ million and 1 in ~2.5 million; Jardine, Kulp, et al., 2016; Sok et al., 2016), that not all individuals may bear relevant lineage predecessors of that particular bnAb class.

Although it remains to be determined empirically, the possibility of pursuing such "cumulative breath" strategies is supported by some potentially encouraging anecdotes. For example, some bnAb intermediates already develop considerable neutralization breadth with more modest SHM levels. In one study, 40%–80% breadth resulted from about 50% of the total SHM levels observed in the V3/glycan-specific bnAb PGT121 (Sok et al., 2013), which already accumulates relatively less SHM (~20% VDJ-aa mutation) than many other bnAbs. However, a potential caveat with this more modest estimated overall mutation level of ~10% for achieving modest breadth in vitro is that at least some additional SHM would likely be produced in vivo as intrinsic bystander mutation. However, this particular issue is at least partially countered in theory by the identification and characterization of a new bnAb lineage, DH270, of the same V3/glycan-directed (N332 supersite) bnAb class, whose matured bnAbs have comparable potency/breadth as PGT121, but whose matured bnAbs accumulates considerably less (<5.8%) SHM (Bonsignori et al., 2017). Potential identification of other new bnAbs with low SHM, and that target distinct Env sites, would also help to further alleviate such concerns.

However, an additional, and likely more important caveat, even with the identification of such bnAb "outliers," i.e., bearing more reasonable SHM levels, is that we do not know the minimal number of mutations required for vaccination to induce (above and beyond those from in vitro mutational studies), since AM occurs in nonlinear fashion, especially in situations where underpinnings of negative selection pressure or conflicted selection (against self, but for neutralization function) normally exist during maturation. Thus, given coevolving Env mimicry could occur at any point of bnAb lineage development, conflicted selection that would result from normal (unbreached) tolerance mechanisms found in most healthy individuals could be problematic anywhere such a coevoluationary "bottleneck" is generated. In other words, even if only a single critical mutation is required for

developing breadth and/or even more generally continuing a lineage maturation trajectory, but is one normally under negative selection (that the particular patient from which the original bnAb was isolated, would obviously not have been subjected to), this would likely demand vaccination to induce exceptional AM maneuvers to overcome. A specific example of such high counter-selection on the virus evolution side of bnAb lineage development are mutations capable of recognizing the CD4-proximal N276 residue glycan, which the VRC01 class of CD4bs[+] bnAbs require for neutralization of native Env. Acquisition of this key glycan, in response to sequential immunization approaches tested thus far in VRC01 KI models (to be discussed further in sections below), appears to be a critical hurdle for bnAb responses, since some maturation to nAb responses does proceed, but VRC01-like precursors only undergo partial maturation, with serum activity restricted to that capable of neutralizing viruses lacking the N276 glycan (Briney et al., 2016; Tian et al., 2016). A similar potential example of mutation required at only a single critical residue, on the bnAb evolution side of lineage maturation, is the G57R substitution in the IA4 intermediate of the DH270 lineage, a mutation coldspot (i.e., a low-probability site for AID activity), that represents a key event for this bnAb to develop its breadth (Bonsignori et al., 2017). Thus, the question of whether reasonable breath via more achievable vaccine-elicited AM pathways, is achievable at a minimum of two (but preferably more Env targets), is another wide-open question for the field.

3.4 Emergence of New HIV Vaccine Formulations and Concepts: The Need for More Iterative Testing

The third key area for bnAb-based vaccine design, that would also benefit immensely from having available more practical and robust experimental animal models, is identifying what forms of HIV immunogens, among the myriad being generated (and which combinations thereof) can best induce breadth of nAb responses to HIV-1. Perhaps even more importantly is whether this only partially matters, i.e., results in incremental differences, without other critical components, i.e., appropriate adjuvanting, T-cell priming, or other vaccine concept. In this regard, the area of testing novel, "bnAb germline-targeting" and sequential boosting immunogens is already beginning to markedly benefit from use of such novel testing platforms, in the form of first generation "bnAb reverted" KI models (Briney et al., 2016; Escolano et al., 2016), and more recently "second generation" versions of such KI models (Tian et al., 2016). Studies in such models (both will be discussed further in the next section and Section 6), are already providing some

initial proof-of-concept (for at least certain bnAb classes), from which potentially key concepts are emerging. For instance, two key related ideas: that higher affinity priming immunogens are required to activate bnAb predecessors, and sequential administration of at least two (and likely several more) related Envs will be required to guide such bnAb responses appropriately, have already transpired from such studies. However, these studies represent only the tip of the iceberg, and given the virtually endless forms and combinations of HIV immunogens currently becoming available to the field, such evaluation, using such practical testing platforms, and versions equally practical but more physiologically relevant for informing vaccine design, will be of paramount importance. Thus, what key theoretical questions regarding immunogen design most critically need more comprehensive, robust empiric testing such platforms can afford?

Two of the more fundamental, related questions are: Does the form HIV immunogens are in matter in terms of specificity and/or potency of initiating bnAb responses? Does this vary for different Env vaccine targets? At one end of the spectrum, long-standing advocates of polyvalent and/or consensus Env-based immunogens have argued that the presence of multiple Env helper T-cell and B-cell epitopes will be most adept at inducing robust GC responses and AM in as many individuals as is possible. Based on this line of reasoning, incorporating conserved Env epitopes from diverse viral strains would provide global coverage of such responses at a population level (Haynes, 2015). Furthermore, it has long been suggested that preferentially focusing Ab responses to those against bnAbs mandate that Env immunogens be in stabilized native trimeric forms, whose structures are believed required to display bnAb epitopes, while occluding many of the more immunodominant non-nAb epitopes, that in natural trimeric Envs would not be accessible for recognition by bnAb[+] B-cells (de Taeye, Moore, & Sanders, 2016; Sliepen & Sanders, 2016). However, vaccination with Env trimers on VLP surfaces (Goepfert et al., 2011; Tong, Crooks, Osawa, & Binley, 2012) or inactivated HIV-1 virions expressing fusion-active trimeric Envs (Lifson et al., 2002) have thus far still only elicited heterologous, tier 1 nAbs (i.e., Abs that are cross-reactive with multiple HIV-1 viral strains having high neutralization sensitivity). Furthermore, recent studies using near-native soluble recombinant trimers have also resulted in induction of only predominantly tier 1 nAbs (Sanders et al., 2015), although their elicitation of autologous, tier 2 nAbs (Abs reactive to sequence-matched viral strains, having moderate neutralization sensitivity) suggest they may represent a useful starting point. Furthermore, it has also been argued that such

immunogens have either not yet been fully optimized (and or iteratively tested) for their ability to optimally activate bnAb precursors (Sliepen et al., 2015). Thus, efforts to increase their affinities for bnAb predecessors by multimerization and/or via other maneuvers, like those being used to optimize native trimeric Envs designed to specifically target V2/glycan bnAb precursors (Andrabi et al., 2015; Gorman et al., 2016) are underway, and will be discussed further below, in Section 5.3.

On the other end of the spectrum, proponents of "minimal" immunogens would argue that synthetically engineered bnAb-containing peptides or protein scaffolds are required for targeting bnAb lineage responses in vaccine regimens, especially for priming responses (Alam et al., 2017; Alam, Dennison, et al., 2013; Alam et al., 2011; Hoot et al., 2013; Jardine et al., 2013; McGuire et al., 2013), since most traditional Env immunogens do not bind most precursors of bnAbs at all or only suboptimally. Furthermore, Env as a complex, multiepitope immunogen, even when in the most optimal conformation, may still produce significant "off-target" responses, due to expressing irrelevant epitopes, a problem that could be especially accentuated if most bnAb epitopes are anergic and have to compete with irrelevant clones to such epitopes, not under such controls (this issue will also be discussed further in Section 5). However, such minimal immunogens are just beginning to be developed and evaluated, and peptide-based or partial protein subunit vaccine strategies in the past have generally been considerably less successful than protein subunit or whole virus vaccines (Huang et al., 2016; McElrath & Haynes, 2010), possibly because they often lack adequate T helper epitopes. In reality, it is also possible that hybrid approaches may be required. For example, the strength or specificity of T-cell help, even in trimeric Env-based immunization regimens, where quality of T-cell help may be inadequate (due to tolerance controls and/or in some instances, restriction of B- and T-cell epitope proximity; Zhang et al., 2014) could still result in preferential activation of irrelevant non-bnAb responses. Regardless of which types or combinations of immunogens are required in prime/boost strategies, this issue, as with the others mentioned above, would also benefit highly from more comprehensive testing in more practical in vivo platforms.

3.5 Balancing Practicality and Physiologic Relevance for HIV Vaccine Testing: Ig KI vs Other Animal Models

All the major knowledge gaps for HIV bnAb vaccine development noted in the three above sections mandate methical, iterative testing, in order to

dissect the roadblocks impeding, and the minimal requirements to developing, bnAb responses to vaccination. This in turn will require more systematic evaluation of individual bnAbs (and their ancestors/maturation branch points) of multiple lineages representative of distinct bnAb classes/Env targets. As already discussed, the most serious limitation in bridging such knowledge gaps (up until very recently) has been a technical one: namely, the lack of appropriate in vivo platforms that allow such questions to be addressed at the required degree of resolution just noted. While no perfect immunization model exists in general, those best suited for this specific task requires the sufficient balance of physiological relevance and practicality (Fig. 3). Currently, the only models with this potential are those genetically


Fig. 3 Comparison of animal models for evaluating bnAb-targeting vaccine regimens. Schematic representation of relative practicality and physiological relevance of various current and planned animal models for testing vaccines aimed at eliciting bnAb responses. Optimal models would be ones that could best bridge the gap between practicality of detection afforded by standard UCA KI frequencies, with the physiological relevance of human unrearranged immune loci. Acceptable current versions with "sufficient" balance of both sets of required features are shown in *blue*, and include existing first and early second generation KI models; "Optimal" platforms for the best balance of iterative, yet physiologically relevant testing (second and third generation bnAb KI platforms; see Section 6 and Fig. 8 for more detail) are shown in *green*. Shown in *red* are models not thought to be practical for these types of studies.

engineered by mouse IgH/L locus–directed targeting of individual (or limited sets of) human prerearranged V(D)J exons encoding precursors of matured bnAbs, or alternatively, components of such V(D)J exons (i.e., their unrearranged human V (D), and J segments, that in vivo, get developmentally assembled into functional rearranged V(D)J exons). What individual criteria must such bnAb knock–in (KI) mouse models fulfill to achieve this unique balance?

On the "practicality" end of the spectrum, bnAb KI mice satisfy two key criteria. First, they represent *highly iterative* testing platforms, since by expressing repertoires enriched for bnAb precursors of individual lineages as starting points, they enable studies to be focused on such lineages, where an unparalleled level of resolution and manageable numbers of maturation products from numerous trajectories can be rapidly examined and tracked in response to immunization. In contrast, such analysis is not feasible to achieve in human vaccine trials, primate studies, or other wild-type (non-genetically modified) animal models with normal polyclonal systems, since individual bnAb roadblocks manifest as a multifactorial set of limitations, resulting in eliciting subdominant bnAb responses, i.e., undetectable by serological-based assays, and thus lack the resolution to more conveniently measure any potential incremental improvements in regimens. The second criteria that bnAb KI models meet for the required practicality is that they have considerable *flexibility*: only in such models can B-cell selection, SHM, and GC/Tfh differentiation-specifying processes be genetically manipulated in the setting of focused bnAb lineages, thus allowing even more precise dissection of regulation and development of individual bnAbs. This can be done either by generating compound models via crossbreeding to other relevant, B-cell differentiation process-impacting KI/KO strains, or by genetically manipulating timing and/or stage of bnAb expression in the repertoire. The frequency and type of enriched repertoires can also be altered; for instance, they can be derived either from HC only or HC + LC reverted bnAb rearrangements, preferentially rearranging germline segments, complete humanized Ig loci, or alternatively, as donor B-cells from one (or more) individual reverted bnAb KI model(s), adoptively cotransferred at varying limiting amounts (along with WT repertoire B-cells) into irradiated (or B-cell deficient) recipient mice. All these maneuvers may be critical, at least initially, in order for relevant "signals" of bnAb breadth development to be revealed and/or enhanced during vaccination, since all empirical studies performed to date have yet to yield an effective HIV vaccine, suggesting

there exist individual roadblocks in bnAb generation that require systematic identification.

On the "physiological relevance" side of the spectrum (Fig. 3), bnAb KI models need to serve as preclinical vaccine testing platforms capable of complementing human trials and nonhuman primate (NHP) studies. Such a complementary role should minimally involve being lead generators for human trials, but ideally, also allow parallel evaluations with trials and/or NHP studies to be made, such that results generated in either setting could be sufficiently informative to the other, and could be directly translated into subsequent iterations of both studies. In order to enable this kind of testing, such models must have both Ab repertoires and conserved processes that impact vaccine-mediated induction and maturation of Abs in that repertoire (including bnAb and their various atypical traits), that are sufficiently close to those present in the normal human immune system. These requirements are minimally met by bnAb KI models, due to the way they have been engineered: not only do they bear the relevant human V(D)J exons from which relevant bnAbs are formed, but also due to their positioning into the Ig loci, all highly conserved mechanisms relevant for bnAb activation and development are retained, including (most importantly for bnAb maturation) those driving GC reactions, where high-affinity Ab formation is orchestrated. Specifically, AM in GCs is achieved through the combinations of SHM, positive selection for high-affinity binding to foreign antigen, and purifying selection (against self-antigen binding), all via nearly identical mechanisms in humans and mice. With further modifications in the way segments are knocked-in, for example, as unrearranged V, D, and J segments rather than prerearranged V(D)J exons, and the frequencies at which they can recombine (such newer generation, emerging bnAb KI models are under development, and will be discussed in Section 6), these conditions have the potential to not only be minimally met, but also made to mimic those in human bnAb development even more closely.

Of note is that the general physiological applicability of the "humanized Ig KI" approach (of which bnAb KI models are a subclass), for specifically testing bnAb responses to vaccination, differs markedly from that of "humanized" mice, i.e., those reconstituted with human immune systems (reviewed in Victor Garcia, 2016), of which perhaps the best characterized and most advanced version is the BLT (bone marrow–liver–thymus) model, i.e., $Rag2^{-/-}\gamma c^{-/-}CD47^{-/-}$ mice reconstituted with human bone marrow, liver, and thymus) (Melkus et al., 2006). The most notable problem with using such human immune-reconstituted models for vaccine testing

(or to understand more fundamental aspects of vaccine–guided bnAb maturation) is that they have generally poor and sporadic Ab responses (potentially due to incomplete B-cell maturation), including weak GC reactions, suboptimal AM; and to varying extents, incomplete class switch recombination (CSR). bnAb KI mice are also physiologically superior vaccine models than regular outbred small animals, which not only have the practical issue of polyclonality (noted above), but also have various Ig locus-related immunogenetic features likely problematic for producing a B-cell repertoire capable of evolving the desired human bnAb specificities (reviewed in Verkoczy & Diaz, 2014). For instance, mice have both markedly shorter D segments than humans (Schroeder, 2006; Zemlin et al., 2003), restricting their abilities to produce long (>20-aa) HCDR3s, a trait found in >2/3 of bnAbs (Mascola & Haynes, 2013; Verkoczy & Diaz, 2014). Additionally, ~50% of bnAbs use diverse human λLCs which cannot be recapitulated at the WT mouse's atypically abbreviated Igλ locus, which in relation to the human Igλ locus, has restricted diversity and poor expression of Vλ segments. Significant differences also exist in Ab repertoire development between rabbits and humans, including the former using a much more limited set of V_H segments and a distinct repertoire diversification mechanism, gene conversion (Allegrucci, Young-Cooper, Alexander, Newman, & Mage, 1991; Knight, 1992), that also pose problems to bnAb generation. By contrast to the various constraints just described for lagomorphs and unmanipulated mice (the two most utilized models in past HIV vaccine studies), any such caveats are circumvented in bnAb KI mice, since, as noted above, such models have been engineered to selectively express human Ig elements required for bnAb development, in place of those in the WT mouse Ig loci (that preclude their development), e.g., knocking–in longer human D segments (or human VDJ exons) at the mouse IgH locus, or human VλJλ rearrangements at the mouse IgL locus.

For the remainder of this review, I will discuss the various types of human bnAb KI strains that have been, and are being, developed by my group and others in the field, with the goal of illustrating how, to varying extents, their intended balance of physiological relevance and practicality should allow more focused examination of how B-cell repertoires expressing human bnAbs are formed and selected, and to what extent broad bnAb responses to novel vaccine strategies can develop. I will start with a historical perspective on the use of Ig KI technology to express V(D)J rearrangements of original (first generation) bnAbs, and more recently, "second generation" and/or "reverted" bnAbs, in order to demonstrate

the role of host tolerance in controlling their production (Sections 4.1–4.3), and to elucidate strategies for overcoming these roadblocks (Sections 4.4–4.6). I then provide initial insights into vaccine-guided activation and development of bnAb lineages that are starting to emerge from recent immunization studies done with new human Ig KI models that either preferentially express reverted V(D)J rearrangements or fully germline (unrearranged) V gene segments of second generation bnAbs (Section 5). Finally, I will review technical advances for higher-throughput production of, or conditional expression in, bnAb KI models, to further accelerate basic studies of vaccine-guided bnAb development and regulation (Section 6). Ultimately, I project how such methodological improvements will make testing of individual bnAb lineages to distinct targets (and/or key members of such lineages) a more systematic exercise, thus making more feasible two critical goals for HIV vaccine development: defining the key parameters required for vaccine-guided bnAb induction and identifying the lineage-directed immunogens and prime/boost strategies that can best do this.

4. HUMAN IG KI MODELS IN ELUCIDATING bnAb TOLERANCE CONTROLS AND TESTING WAYS TO OVERCOME THEM

Negative selection of B-cells does not occur as a single discrete process, but encompasses a continuum of complex and related phenomena. Indeed, the various effects of immune tolerance on B-cell development are driven by various factors during encounter of self-antigens with B-cells, including the form in which self-antigens are presented (Hartley et al., 1991), the affinity at which they bind (Chen, Nagy, Radic, et al., 1995; Li, Jiang, Prak, Radic, & Weigert, 2001), the location/site of their interactions with B-cells (Murakami et al., 1992; Russell et al., 1991), and the stage of B-cell maturation at which this encounter occurs (Benschop, Brandl, Chan, & Cambier, 2001). Furthermore, negative selection of B-cells occurs at several checkpoints during their ontogeny (Wardemann et al., 2003) and by various mechanisms that can impact B-cell frequency, BCR signaling responsiveness, and/or BCR specificity (reviewed in Goodnow, Vinuesa, Randall, Mackay, & Brink, 2010; Shlomchik, 2008). Since the late 1980s, Ig transgenic models in which B-cells specific to defined self-antigens, have been engineered from single prerearranged specificities ($V_H DJ_H$ and/or $V_L J_L$ rearrangements) either

randomly integrated into the genome (i.e., conventional Ig transgenic models), or relatively more recently, knocked-in to the IgH and L loci (i.e., site-directed Ig transgenic, a.k.a. knock-in (KI) models), have been invaluable in providing the resolution required to systematically dissect negative selection processes (reviewed in Goodnow, 1992; Kumar & Mohan, 2008). These Ig tg/KI-elucidated mechanisms include central deletion (Erikson et al., 1991; Hartley et al., 1991; Nemazee & Burki, 1989; Okamoto et al., 1992), LC receptor editing (Gay, Saunders, Camper, & Weigert, 1993; Tiegs, Russell, & Nemazee, 1993), V_H replacement (Chen, Nagy, Prak, & Weigert, 1995), peripheral anergy (Goodnow et al., 1988; Goodnow, Crosbie, Jorgensen, Brink, & Basten, 1989), follicular exclusion (Cyster, Hartley, & Goodnow, 1994), and splenic marginal zone or peritoneal sequestration (Hayakawa et al., 2003; Li, Li, & Weigert, 2002; Murakami et al., 1992). What is also clear in these various tg/KI systems is that tolerance is manifested in a gradient of "severity," that has taught us many of the principles of what factors influence in vivo tolerization outcomes, as well as the concept that not all Abs predicted to be auto-Abs by clinical definitions have tolerizing effects in vivo. Below, I will discuss how Ig KI mice, akin to these classic models, but specifically made to express V(D)J rearrangements of several prototypical bnAbs, have been used to formally demonstrate if, and dissect how, negative selection mechanisms limit their production, and more recently, how such models have now become the accepted standard to evaluate the potential role of such processes for newer bnAbs, with several KI models expressing such "second generation" bnAbs (or their precursors/lineage ancestors) now having been developed and currently under analysis, both in the presence or absence of vaccination.

4.1 Initial Work in KI Mice Demonstrating Negative Selection of MPER⁺ bnAb-Expressing B-Cells

Prior to 2009, only a handful of monoclonal bnAbs (2F5, 4E10, 2G12, b12, and Z13e) had been identified. Of these "first generation" bnAbs, only three (2F5, 4E10, and 2G12) expressed naturally derived HC/LC pairs by virtue of having been directly isolated from chronically HIV-1-infected subject peripheral blood mononuclear cells (PBMCs) using classical hybridoma technology, whereas the other two were obtained from phage display libraries of randomly recombineered Abs. Of these three early bnAbs obtained by hybridoma cloning, both 2F5 and 4E10, directed to adjacent linear epitopes in the gp41 MPER, were reported to exhibit

traits that represent strong predictors of negative B-cell selection: significantly elongated and hydrophobic HCDR3s, and in vitro polyreactivity and/or autoreactivity, as determined by immunohistochemical staining of HEp-2 cells and a standard clinically defined autoantigen panel, respectively (Haynes, Fleming, et al., 2005). This led to the hypothesis that induction of bnAb responses was impaired by B-cell tolerance mechanisms (Haynes, Moody, et al., 2005). Analogous to the approaches previously used to test in vivo tolerization of KI B-cells reactive to DNA (Chen, Nagy, Radic, et al., 1995; Erikson et al., 1991), erythrocytes (Murakami et al., 1992; Okamoto et al., 1992), or to artificially introduced self-antigens created via dual KI/tg systems, such as the α-MHC Ig tg/KI + MHC 3–83 tg (Braun, Rajewsky, & Pelanda, 2000; Nemazee & Burki, 1989) or α-hen egg lysozyme (HEL) Ig tg/KI + HEL tg models (Hartley et al., 1991), evidence supporting this hypothesis was first demonstrated in 2F5 $V_H DJ_H$ KI mice, which exhibited profound deletion (∼95%) of B-cells expressing BCRs in bone marrow and a significant majority of the remaining B-cells in the periphery that were anergic (Verkoczy et al., 2010). Subsequently, three independent groups expressed the original (mutated) $V_H DJ_H$ and $V_H DJ_H + V_L J_L$ rearrangements of 2F5 and/or 4E10 (Chen, Zhang, Hwang, et al., 2013; Doyle-Cooper et al., 2013; Finton et al., 2013; Verkoczy, Chen, et al., 2011; Verkoczy et al., 2010) and remarkably, all 2F5/4E10 KI models generated had very similar profound blockades at the pre-B to immature B-cell transition in the bone marrow, characteristic of clonal deletion at the first tolerance checkpoint, and similar to those seen in Ig KI/tg mice expressing high affinity and/or membrane-bound self-antigens (Chen, Nagy, Radic, et al., 1995; Erikson et al., 1991; Hartley et al., 1991; Nemazee & Burki, 1989). The CD4bs-specific monoclonal bnAb b12, the other "first generation" bnAb reported to exhibit in vitro poly-/autoreactivity (Haynes, Fleming, et al., 2005), was found to lack any obvious in vivo tolerizing self-reactivity in KI mice expressing its V(D)J rearrangements (Ota et al., 2013), although the physiologic significance of this finding currently remains ambiguous, since b12's origin from a phage library makes it unclear if a bona fide comparable HC/LC pairing exists in vivo, and additionally, detailed molecular or functional signaling analysis of the peripheral B-cell subsets in these mice was not reported. Nevertheless, this finding does raise the issue of drawing premature conclusions regarding how bnAbs may be controlled by negative selection in vivo, based strictly on readouts of standard in vitro poly-/autoreactivity assays, an issue that will be revisited further in several parts of this review.

4.2 Central Deletion and Other B-Cell Tolerance Mechanisms Observed in bnAb KI Models

Despite the stringency of central deletion observed in 2F5 and 4E10 VDJ + VJ KI mice, it was not found to be complete, as small populations of residual KI B-cells populate the periphery of both models, which could serve as targets for immunization. These residual KI B-cells, however, were found to be limited by additional, secondary tolerance mechanisms, including having poor BCR expression and signaling, characteristic of being anergic (functionally silenced) (Cambier, Gauld, Merrell, & Vilen, 2007), and/or undergoing extensive LC receptor editing events that mitigated self-reactivity and promoted rescue from clonal deletion (Chen, Zhang, Hwang, et al., 2013; Doyle-Cooper et al., 2013; Verkoczy, Chen, et al., 2011). Notably, many peripheral clones remained anergic, despite having undergone an extensive degree of LC editing (Chen, Zhang, Hwang, et al., 2013; Verkoczy, Chen, et al., 2011), which along with the finding that V_HDJ_H, i.e., "HC only" versions of these KI models (in which only V_HDJ_H rearrangements are expressed and thus free to pair with the entire mouse LC repertoire) still exhibited profound deletion and anergy tolerance controls (Chen, Zhang, Hwang, et al., 2013; Doyle-Cooper et al., 2013; Finton et al., 2013; Verkoczy, Chen, et al., 2011; Verkoczy et al., 2010), suggesting that the 2F5/4E10 HC self-reactivities are dominant and thus not efficiently vetoed by LC editing.

In terms of further understanding the tolerance mechanisms controlling bnAb induction, the 2F5 VDJ + VJ strain, as the prototype bnAb KI tolerance model, has been the most extensively studied thus far (Fig. 4), and as such has provided some additional insight into these processes. Specifically, in addition to the processes of deletion, anergy, and receptor editing noted above, further studies have also led to identification of a novel process termed affinity reversion/Ab redemption that represents a "last resort" mechanism for anergic $2F5^+$ B-cells that persist into mature B-cell subsets (including the aforementioned "uneditable" anergic population) for escaping apoptosis via purifying selection (Verkoczy et al., 2013). The same phenomenon has independently been uncovered and elegantly described in a well-controlled set of HEL KI models by Goodnow and colleagues (Sabouri et al., 2014). Recently, evidence for this process in limiting completion of bnAb maturation has been observed in the development of 2F5-like lineages in vaccinated primates (Zhang et al., 2016). Based on these emerging data in support of this process, one hypothesis to account for the high degree of SHM in bnAbs has been proposed, wherein the incomplete

Fig. 4 B-cell tolerance controls in the 2F5 bnAb KI mouse model. Pictorial summary of bnAb regulation and induction studies done in the setting of 2F5 $V_HDJ_H^{+/+} + V\kappa J\kappa^{+/+}$ KI mice. The original (affinity matured) version of 2F5, upon knocking its VDJ/VJ rearrangements into B-cells, fails to pass multiple tolerance checkpoints (Chen, Zhang, Hwang, et al., 2013; Verkoczy, Chen, et al., 2011; Verkoczy et al., 2010). However, while nearly all 2F5[+] B-cells are clonally deleted at the first checkpoint (the pre-imm. B transition), ~5% populate the periphery, but most have been functionally silenced (rendered "anergic"). Among these residual anergic B-cells, a small subset can remove all self-reactivity and escape tolerance altogether, but due to the inability of 2F5 KI LC-targeting receptor editing to remove dominant 2F5 HC self-reactivity, purifying selection occurs later in development, by a T-dependent, SHM-driven process, "Affinity reversion/Ab redemption" (Haynes, Verkoczy, et al., 2014; Verkoczy et al., 2013; Verkoczy & Diaz, 2014). Finally, serum bnAb IgG responses can be elicited in 2F5 KI mice immunized with an MPER peptide–lipid–TLR agonist vaccine regime through reactivation of the unedited (MPER[+]) anergic KI B-cells not yet subjected to purifying selection (Chen, Zhang, Hwang, et al., 2013; Verkoczy, Chen, et al., 2011). *Adapted with permission from Verkoczy, L., Alt, F.W., Tian, M. (2017). Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunological Reviews, 275, 89.*

overlap of bnAb epitopes with self-antigens creates a selection "tug-of-war" during AM: for HIV neutralization affinity, but against self (Haynes, Verkoczy, et al., 2014; Kelsoe et al., 2014; Verkoczy & Diaz, 2014). Since bnAbs appear to utilize tortuous AM pathways to develop breadth during their coevolution with HIV in chronically infected subjects (Mascola & Haynes, 2013), it will now be of interest to explore the relevance of affinity reversion during vaccine approaches for eliciting various bnAb lineages, since such a mechanism, if more universally relevant, would have obvious conceptual relevance in terms of guiding novel immunogen design approaches. In such cases, "escape clones" that have decoupled Env and self-reactivities, i.e., with neutralizing potential, but lacking self-binding, could be identified and used to map Env mutants retaining only residues critical for function, and subsequently used as boosting immunogens, to drive B-cells, once they have been appropriately induced by priming to overcome anergy.

From these studies in 4E10/2F5 KI models, three key, related questions have arisen: (1) Do tolerance controls limit induction of all MPER$^+$ bnAbs? (2) To what extent do they control responses of bnAbs targeting other Env regions? (3) Are they also operational in bnAb precursors and/or intermediates, which as such, at least partially contribute to high SHM levels seen in fully matured bnAbs? Understanding tolerance prevalence across bnAb lineages to distinct Env regions now becomes a critical question for the field, because obtaining such knowledge will be a critical component in defining their relative tractability as potential vaccine targets, specifically with respect to informing as to whether vaccine strategies should either be directed to lineages with no self-reactivity, or alternatively, be focused on modulating tolerance. Based on the studies performed in the "first generation" 2F5/4E10/b12 bnAb KI lines, it is clear such models represent the "gold standard" to now definitively test if and how in vitro self-reactivity physiologically impacts development of "second generation" bnAbs (bnAbs with more potency and/or breadth, and identified in 2009 onwards), and their precursors (before or during immunization), for two reasons. First, as alluded to in the previous section, the presence or absence of bnAb self-reactivity in vitro is often, but not always a predictor of their in vivo tolerization (reviewed in Verkoczy & Diaz, 2014). For instance, false negatives can arise due to self-antigens having restricted expression or affinities sufficient to trigger deletion in vivo (Lang et al., 1996) but below detection in vitro. Conversely, false positives may occur when in vitro reactivities to self-antigens do not reflect those capable of invoking tolerance at physiologically relevant sites of B-cell encounter. Second, because host tolerance occurs in a continuum of developmental checkpoints and processes (Kelsoe et al., 2014; Verkoczy, Kelsoe, et al., 2011) only through analysis via their expression in the setting of Ig KI models can precise mechanisms responsible for limiting bnAb production and most critically, ways to manipulate such processes, be identified, as has been previously done for examining the developmental fates of various auto-Ab specificities.

4.3 Further Evidence of Host Controls in Newer bnAb Precursor KI Strains, and in Other Recent Studies

Although potential in vivo tolerization has only been evaluated for many of the second generation bnAbs or their lineage members, several initial insights have begun to emerge from studies in recently produced KI models

expressing "germline-reverted" or UCA rearrangements from some of these newer bnAbs. One such example is a recent study in which mice expressing 2F5's unmutated ancestor (UA) $V_HDJ_H + V\kappa J\kappa$ rearrangements were generated, and found to be under more profound deletion and anergy controls relative to the original (mutated) 2F5 dKI mice (Zhang et al., 2016), demonstrating in certain instances, high SHM levels in bnAbs can accumulate at least in part due to elimination of self-reactivity. In this particular case, the accumulation of SHM correlated and relative lowering of in vivo tolerization of this bnAb and its UA precursor could potentially be explained by AM to breadth development having focused this bnAb precursor's specificity from one of high initial in vitro polyreactivity/higher lipid affinity (Alam et al., 2011) to specificity for only one (or a few) self-antigen(s). A second recent example where the impact of expressing a second generation bnAb precursor on B-cell development has been evaluated is a study in which a gl-3BNC60 VDJ + VJ KI model, coexpressing V germline-reverted V_HDJ_H and V_LJ_L rearrangements of 3BNC60, a "CD4 mimic" VRC01-class CD4bs bnAb (McGuire et al., 2016). In this strain, KI B-cells were partially deleted in the bone marrow, and peripheral cells were either anergic or exhibited extensive editing of their gl-3BNC60 VJ rearrangement via secondary rearrangements of their λLC locus. Most recently, the effect of expressing another second generation bnAb precursor, isolated from the prototype "HCDR3-binder" CD4bs bnAb lineage, CH103, on B-cell development was evaluated (Williams, W., Haynes, B., & Verkoczy, L., manuscript submitted). In this VDJ + VJ model, similar to the 3BCN60 GL_{HL} (VDJ + VJ) KI strain, partial clonal deletion was observed, but with this particular bnAb specificity, deletion occurred at the second tolerance checkpoint (i.e., the transitional to mature B-cell stage), and the mature B-cell subset was predominantly comprised of naïve B-cells that had undergone receptor editing of their knocked-in UCA CH013 LCs. Interestingly, the fraction of remaining clones that did manage to retain both their HC + LC KI alleles (and thus were anergic), represented a very minor subset, <10% and 0.5% of the mature subset in homozygous and heterozygous versions of this strain, respectively, suggesting LC editing was the major tolerance mechanism in this model. Interestingly, LC editing also appeared to be highly restricted (predominantly to a single Vκ family), reminiscent of the "medium-affinity" version within the 3H9 anti-DNA series of Ig KI models, 3H9/56R (Li et al., 2001, 2002), suggesting that while editing could veto CH103 self-reactivity, it could only do so with a highly restricted set of "LC editors."

In contrast to these two reports, $V_H1–2$/KI mice expressing the unrearranged germline segment $V_H1–2$, found in all members of the VRC01 bnAb class, when paired with the VRC01 germline V_LJ_L rearrangement did not have any defects in B-cell development. However, a robust vaccine regimen tailored for optimal priming and with a rational sequential boosting strategy (discussed in detail further below) could only induce partial maturation of VRC01-like precursors, with serum neutralization activity of mutant viruses (lacking key CD4bs-proximal glycans), but not of WT (glycan-containing) ones (Tian et al., 2016). Since the VRC01 antibody, although lacking polyreactivity in protein arrays, has high avidity for the conserved ligase UBE3A, like several other CD4bs[+] bnAbs (Liu et al., 2015), it remains to be seen if this vaccine-guided maturation blockade is a result of negative selection (possibly UBE3A-mediated) in the GC reaction. Interestingly, the VRC01 and 3BNC60 lines express the same $V_H1–2$ segment as well as the same 5-aa-LCDR3 residues, despite their marked preimmune developmental differences (i.e., precursor VRC01 with normal B-cell development and precursor 3BNC60 exhibiting deletion, anergy, and editing), implying their notably different LC Vκ segments, i.e., Vκ3–20 and Vκ1–33, respectively, may specify these distinct developmental/selection fates. Nevertheless, more generally, these data provide evidence that the processes of B-cell elimination, silencing, or modification apply not only for all MPER[+] bnAbs tested thus far in vivo, but also most (if not potentially *all*) predecessors of CD4bs[+] bnAbs evaluated to date, at some point in their development, either before or during vaccination.

Equally important developments have also emerged from two key new studies performed in settings other than KI models, which further support findings of considerable tolerance prevalence across bnAb lineages. In one of these studies, a protein array of ∼9400 host proteins was used to screen a large array of HIV Abs (including many second generation bnAbs directed to the four major Env epitope clusters) for off-target binding, and found >2/3 were poly-/autoreactive (Liu et al., 2015), including two of the most potent and broad ones, the MPER[+] bnAb 10E8 and the CD4bs-specific bnAb VRC01, both for which self-reactivity was not originally detected in standard in vitro assays (Huang et al., 2012; Wu et al., 2010; Zhou et al., 2010). Importantly, only one nonneutralizing HIV Ab tested in this assay exhibited polyreactivity, suggesting poly-/autoreactivity is a property of bnAb functional specificity rather than a byproduct of the inflammatory/dysregulation milieu that typifies longer-term chronic HIV-1 infection

(Haynes, Moody, Liao, Verkoczy, & Tomaras, 2011; Moir & Fauci, 2013).
Also consistent with host controls limiting many (or most) bnAbs is a new
study providing direct evidence in support of the corollary that bnAbs
should be more easily generated in autoimmune patients (due to defective
central and/or peripheral tolerance checkpoints), a concept that is consistent
with anecdotal observations of disproportionately low frequencies of SLE^+
patients also having HIV infection (Barthel & Wallace, 1993; Calza et al.,
2003; Kaye, 1989; Mylonakis et al., 2000; Palacios, Santos, Valdivielso, &
Marquez, 2002). In this new, comprehensive study, two HIV-infected
cohorts differing in their abilities to produce bnAbs were compared, and rel-
ative to matched subjects that failed to generate bnAb responses, those mak-
ing bnAbs had significantly higher frequencies of circulating plasma auto-
Abs, higher numbers of $CD4^+$ T follicular helper cells and lower numbers
of T regulatory cells, the latter which also have higher levels PD-1 expres-
sion that has also been associated with impaired regulatory capacity (Moody
et al., 2016).

Thus, considerable data are mounting for the role of B-cell tolerance in
limiting bnAb development, and taken together with the above recent
cohort comparison study, points to a rational path forward for vaccine
development that not only considers immunogens capable of recreating
(and likely needing to improve on) the viral events occurring during nat-
ural infection, but adjuvant formulations that can also simulate the
relevant immune perturbations identified in some individuals during
chronic infection. In the two sections below, some early studies in bnAb
KI mice and other animal models, aimed at overcoming negative B-cell
selection in order to enhance suboptimal (b)nAb responses to HIV-1, will
first be reviewed, followed by discussing newer tolerance checkpoint inhi-
bition strategies, either using mAbs and/or small molecule inhibitors
(SMIs) under consideration for carrying such types of studies in a more
directed fashion.

4.4 KI Mice as Models to Identify Strategies to Break bnAb Anergy

As just discussed above, from accumulating data in multiple bnAb KI
models, it appears many, if not most bNAb lineages (even some found ini-
tially to lack in vitro poly-/autoreactivity, e.g., 3BNC60) will be limited by
the various B-cell tolerance controls at some point in their evolution.
Assuming tolerizing self-reactivity of bnAbs is indeed a prevalent issue

(i.e., present in bnAbs against multiple Env targets, and/or at key branchpoints in common maturation pathways of many lineages), then several major questions now emerge for understanding how to induce bnAbs. Two key, related ones are: (1) Can bnAb self-reactivity can be overcome by vaccine strategies? (2) If so, can inducing them by vaccination be done safely? With respect to the first question, a common theme emerging from studies in 2F5 UA, gl-3BCN60 VDJ + VJ KI, and now, CH103 UCA VDJ + VJ mice, is that although B-cells that express bnAb precursors as BCRs appear to often be tolerized even prior to vaccine-driven maturation (McGuire et al., 2016; Zhang et al., 2016), it is nevertheless encouraging that not all such B-cells are culled early in development by clonal deletion. This results in residual anergic KI$^+$ B-cell populations that persist in peripheral tissues at various developmental stages, and thus are available for vaccine regimens to target/reactivate. However, this is not trivial to do, since anergic B-cells are preferentially selected against by immunization-mediated exclusion (Cyster et al., 1994). Furthermore, it is now becoming better appreciated that B-cell anergy itself, does not manifest as a single discrete phenotype, both in terms of stages at which it can potentially occur and the phenotypic and functional heterogeneity of the B-cells it functionally silences (Cambier et al., 2007). Thus, the potential reversibility of BCR unresponsiveness of various anergic B-cells populations to immunization may vary. Finally, reversing anergy does not preclude reactivated self-reactive B-cells from having their self-mimicking Env specificity eliminated by some of the V(D)J-modifying processes discussed above, and thus, depending on the stage in B-cell development at which anergy is broken, this can involve preferential selection for clones bearing BCRs that either have undergone receptor editing (Doyle-Cooper et al., 2013; Verkoczy, Chen, et al., 2011; Zhang et al., 2016), and/or in the case of those in mature B-cell compartments specifically, which have been subjected to purifying selection via SHM-targeted elimination of self-antigen binding Ab residues, i.e., Ab redemption/affinity reversion (Sabouri et al., 2014; Verkoczy et al., 2013).

Previous studies examining signals required to overcome B-cell unresponsiveness in the prototypical series of α-HEL + soluble HEL anergy KI/transgenic models have shown that addition of stronger or more specific T-cell help (Sekiguchi et al., 2002; Seo et al., 2002) and/or higher avidity (multimeric) BCR signals (Cooke et al., 1994; Goodnow, Brink, & Adams, 1991) to enhance B-cell survival (in adoptive transfer settings where such signals are normally limiting), can reactivate anergic B-cells to secrete class-switched Abs, and other studies have similarly shown that BCR/TLR

coligation can trigger residual anti-DNA$^+$ self-reactive peripheral B-cells (Chaturvedi et al., 2008; Lau et al., 2005; Leadbetter et al., 2002; Marshak–Rothstein & Rifkin, 2007). Interestingly, two recent studies performed in wild-type mice have demonstrated that overall anti-HIV Ab responses can be enhanced, when Env immunizations are carried out in the presence of cytokines capable of providing strong costimulatory signals and/or enhanced peripheral B-cell survival (Dosenovic et al., 2012; Gupta et al., 2015). In one of these studies, preadministration with BAFF/BlyS resulted in increased frequencies of self-reactive B-cells that was accompanied by increased potencies of tier 1 serum nAb responses to Env gp120 immunization (Dosenovic et al., 2012). In the other study, DNA vectors expressing multimerized BAFF or APRIL, when added to an Env gp140 + IL-12 immunization regimen, induced more robust GCs and modestly enhanced autologous tiers 1 and 2 serum nAb titers (Gupta et al., 2015). However, due to the limitations of performing immunization studies in wild-type mice I discussed earlier, related both to the restrictions imparted on potential bnAb responses by murine immunogenetics and the current subdominance of serum bnAb responses in fully polyclonal settings, (and including Env specificities of Ab responses in these studies being cumulative and variable) it could not be ascertained if or how individual bnAb lineages were initiated by such modified vaccine regimens.

In bnAb KI studies, where it is possible to evaluate specific effects of anergy-targeting vaccine regimens on the development of individual bnAb lineages, results have begun to provide proof-of-principle that self-reactivity of bnAbs (or their precursors) can indeed be overcome by immunization. In gl-3BCN60 VDJ + VJ KI mice, McGuire et al. found that anergic KI$^+$ cells could be reactivated, but only when 426c.TM4ΔV1–3, a soluble GL-targeting gp140 immunogen, was highly multimerized (McGuire et al., 2016), thus recapitulating previous findings of the experimental anergy models, such as in various anti–HEL tg/KI strains, in which particulate HEL antigens can reactivate anergic B-cells that soluble HEL failed in doing so (Goodnow et al., 1991; Sabouri et al., 2014). However, even with this modification, the gl-3BNC60 V(D)J rearrangements underwent almost no SHM. Likewise, in 2F5 UA VDJ + VJ KI mice, Zhang et al. demonstrated that a residual anergic KI$^+$ B-cell subset could be targeted for expansion/activation by a vaccine regimen comprised of MPER peptides, when conjugated to liposomes and formulated with TLR agonists, but these expanded clones underwent minimal immunoglobulin CSR and SHM (Zhang et al.,

2016). This raises the possibility that in both models, additional signal(s) may be required to activate a T–dependent response. Interestingly, Verkoczy et al. previously found this same MPER peptide/liposome/TLR agonist regimen was also capable of inducing residual anergic dKI$^+$ clones in original (matured) 2F5 VDJ + VJ mice to produce high (mg/mL) titers of serum bnAb IgGs (Fig. 4) (Verkoczy et al., 2013). However, unlike 2F5 UA KI$^+$ cells, they were able to undergo class switching (possibly due to being under less profound tolerance controls (Zhang et al., 2016) and/or the mature 2F5 Ab having higher affinity for the MPER epitope than the 2F5 UA Ab; Alam et al., 2011). It is noteworthy that despite the considerable class switching observed by vaccine-mediated reactivation of 2F5 mature KI$^+$ anergic B–cells, this was genetically demonstrated to occur via a T–independent pathway (Verkoczy et al., 2013), suggesting T–cell help and/or BCR signals were insufficient for activating 2F5 mature dKI$^+$ B–cells, and to an even greater degree, 2F5 UA dKI$^+$ B–cells. Notably, while this earlier study also found that both presentation of the MPER 2F5 bnAb epitope in liposomes and TLR adjuvanting were critical to break anergy (Verkoczy et al., 2013), it did not ascertain if this was due to antigen multimerization in combination with TLR coligation (thus working as a classic type 2 T–independent immunogen), or if more specific components in the regimen were involved. One clue supporting the latter possibility has come from follow–up studies that further dissected the regimen, in which specific presentation of the MPER peptide in liposomes, i.e., in an orientation designed to mimic the epitopes as they would be expressed on HIV–1 virions (in contrast to general multimeric display), and only with the TLR–4 agonist monophosphoryl lipid A (vs other TLR agonists tested), were both key to reverse the anergic state of peripheral 2F5 dKI$^+$ B–cells and for the induction of high serum bnAb IgG titers in 2F5 and 4E10 VDJ + VJ mice (Bouton-Verville, H., Verkoczy, L., et al., manuscript in preparation; Chen, Zhang, Bouton-Verville, et al., 2013), suggesting a key, specific role for lipid components in overcoming anergy of MPER$^+$ bnAbs. An intriguing remaining question regarding overcoming MPER bnAb anergy is whether strength of T_H priming and degree of tolerization are related (i.e., Is stronger and/or more specific T–cell help required to fully reactivate and drive maturation of more profoundly anergic bnAb precursors?), an issue that can now be rigorously examined via parallel evaluation of priming strategies in mature 2F5 KI and 2F5 UA KI models. More generally, it will also be of interest to understand if signals for triggering anergic KI cells in the

gl–3BCN60 and 2F5 UA KI models are similar to those potentially needed to reactivate bnAb precursors targeting other Env regions.

4.5 Testing More Targeted Tolerance Checkpoint Modulation Approaches in bnAb KI Mice

4.5.1 Modulation of Peripheral bnAb Tolerance Using CD4 T-Cell Inhibition Therapy

Many of the same genes and molecular signaling pathways that control the negative selection checkpoints involved in vetting self-reactive B-cells (Fig. 4) including clones expressing bnAbs (and/or their predecessors), have considerable overlap with those involved in tumor suppression (reviewed in Goodnow, 2007). Since many drugs targeting checkpoint survival genes and differentiation pathways have been developed by the cancer field in the clinical setting, then therapies involving inhibitors of such checkpoints, by extension, could also be available for use to more transiently modulate distinct B-cell tolerance checkpoints that prevent bnAb maturation, either prior to or during HIV immunization. Many of these more successful approaches tried thus far for cancer (i.e., which have resulted in significant clinical advances, and in many patients has elicited long-term clinical benefits) are immune checkpoint therapies that target regulatory pathways limiting T-cell proliferation and enhanced immune responses to malignancies (Sharma & Allison, 2015a, 2015b), and as such, are most relevant for peripheral B-cell tolerance checkpoints. Following the lead of these more effective cancer treatments, HIV-1 vaccine immunogens using such treatment regimens have therefore now begun to be carried out in both macaques, and in models with more pronounced, selective tolerization at the second tolerance checkpoint (transitional to mature B-cell stage) and/or even later during the GC reaction (Kelsoe, G., Haynes, B., & Bradley, T., personal communication). In this regard, CH103 UCA dKI and gl-3BNC60HJ (VDJ + VJ) mice would be good initial readouts for testing such approaches. Examples of such "modified" HIV-1 regimens include those using Abs previously used in cancer therapeutics, namely Abs against CTLA-4, the programmed death-1 receptor, i.e., PD-1, and the IL-2 receptor α-chain, i.e., CD25 (Belkaid & Tarbell, 2009; Chambers, Kuhns, Egen, & Allison, 2001; Sharma & Allison, 2015a, 2015b). Although both functionally complicated, CTLA-4 and PD-1 are believed to have nonoverlapping modes of action: while CTLA-4 is generally thought to inhibit costimulation (Chambers et al., 2001; Teft, Kirchhof, & Madrenas, 2006), PD-1 works by differentially interfering with signals mediated through the T-cell receptors

(TCR) which on conventional T-cells, results in delivery of inhibitory signals, while on T_{regs}, enhance proliferation and survival (Keir, Butte, Freeman, & Sharpe, 2008; Sharpe, Wherry, Ahmed, & Freeman, 2007). Thus, if the main goal of bnAb–potentiating vaccine strategies is to increase survival of peripherally tolerized mature follicular B-cells, then one class of regimens appropriate for doing so could be ones that include anti-CTLA-4 and anti–PD-1 checkpoint inhibitors, whose predicted single (or combined) actions in the context of peripheral B-cell tolerance, should be to enhance T helper cell activity, either in T-cell zones to promote early B-cell recruitment and expansion, or later during GC responses, to increase T_{FH} activity. Similarly, appropriately administered anti-CD25 treatment should allow preferential depletion of T_{reg} and T_{FReg} populations (Belkaid & Tarbell, 2009). Thus, if the goal of a modified "bnAb–potentiating" vaccine strategy is alternatively (or additionally), to prolong vaccine-induced AM of bnAb lineages in GCs, for example during late boosts in sequential-based regimens (detailed further below), then another type of modified "checkpoint-modulating" HIV regimen could be one transiently employing antibodies to CD25, in order to reduce T_{Reg} and T_{FReg} numbers.

4.5.2 Next Generation of Peripheral bnAb Tolerance Modulation: SMI-Based Regimens

While proving successful in cancer treatment, the above strategies may nevertheless have various unintended, off-target effects, which in the setting of a preventative HIV-1 vaccine, would not pass the higher bar in terms of safety considerations. However, even were such approaches not practical for clinical vaccine trials, they will still contribute to our emerging understanding of why even the best HIV immunogens and regimens available still fall well short of eliciting significant protective responses. Meanwhile, the search for more selective, ancillary small molecule inhibitor (SMI) strategies that can be administered locally (thus further reducing the likelihood of inducing off-target effects that systemic administration may evoke), should be aided by ongoing discovery of new signaling pathways and transcription factors involved in GC, memory, and plasmacyte formation. Ultimately, to further specify and/or potentiate the precise delivery of such SMIs, administering them in B-cell subset targeting or more potent DNA/RNA platforms also under development by several groups could be used, and timing of their administration during vaccination will likely also likely be critical. Also noteworthy for all these endeavors is that they will require highly iterative testing, which are thus

likely to best be done in appropriate bnAb KI models. As discussed in the previous section, distinct versions of such models are now emerging from several groups, which truly embody prototypes for different checkpoint blockades of distinct types of bnAb lineages, and many more will be reported shortly; thus an ample "arsenal" of bnAb models is anticipated to be available for such testing. Finally, several interesting candidates have been recently identified, having potentially key roles in the still poorly understood molecular programs of GC formation and selection involving the finer precise aspects of GC entry, duration, and exit as well as Tfh differentiation/activation, and thus for which developing novel, more selective SMIs/activators and their subsequent iterative testing will be highly significant. Examples of such factors include molecules implicated in the GC program, such as IRF4 and IRF8, transcriptional regulators of the GC/plasmacyte axis master switches bcl6 and Blimp-1 (Klein et al., 2006; Lee et al., 2006; Sciammas et al., 2006), the AID-associated GC-restricted GTPase "SLIP-GC" (Richter et al., 2009, 2012), the GC-associated nuclear protein "GANP" (Kuwahara et al., 2004, 2001; Sakaguchi et al., 2005; Singh et al., 2013), and other novel molecules involved in the Tfh differentiation program, like Activin (Locci et al., 2016).

4.5.3 SMI-Based Strategies for Modulating Central bnAb Tolerance

As with the SMI-based strategies noted above for releasing bnAb[+] B-cells from peripheral tolerance controls, those that precisely target genes regulating pathways involved in the central (first) tolerance checkpoint could also be used, specifically in strains like 2F5 dKI mice, the prototypical central tolerance model (Fig. 4), or in other newer KI models that will be emerging, with similar tolerization-associated developmental blockades in the bone marrow. Two current studies using SMIs aimed at releasing bnAb[+] B-cells from central tolerance controls, in order to increase the frequency of bnAb precursors in the available naïve repertoire, are underway. In one study, promising results have just been reported in which transient use of the SMI hydroxyl-chloroquine, a compound already FDA-approved for malaria treatment, has been used to modulate a newly identified axis involved in central tolerance, the BCR/Myd88/AID pathway (Kuraoka et al., 2017). In this study, the goal was to exploit the synergy between BCR and MyD88 signaling required for maintaining central B-cell tolerance and the knowledge that intracellular acidification is a necessary step in activating intracellular TLR signaling. Thus, to overcome Myd88/AID-mediated central tolerance, mature, and UA 2F5 dKI mice were treated with a

7-day regimen of hydroxy-chloroquine, an inhibitor of the key TLR acidification step, which markedly relaxed bnAb$^+$ B-cell tolerance, as manifested by significantly increased numbers of transitional, mature follicular, and marginal zone 2F5 KI$^+$ B-cell subsets. In another study currently underway (Verkoczy, L. in collaboration with Haynes, B., & Kelsoe, G., personal communication), inhibitors of the PI3K signaling axis, another central tolerance/ positive selection switch (wherein PI3K has been shown to be key for positively selecting immature bone marrow B-cells; Llorian, Stamataki, Hill, Turner, & Martensson, 2007; Verkoczy et al., 2007), are being evaluated. Specifically, various SMIs selective for downstream negative effectors of PI3K (Benhamou et al., 2016; Coffre et al., 2016; Verkoczy et al., 2007), including those targeting *foxo1*, a transcription factor which plays a key role in promoting RAG expression required for LC receptor editing (and thus impeding positive selection) (Amin & Schlissel, 2008; Chow, Timblin, McWhirter, & Schlissel, 2013), are under investigation, for their abilities to increase 2F5 KI$^+$ B-cell frequencies and BCR signaling responsiveness. The recent identification of specific microRNAs regulating central tolerance signaling pathways (Coffre et al., 2016; Gonzalez-Martin et al., 2016; Lai et al., 2016), including the PI3K/foxo1 pathway (Coffre et al., 2016), presents yet another potential layer of transient manipulation that similar molecule-specific strategies could exploit in the near future.

4.6 KI Models for Testing Pathogenicity of bnAbs Targeting Self-Mimicking Env Epitopes

As we noted above in Section 4.1, Ab poly-/autoreactivity, as defined by in vitro assays often, but not always correlate with in vivo tolerizing activity. This assertion is borne out by the presence of natural pools of B-cells that would be defined as polyreactive and/or autoreactive by standard clinical assays in all healthy individuals, including an estimated 20% of the mature naïve B-cell repertoire circulating in blood (Wardemann et al., 2003). Such "acceptable" in vitro poly-/autoreactivity is also harbored by a large fraction within reservoirs of more specialized mature B-cells such as the peritoneal B-1 (Hardy, 2006) and splenic marginal zone (Martin & Kearney, 2002) compartments, the latter in particular also shown to be enriched for specificities resembling precursors of some bnAbs such as the VRC01 class (Pujanauski, Janoff, McCarter, Pelanda, & Torres, 2013). Furthermore, there also exist examples of mAbs clinically identified as auto–Abs, that have been subsequently shown to have no effect on B-cell ontogeny when transgenically expressed in mice as BCR specific for the Pemphigus autoantigen,

DSG3 (Ota et al., 2004) or the La antigen of SLE (Aplin et al., 2003). Conversely, and more likely the case (due to current technical and theoretical limitations with relevant detection methodologies) Abs with tolerizing specificities could be missed in screens using standard autoantigen panels, including ones exhibiting tissue-specific expression, or with ultra-low in vitro affinities to effect tolerance controls in vivo. Examples of such Abs include those knocked-in or transgenically introduced as BCRs specific for physiological antigens like erythrocytes (Murakami et al., 1992), pancreatic insulin B-islets (Rojas, Hulbert, & Thomas, 2001), IgG2 (Wang & Shlomchik, 1997), ATA determinant, i.e., glycosylated Thy-1 (Hayakawa et al., 2003), and Goodpasture antigen α3 collagen (Zhang et al., 2008).

A related concept to the one above, namely that in vitro poly-/autoreactvity of Abs does not always evoke in vivo tolerization, is that self-reactive Abs capable of evoking B-cell deletion/anergy do not necessarily trigger pathogenic effects, even after have undergone IgG-switching and/or extensive SHM. However, since accumulating data in multiple bnAb KI model studies predicts many (if not most) bNAb lineages (even those lacking detectable in vitro poly-/autoreactivity, e.g., 3BNC60) will most likely be limited by various B-cell tolerance controls, at some point in their evolution, it will be critical to know which lineages capable of generating breadth pathogenic, in order for their safe elicitation by vaccine strategies. In this regard, bnAb KI mice, which have already proven to be especially powerful platforms to dissect the fate of bnAb lineages in various immune tissues and to test if and how to reactivate tolerized bnAb lineage members, can now also be used, along with more powerful in vitro screening methodologies to evaluate their polyreactivity vs autoreactivity, such as by protoarray (Bonsignori et al., 2014; Liao, Lynch, et al., 2013; Liu et al., 2015; Yang et al., 2013) and PhIP-Seq library analysis (Finton et al., 2013; Larman et al., 2011), to better understand what types of reactivated self-reactive bnAbs may be more problematic, in terms of any potential adverse pathogenic effects. Ultimately, these types of platforms can also be used to directly test for any negative, off-target physiological effects of any promising bnAb lineage already studied in such models.

An example of the utility of bnAb KI models for the purposes noted above, is a series of studies done in the related, original (affinity matured) 2F5 and 4E10 dKI models. Specifically, two earlier studies have found that 2F5 and 4E10 exhibit vastly different in vitro self-reactivity profiles, despite their proximal epitopes in gp141 MPER. In an earlier study, 4E10 was found to exhibit substantially higher reactivity to lipids than does 2F5

(Haynes, Fleming, et al., 2005). In a later study, using more comprehensive screening of 9500 host proteins using protein arrays (Yang et al., 2013), 4E10 was found to not only have strong affinity for an RNA splicing factor, splicing factor 3b subunit 3 (SF3B3), but also exhibited exceptionally broad polyreactivity, while 2F5 demonstrated no/minimal polyreactivity, but instead, had high, specific affinity for kynureninase, a highly conserved candidate autoantigen involved in tryptophan metabolism, that represents the only known protein to contains an epitope in its α–helical H4 domain that is an exact sequence mimic of the linear 2F5 minimal epitope specified by the ELDKWA motif found in the gp41 MPER ectodomain. Notably, the specific in vivo tolerization patterns observed in the 2F5 and 4E10 dKI models also appeared to mirror the differential in vitro reactivities identified for these two bnAbs (Chen, Zhang, Hwang, et al., 2013). In particular, LC editing selectively mediated removal of the 2F5 MPER epitope in peripheral follicular B-cells of mature 2F5 dKI mice, whereas it preferentially targeted polyspecific/lipid binding (over MPER epitope binding) in those from 4E10 mature dKI mice. Also of note, induction of serum Abs to the 4E10 epitope in MPER has proved more difficult than inducting those directed to the 2F5 epitope, upon immunization with similar MPER–liposome-based regimens, in several experimental animal models, including opossums, 2F5/4E10 dKI mice, and in rhesus macaques (Bouton-Verville, Verkoczy, et al., manuscript in preparation; Yang et al., 2013; Zhang et al., 2016), further suggesting disparate in vivo outcomes by vaccination for inducing nAbs directed to these related epitopes.

Of the highest relevance, however, is that in addition to the consequences of the distinct in vitro self–reactivities these related MPER^{+} bnAbs effect on tolerization and immunization, they have now also been found to distinctly impact pathogenicity. In particular, while significant lupus anticoagulant activity and blocking effects in clotting tests has been reported for 4E10 in vitro (likely at least partly resulting from its strong reactivity to cardiolipin), none was reported for 2F5 (Li et al., 2011). Furthermore, when passively administered to humans, 4E10 was biologically active and exhibited prolonged partial thromboplastin and prothrombin times in vivo, whereas no obvious clinically adverse effects were reported in passive infusions with 2F5 (Vcelar et al., 2007). Thus, while 4E10 has clearly been demonstrated to have negative physiologic effects both in vitro and in vivo associated with its broad polyspecificity and affinity for lipids, 2F5 did not appear to have any such effects in similar assays. However, any other off-target effects resulting from its induction could not be ruled out in these

earlier studies, given that its specificity for kynureninase had not yet been determined, nor had it's the physiological significance of its autoreactivity been examined in a vaccination setting. Remaining concerns about eliciting 2F5-like bnAbs as a safe vaccine target have largely been alleviated in a recently completed pathogenicity study performed in both the 2F5 mature dKI model and in rhesus macaques immunized with the MPER–liposome regimen (Bradley et al., 2016). In this report, despite elicitation of high circulating plasma IgG 2F5 in 2F5 dKI mice or 2F5-like kynureninase cross-reacting Ab titers in the nonhuman primates, no associated autoimmune disease were seen in either model. Furthermore, no disruptions in kynureninase enzyme activity or tissue tryptophan metabolism were observed in blood or in numerous tissues assessed, including the brain, indicating the 2F5 bnAb's inherent autoreactivity does not induce tissue damage in vivo.

As has been previously noted (Haynes, Moody, et al., 2005; Kelsoe et al., 2014), host mimicry by HIV-1, for example, involving 2F5's linear MPER epitope with kynureninase (Yang et al., 2013), provides a powerful method of concealing its vulnerable bnAb epitopes. Such epitopes essentially "hide in plain sight," via the various selection processes that purge the very B-cells required for protective immunity, i.e., those acquiring bnAb specificities. Thus, in addition to their clinical relevance in confirming nonpathogenicity of bnAbs reactive for self-mimicking Env epitopes (e.g., 2F5), studies in mature versions of bnAb KI models (e.g., the "original" 2F5 dKI strain noted above), in combination with host protein arrays for defining physiologically distinct outcomes of 4E10 and 2F5 self-reactivities, also raise some fundamental questions for HIV vaccinology, regarding both prevalence of HIV host mimicry at different bnAb epitope clusters in Env, and the potential relationship of any such mimicry with pathogenicity.

First, regarding the prevalence of HIV mimicry, other potential bnAbs in addition to 2F5, have no/minimal polyspecificity but conserved autoreactivity, such as the high affinity many of the CD4bs[+] bnAbs have with UBE3A ligase (Liu et al., 2015). It remains to be seen if these examples only represent the tip of the iceberg. Indeed, antigenic mimicry of mammalian host structures has been described as an effective evasion mechanism for many bacterial and fungal pathogens (reviewed in Patel & Kearney, 2016), including some bacterial examples such as neuronal ganglioside mimicry by bacterial liposoligosaccharides (LOS) from *Campylobacter jejuni* strains (Bowes et al., 2002; Yu, Ariga,

Usuki, & Kaida, 2011), Lewis blood antigen group mimicry by LOS of *Helicobacter pylori* strains (Appelmelk et al., 1996), and mimicry by the adhesin FimHI (expressed on fimbriated bacteria) of lysosomal membrane protein-2 (LAMP-2) (Kain et al., 2008). Furthermore, many of these examples involve bacterial mimicry of glycan-dependent epitopes, which thus implies HIV mimicry may not just be relevant to MPER and CD4bs$^+$ bnAbs, but given the unusual degree of glycosylation that Env uses to cloak many of its vulnerable sites (Burton & Hangartner, 2016; Pantophlet & Burton, 2006), this likely extends to the V2 and V3 glycan-dependent bnAb epitope clusters in Env. One potential vaccine strategy based on exploiting glycan mimicry to break tolerance of cross-reactive bnAb epitopes in such potential regions has been one identifying the striking similarities of rhizobial LOS backbone with mammalian oligomannose (Clark et al., 2012), which was demonstrated structurally by a crystal structure of the glycan-dependent bnAb 2G12 with this bacterial structure (Stanfield, De Castro, Marzaioli, Wilson, & Pantophlet, 2015). One potential logistic issue with vaccine strategies that exploit HIV mimicry, however, is the previously discussed concept of affinity reversion/Ab redemption (Haynes, Verkoczy, et al., 2014; Sabouri et al., 2014; Verkoczy et al., 2013; Verkoczy & Diaz, 2014), since the cross-reactivity of Ab specificities generated by AM in the GC reaction are likely to be close between the relevant self- and foreign antigens, and thus could result in especially protracted rounds of "conflicted selection." Thus, appropriate boosting for such approaches will not only require highly detailed knowledge of what these precise overlaps between self and nonself-antigens are, but also highly iterative in vivo platforms like bnAb KI models for testing immunogens designed based on such considerations.

Second, regarding the issue of HIV mimicry and potential pathogenicity, it is tempting to speculate that other bnAbs, similar to 2F5, with more directed, HIV mimicry-associated specificity (and as opposed to bnAbs with more general "off-target" polyreactivities like 4E10), may have higher likelihoods of also lacking pathogenicity. However, not all host-resembling epitope expression by pathogens may be devoid of inducing "off-target" physiologic effects, as in some cases, such microorganisms have been implicated (albeit somewhat loosely) in autoimmunity development (Cusick, Libbey, & Fujinami, 2012). Nevertheless, this again points to the importance of testing pathogenicity on a "case-by-case" basis, for any bnAbs lineage for which a viable vaccine strategy based on HIV mimicry can be developed,

using relevant bnAb KI models expressing such specificities. Since many more such models are now being made due to the emerging high-throughput technology (discussed further below in Section 6), this additional, relevant layer of testing should become rather routine.

5. bnAb KI MODELS FOR TESTING NEW HIV VACCINE STRATEGIES

5.1 The Advent of bnAb Precursor-Targeting Immunogens

A potentially key roadblock which has been identified for HIV vaccine design, and for inducing bnAbs in particular, has been the observation that most recombinant Env immunogens the field has been generating and testing up until relatively recently, interact suboptimally with unmutated ancestor or experimentally reverted "precursor" versions of original (affinity matured) bnAbs (Haynes, Kelsoe, et al., 2012; Hoot et al., 2013; Mascola & Haynes, 2013; Ota et al., 2012; Xiao et al., 2009). This has led to the hypothesis that most naïve B-cells in the preimmune repertoire, which express unmutated precursor bnAbs as BCRs, fail to be activated by such immunogens, because they either fail to engage them altogether, or bind them at affinities that in theory, would be insufficient for priming them in vivo (Dal Porto, Haberman, Kelsoe, & Shlomchik, 2002). A related hypothesis is that Env immunogens in nonnative forms not only bind bnAbs at insufficient affinities, but also lack adequate specificity for them, instead binding multiple other "off-target" paratopes on competing naïve B-cell clones (Mascola & Haynes, 2013; McGuire et al., 2014; Pantophlet & Burton, 2006; Wu et al., 2011). Thus, to overcome these limitations, considerable efforts by several groups in the last few years have been placed on designing immunogens that can specifically target and engage precursors of various bnAb classes (Alam, Dennison, et al., 2013; Alam, Liao, et al., 2013; Andrabi et al., 2015; Bhiman et al., 2015; de Taeye et al., 2015; Gorman et al., 2016; Hoot et al., 2013; Jardine et al., 2013; Kwon et al., 2015; Liao, Bonsignori, et al., 2013; Liao, Lynch, et al., 2013; Ma et al., 2011; McGuire et al., 2013; Sanders et al., 2015; Sliepen et al., 2015).

Several types of approaches have been employed in designing such "bnAb priming" immunogens. One of the two original strategies has been to use time-of-infection information from longitudinal sampling (Bhiman et al., 2015; Liao, Lynch, et al., 2013), in particular, using the Env of the TF which binds the bona fide UCA of a given HIV-1-infected subject's

coevolved bnAb lineage, as the template from which the priming immunogen is generated. While this concept of deriving "natural" Env priming immunogens from a given bnAb coevolved lineage's TF virus was first described for the "HCDR3-binder" CD4bs bnAb lineage CH103 (Liao, Lynch, et al., 2013), similarly derived priming immunogens for other lineages have now also been described, including the CH103-cooperating "CD4 mimic" CD4bs bnAb lineage CH235 (Bonsignori et al., 2016; Gao et al., 2014) and the V1V2/glycan-directed bnAb lineage VRC26–CAP256 (Bhiman et al., 2015; Doria-Rose et al., 2014). The alternative, original strategy proposed for developing bnAb precursor-priming immunogens is a "reverse engineering" approach, which involves a combination of in vitro mutation/selection and in silico computational methodologies to synthetically engineer candidate immunogens capable of binding multiple precursors and mature BCRs within a given bnAb "class," i.e., directed to a common bnAb epitope cluster in Env (Jardine et al., 2013; McGuire et al., 2013). Thus far, such "germline-targeting" (GT) immunogens have been experimentally generated for the "VRC01/CD4 mimic" class of CD4bs bnAbs, based on this reverse engineering approach, and thus far, among all the candidate bnAb precursor-directed immunogens, have also been the most extensively evaluated, in terms of their ability to prime and B-cells in vivo, using several VRC01 germline KI models (discussed further in the next section). Finally, three additional, novel approaches have been described to enhance affinities at which bnAb precursors can bind near-native trimeric Env immunogens. Such near-native trimers are already thought to be more specific for bnAbs than other forms of Env immunogens (such as monomeric gp120s), due to being in more "closed" conformations that should allow greater access to bnAb epitopes, while occluding greater numbers of non-nAb epitopes, the former because certain bnAb epitopes are only being present when Env is in native-like conformations and the latter because appropriate constraints are placed on the angles at which Abs can approach various key Env regions of vulnerability (de Taeye et al., 2016, 2015; Sanders et al., 2015; Sliepen & Sanders, 2016). Two such "enhancement" strategies for generating higher affinity versions of near-native trimers have been employed on those engineered to preferentially target V2/glycan-specific bnAb precursors. One of these strategies has been to select such immunogens from large-scale screens of viral isolates that can neutralize "germline-reverted" versions of several prototypical V2/glycan bnAbs, e.g., PG9, CH01, PGT145, and CAP256 (Andrabi et al., 2015). Alternatively, higher affinity, V2/glycan-targeting near-native trimers have

been produced by engineering chimeric trimers, in which V2/glycan epitopes from viral isolates having enhanced binding to V2/glycan bnAb UCA precursors have been grafted into "DS-Env" stabilized trimers (Gorman et al., 2016; Kwon et al., 2015). The third recent, potentially most comprehensive approach currently underway for making such enhanced trimeric immunogens, is a series of additional modifications being made in the best described a native-like trimer, the BG505 SOSIP 664 Env platform, which has been stabilized by disulfide bonds to link gp120 and gp41 (which has been truncated at position 664 resulting in deletion of the MPER), as well as an additional mutation to stabilize gp41. This stabilized, near-native trimer immunogen can already bind certain classes of bnAb precursors with appreciable affinity, e.g., V1V2/glycan-directed bnAb precursors (Sliepen et al., 2015); but additional mutations are currently being designed to further enhance binding to various CD4bs-specific and/or V1V2/glycan-specific bnAb UCA/reverted precursors (Sanders, R., personal communication).

All these above-noted priming immunogens have thus not only been selected for their specificity in targeting bnAb precursors, but their ability to bind them at low μM (and often, nM) affinities, based on the rationale such affinities are well above minimal theoretical thresholds for effectively engaging and activating the preimmune B-cell repertoire in vivo (Dal Porto et al., 2002; Dal Porto, Haberman, Shlomchik, & Kelsoe, 1998; Shih, Meffre, Roederer, & Nussenzweig, 2002) and thus have been generated with the intent of "kick-starting" such bnAb precursors and/or initiating lineage development in vivo. In some cases, the potential of such GT immunogens for priming/activating bnAb precursors has been further validated by demonstrating their capability to induce robust calcium flux in bnAb-transfected B-cells in vitro (Jardine et al., 2013; McGuire et al., 2013). In the next section, we will review some of the initial immunization priming studies done and/or underway in various KI models for evaluating candidate bnAb precursor-priming immunogens, some (mostly for the VRC01-class bnAbs) which are now beginning to demonstrate they indeed can activate and elicit bnAb precursors, and thus behave in vivo as have been hoped.

5.2 Evaluation of bnAb Activation/Priming by Precursor-Targeting Immunogens in KI Models

Immunization studies in various types of Ig-humanized KI models have now begun to provide convincing evidence, at least for certain bnAb classes, that

"precursors" of bnAbs can be kick-started by "priming" immunogens. As noted above, much of this work is still very much at the proof-of-concept stage, since it has focused thus far predominantly on evaluating immunogens for activating precursors of one bnAb type in particular, the VRC01-like (CD4 mimic) class of CD4bs$^+$ bnAbs, using several KI models, all engineered to express human V_H1–2, a germline segment common to these bnAbs. Below, however, we will not only discuss these studies in detail, but also review other, more recent "priming studies" to evaluate immunogens targeting precursors of the V3 high-mannose PGT121-like (N332 supersite) class of bnAbs, as well as currently ongoing investigations of immunogens aimed at initiating the other bnAb classes/lineages, in various novel KI models.

To evaluate priming immunogens targeting precursors of the "CD4 mimic" class of CD4bs$^+$ bnAbs, two precursor bnAb KI models, VRC01gH and 3CBN60 GLV_H, were constructed (Dosenovic et al., 2015; Jardine, Kulp, et al., 2016). These models were engineered with enforced expression of V_HDJ_H rearrangements (via their integration into the J_H cluster) of either VRC01 or 3CBN60, a VRC01 family member. Both rearrangements used the common germline V_H1–2 segment, but retained the mutated HCDR3 regions of the original VRC01 and 3CBN60 bnAbs, respectively (Fig. 5A and B). In both models, B-cell development appeared to be largely normal. Furthermore, in the VRC01gH model, 85% of B-cells expressed the VRC01gH (Jardine et al., 2015), whereas essentially all naive B-cells in the 3CBN60 GLV_H model expressed the "knocked-in" GLV_H–3BNC60 rearrangement (Dosenovic et al., 2015). In both cases, the cognate bnAb LCs were not knocked-in, under the premise that mouse LCs with 5-aa CDR L3 could function in association with V_H1–2-expressing HCs as VRC01 precursors.

With respect to the VRC01gH model specifically, immunization studies were performed to evaluate the efficacy of a candidate VCR01 Ab-priming immunogen, eOD-GT8 (Jardine et al., 2015). This immunogen was derived from the original concept of converting Env into a form that could bind VRC01 precursor Abs with sufficient affinity, by overcoming the major impediment to this: removing the CD4bs-proximal N-linked glycans near the CD4bs. Removal of these glycans was done by mutating the glycosylation site at N276 in loop D and the N460 and N463 sites in the V5 domain of a clade C virus (426c), significantly enhanced the binding affinity between the mutant Env and precursor VRC01 Abs (McGuire et al., 2013). However, the triple glycosylation mutations alone did not provide a complete solution to the problem of Env/glVRC01 interactions, since the triple

Fig. 5 Comparison of various current mouse bnAb KI/chimeric models for testing CD4bs bnAb-targeting vaccine strategies. Schematic illustration of "first generation" VRC01gH, 3BNC60 GLV$_H$, 3BNC60 MuV$_H$, or gl-3BNC60 HC/LC mouse KI, or "second generation" CH103 UCA heterozygous HC/LC and V$_H$1–2 (or V$_H$1–2/LC) chimeric model alleles generated to evaluate the ability of CD4bs-targeting sequential immunization strategies to induce VRC01-like Abs. Also shown are estimated precursor frequencies in the naive peripheral repertoire and if any tolerance mechanisms exist prior to immunization. Note the subtle, yet immunologically key, differences between the prerrranged models, most notably, the UCA vs reverted rearrangements used, and the partial removal of the Jκ LC cluster in the CH103 UCA dKI model, vs its complete removal in the other KI models. *Adapted with permission, from Verkoczy, L., Alt, F.W., Tian, M. (2017). Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.* Immunological Reviews, 275, 89.

mutant 426c Env bound some, but not all, precursor VRC01–class Abs. To deal with this issue, a more dramatic modification of Env, i.e., engineering a minimal gp120 outer domain (eOD), was the starting point for development of the eOD-GT8 immunogen (Jardine et al., 2013; Jardine, Kulp, et al., 2016). While the original eOD base interacted poorly with gl-VRC01 Abs, it was eventually engineered into the broad precursor VRC01–binder, eOD-GT8, via several iterations of structure–based modifications (Jardine, Kulp, et al., 2016).

For immunization purposes, eOD-GT8 was formulated as 60mer nanoparticles, with the goal of binding BCRs at higher avidity than as a monomer, thus potentially activating B–cell cross–linking. Immunization of VRC01gH mice with eOD-GT8 60mer elicited memory B–cells that expressed VRC01-like Abs. Specifically, about 90% of CD4bs-specific

IgG$^+$ B-cells expressed Abs bearing the VRC01gH paired to mouse LCs with 5-aa CDRL3s; moreover, the CDRL3s were enriched for a partial VRC01 consensus motif QQYXX. Interestingly, among the adjuvants used to formulate the eOD-GT8 60mers with (alum, Iscomatrix, and Ribi), Ribi appeared to induce the most SHM. Functionally, these Abs bound specifically to the CD4bs, but exhibited no neutralization activity, due to the limited overall SHM frequencies observed. Nevertheless, these results indicate that the eOD-GT8 60mer is an effective priming antigen for activating B-cells expressing VRC01 precursor Abs. In contrast, immunization with the native trimeric Env protein, BG505 SOSIP, elicited no VRC01-like Abs, likely due to its poor interaction with VRC01 precursors.

Similar immunization "priming-phase" studies have also been done in the germline-reverted "3BNC60 GLV$_H$ model," to evaluate the ability of eOD-GT8, and a second candidate VCR01 GT immunogen, multimeric 426c TM4ΔV1–3, to prime VRC01-class bnAb precursors (Dosenovic et al., 2015). The 426c.TM4ΔV1–3 immunogen (McGuire et al., 2016) contains mutations in three N-linked glycosylation sites near the CD4bs as well as truncations of variable loops 1–3 (ΔV1–3), modifications that significantly improved the binding affinity of 426c Env toward VRC01 Ab precursors. One or two immunizations of 3BNC60 GLV$_H$ mice with these GT immunogens induced robust Ab responses; and some had CD4bs specificity, especially so with eOD-GT8. As seen in the VRC01 gH model, B-cells expressing 5-aa CDRL3s were highly infrequent in the naïve repertoire of 3BNC360 GLV$_H$ mice, but CD4bs-specific sorted memory cells with 5-aa CDRL3 signatures could be found after priming. Also like the VRC01 gH model, multiple immunizations with recombinant native-like trimers Envs failed to elicit significant CD4bs-specific serum Ab responses, as would be expected, since the reverted 3BNCC60 Ab fails to bind this trimer in vitro. Additionally, neither mAbs nor serum Abs in mice from which 5-aa CDRL3s were observed exhibited neutralization activity, also as expected from priming with a single precursor-targeting immunogen (and no boosting). However, one notable difference in this model is that only one out of four immunized mice displayed the classical 5-aa CDRL3 signature, and only a minor fraction of clones sorted for CD4bs-specificity exhibited this feature, in contrast to the majority sorted from immunized VRC01 gH mice.

Interestingly, when parallel immunization studies were carried out in a version of the 3BNC60 KI mouse model (MuV$_H$) that instead of expressing germline-reverted V$_H$DJ$_H$ rearrangements, expressed mature 3BNC60

$V_H DJ_H$ rearrangements (Dosenovic et al., 2015) (Fig. 5C). In this system, an Ab composed of mature 3BNC60 HC pairing with a LC with 5-aa CDR L3 was thought of as a synthetic 3BNC60 "intermediate," and the model was designed to test the ability of immunogens to promote further maturation of this intermediate, primarily through optimization of the LC. The introduction of a mature 3BNC60 HC into this model dramatically improved its immune response to eOD-GT8 60mer and native Env trimer, BG505 SOSIP. In both cases, immunization led to marked induction of CD4bs-specific Abs and neutralization activities in sera. Correspondingly, the frequency of CD4bs-specific IgG^+ B-cells in MuV_H mice increased dramatically in response to immunization with either eOD-GT8 or BG505 SOSIP, and most of these B-cells expressed mouse LCs with 5-aa CDR L3s, which contains an E residue at the fourth position, a signature of VRC01-class Abs. Moreover, these cloned Abs were CD4bs-specific and recapitulated the serum neutralization activities. Overall, BG505 SOSIP elicited broader neutralization activities than eOD-GT8 60mer. These results reinforce the notion that maturation of intermediate Abs will require more native-like Env immunogens, an issue that will be discussed in detail in below sections regarding boosting concepts for broadening bnAb responses.

The reason for this dramatically lower induction of VRC01-like Abs in the 3BNC60 GLV_H model, relative to the VRC01gH model, is intriguing, and remains to be formally determined, but can likely be attributed to differences in binding affinities that VRC01 gH and 3BNC60 GLV_H-expressing B-cell clones have for eOD-GT8 in vivo. As already noted, both knocked-in HCs utilize the same germline $V_H 1-2$ segment, but contain HCDR3 from the mature VRC01 and 3BNC60 bnAbs. In this regard, when the reverted/gl-VRC01 and 3BNC560 are made in vitro as IgG Abs, eOD-GT8 interacts with gl-VRC01 Ab at roughly a log higher affinity than does gl-3BNC60. Alternatively (or additionally), while the overall preimmune B-cell repertoire in the 3BNC60 GLV_H KI model is not under any obvious developmental blockades, the rare clones expressing 5-aa CDRL3s may be under negative selection mechanisms, thus may be at a selection/survival disadvantage, relative to off-target clones (which are not under tolerance control), in response to immunization. Consistent with this possibility, is the finding that unlike the normal preimmune B-cell repertoire of 3BNC60 GLV_H mice (which only express the gl-reverted HC rearrangement, and can thus pair with diverse mouse LCs), that of 3BNC60 GLV_{HL} mice, a model forced to initially express not only the gl-reverted HC rearrangement, but also the 5-aa HCDR3-containing

gl–reverted LC rearrangement of 3BNC60, is under considerable negative selection (McGuire et al., 2016) (Fig. 5D), including exhibiting partial clonal deletion in the bone marrow, and a residual peripheral repertoire that is largely comprised of naïve B-cells which have undergone receptor editing via replacement of their knocked-in germline-reverted 5-aa LCDR3-containing LCs with endogenous mouse λLCs. Furthermore, clones which did manage to retain both their KI gl HC + LCs were under anergy controls.

A significant caveat with the priming studies done in the above-described VRC01 gH and 3BNC60 GLV$_H$ models is that in retaining mature HCDR3s from the original bnAbs, they are not equivalent to bona fide VRC01 precursors. Furthermore, both models express prerearranged VDJs bearing V$_H$1–2 linked to fixed HCDR3s, whereas in the human Ab repertoire, V$_H$1–2 is linked to diverse HCDR3s, a subset of which may be compatible with the development of VRC01-like Abs. Thus, to evaluate the validity of eOD-GT8 as a priming immunogen in a repertoire with diverse VRC01 precursors (i.e., in a setting where human V$_H$1–2 could be expressed in association with a repertoire of HCDR3s), a "V$_H$1–2" KI model has more recently been generated, where the human V$_H$1–2 segment is knocked-in to selectively replace a single mouse V$_H$ segment (Fig. 5E) (Tian et al., 2016). Since unrearranged V$_H$1–2, along with mouse D and J$_H$ segments needs to undergo normal V(D)J recombination in this system, the frequency of B-cells expressing potential VRC01 precursors are expected to be very low, thus presenting practical difficulties for immunization studies. In order to circumvent this issue, i.e., generate a diverse repertoire of V$_H$1–2-expressing Abs, but at high enough frequencies to allow for a robust immunization readout, the V$_H$1–2 KI model was engineered with two specific modifications. First, V$_H$1–2 was substituted specifically for mouse V$_H$81X, the V$_H$ segment at the endogenous IgH locus that is most proximal to the D segments, which at least in part explains its most frequent-utilization among all V$_H$ segments, during HC rearrangement (Alt, Zhang, Meng, Guo, & Schwer, 2013). Second, the bias for V$_H$81X rearrangement was made even more pronounced, by deleting a regulatory element at the intergenic region between V$_H$ and D segments, IGCRI (Guo et al., 2011). Thus, by replacing V$_H$81X with V$_H$1–2, in the context of IGCRI deletion, approximately 45% of peripheral B-cells expressed V$_H$1–2 in this KI model (Tian et al., 2016), yet could still retain their ability to recombine with all mouse D and J$_H$ segments, and thus their potential for creating a diverse set of HCDR3s. Given these features, this model provided the opportunity to evaluate the ability of eOD-GT8 to selectively engage the VRC01

precursor among a diverse pool of V_H1–2^+ B-cells. Priming of this model with the eOD-GT8 60mer formulated with poly I:C adjuvant elicited robust IgG^+ $CD4bs^+$ serum Ab and memory B-cell responses. Of the LCs expressed by $CD4bs^+$ memory B-cells, the frequency of 5-aa CDRL3s, although minor (in the same range as those elicited in the 3BNC60 model) was considerably higher than those found in the preimmune repertoire, and higher doses (60 μg) of eOD-GT8 appearing elicited the highest frequencies. Along with the 5-aa CDRL3 signature, CDRL3s were enriched for the partial consensus VRC01 motif of QQYXX, also as found previously in the standard VRC01 gH and 3BNC60 GLV_H KI models. In binding assays, the elicited VRC01-like Abs were specific for CD4bs, but also like in the other models, had not matured sufficiently to develop neutralization activity. Thus, these results indicate that even in a more challenging environment, i.e., one expressing a more complex repertoire capable of generating diverse HCDR3s, it was still feasible to selectively activate B-cells expressing VRC01-like precursors with the high-affinity VRC01-class priming immunogen, eOD-GT8.

Although the V_H1–2 KI model contains a diverse repertoire of V_H1–2^+ HCs, the frequency of B-cells expressing V_H1–2 (45%) was far higher than in the human Ab repertoire ($\sim$3%) (Arnaout et al., 2011; DeKosky et al., 2015; Sok et al., 2016). Furthermore, this model uses mouse D and J regions, the latter that lack high homology to human J segments. Thus, as the "highest bar" to evaluate the potential of eOD-GT8 to engage genuine VRC01 precursors, two related studies have been more recently reported. First, the frequency of such bona fide precursors in humans was evaluated by isolating eOD-GT8 binding B-cells from human peripheral blood (Jardine, Kulp, et al., 2016). From 61.6 million naïve B-cells, 26 isolated B-cells (1 in 2.4 million) were found to express Abs bearing V_H1–2 HC and LCs with 5-aa CDRL3s. Moreover, based on the structural studies, isolated VRC01-like Abs bound the CD4bs essentially the same way as VRC01-class Abs. Second, to further evaluate the efficacies of eOD-GT8 as a priming immunogen in a fully polyclonal and Ig-humanized environment, priming with eOD-GT8 was conducted in Kymab mice, in which the complete human IgH, Igκ and Igλ minigene segment repertoires were incorporated into the corresponding mouse loci (Lee et al., 2014). In these mice, human V_H1–2 HC^+ B-cells represent somewhat similar frequencies ($\sim$1%) as found in the human repertoire (Arnaout et al., 2011; DeKosky et al., 2015; Sok et al., 2016), but those with 5-aa CDRL3s are found at 0.018%, 90-fold lower than in humans (Sok et al., 2016). When accounting

for the lower total B–cell numbers mice have, relative to humans, VRC01–like precursors were expected to be even more infrequent in Kymab mice than in humans. Supporting this prediction, no VRC01–class B–cells were identified by eOD-GT8 sorting of 300 million B–cells from naïve Kymab mice (Sok et al., 2016); using the same approach for detecting the 1 in 2.4 million in humans (Jardine, Kulp, et al., 2016). In spite of this paucity of VRC01–class precursors in Kymab mice, priming with the eOD-GT8 60mer elicited VRC01–like Abs in 29% of immunized animals, with ~1% of CD4bs$^+$ Abs in responding mice expressing V_H1–2 HCs paired to various LCs that corresponding to those found in VRC01–class Abs, and which bore 5-aa CDRL3s (Sok et al., 2016). As with the VRC01 gH, 3CBN60 GLV_H, and V_H1–2 KI models, these CDRL3s were also enriched for the partial VRC01 consensus QQYXX. Also similar to the priming results in the other KI models, none of the elicited VRC01–like Abs matured enough to attain neutralization activities, and immunization with a near–native Env trimer, BG505 SOSIP, failed to elicit VRC01–like Abs in the Kymab model. Thus, these studies represent the most stringent test proving that eOD-GT8 can serve as an effective priming immunogen, and along with studies evaluating the multimeric 426 core immunogen, provides a beachhead that priming with immunogens capable of binding VRC01 precursors at high affinity in vitro are required to activate/initiate development of VRC01–class Abs in vivo.

Also very recently, evaluation of other priming immunogens, those aimed at inducing the V3 high-mannose patch–specific "N332 supersite" class of bnAbs, have been conducted in two PGT121 KI models (Escolano et al., 2016). One of these models, $GL_{HL}121$, was constructed to express a "precursor" germline (gl) PGT121 Ab (Steichen et al., 2016), whose HC rearrangement is comprised of germline V and J segments *plus* the HCDR3 of the least-mutated member in the PGT121 lineage, while the other model, Mut_HGL_L121, was constructed to express a synthetic intermediate PGT121 Ab, comprised of the original (affinity matured) PGT 121 bnAb's mutated HC rearrangements, but paired to the gl-PGT121 LC rearrangement. As with the VRC01gH and 3CBN60 GLV_H models noted above, the rearranged V_HDJ_H exons of these two KI models were integrated into the mouse J_H, locus, but these models differed from the VRC01–class KI models, in that PGT121 gl-V_LJ_L rearrangements were also integrated into their Jκ clusters. Immunization studies in these two models were performed to evaluate the efficacy of two candidate precursor/reverted PGT121-binding immunogens in particular, 10MUT and

11MUTB. Similar to the reverse engineering approaches used to design the VRC01-class targeting immunogens 426c and eOD-GT8, 10MUT and 11MUTB were generated into precursor/gl–PGT121 binders via several rounds of mutagenesis and selection of a native trimeric Env protein, BG505 T332N, which exhibited no appreciable binding to reverted gl–PGT121 Abs (Steichen et al., 2016). In both models, B-cell development appeared to be essentially normal and all B-cells expressed both knocked–in HC and LC rearrangements, consistent with the lack of noticeable (in vitro) poly-/autoreactivity if the PGT121 Ab. As expected, repeated immunization of GL_{HL} 121 and $Mut_H GL_L$ 121 mice with native trimeric Env proteins YU2 or BG505 SOSIP, failed to elicit any detectable Ab response, whereas a single immunization with the germline-binding immunogen 10MUT was sufficient to elicit readily detectable 10MUT-binding Abs that were PGT121-like, as interactions with 10MUT were abolished by mutational analysis of the PGT121 epitope.

There are two substantial caveats to these KI models that warrant further investigation. First, the GL_{HL} model uses a "least–mutated" member structural inference with key HCDR3 mutations remaining, and thus represents a quasi–intermediate Ab that may have bypassed an earlier selection blockade and/or may not exist in the human repertoire. Second, the fact that PGT121 bears a very long HCDR3 makes it probable of having been stringently culled, prior to LC pairing, thus any bona fide PGT121 precursors are likely to be present at exceptionally low frequencies (less than VRC01). Thus, it remains to be seen if bona fide PGT121 precursors can be found in all healthy humans and activated in Kymab mice by "N332 supersite" Ab-priming immunogens such as 10MUT. Nevertheless, in conjunction with the priming studies with VRC01-class targeting immunogens, these initial studies in PGT121 KI models further highlight both the value of Env reverse engineering as an approach to develop potentially efficacious immunogens and human Ig KI mouse models, as lead/translational in vivo platforms for testing their potential.

5.3 Key Issues for bnAb Precursor Activation and Ongoing Priming Studies in KI Models

As noted above, significant progress has been made with learning how to prime VRC01-like bnAb development using high-affinity precursor-targeting immunogens, and promising initial results also appear to be emerging with those aimed at priming the PGT121 bnAb class. However, as discussed in Section 3.3, an efficacious HIV vaccine will likely need to induce

several bnAb classes, for several reasons, including: (i) achieving adequate cumulative breadth (especially if high SHM levels are truly required, since this will be challenging for vaccination to feasibly recapitulate), (ii) minimizing viral escape, and (iii) overcoming immunogenetic mediated response diversity between vaccinated individuals (e.g., due to MHC class II haplotype variation, or for bnAbs with especially long HCDR3s like PGT121, due to repertoire frequencies being potentially so low that not all individuals bear relevant lineage precursors of a particular bnAb class). In this regard, studies to evaluate candidate priming immunogens to various other bnAbs (or bnAb lineages) in several novel bnAb precursor KI models are currently underway, including those in CH103 UCA KI (Williams, Haynes, & Verkoczy, submitted), CH01 UCA KI (Verkoczy, L. & Haynes, B.F., unpublished results), DH270 UCA KI (Alt, F.W. & Tian, M., unpublished results), and 2F5 UCA KI (Zhang et al., 2016) or DH512 (i.e., 10E8-like) UCA KI (Alt, F.W. & Tian, M., unpublished results) models, to assess candidate priming immunogens for targeting, respectively, the HCDR3-binder class of CD4bs$^+$ bnAbs (Gao et al., 2014; Liao, Lynch, et al., 2013), V2 apex-directed bnAbs (Alam, Dennison, et al., 2013; Alam, Liao, et al., 2013; Andrabi et al., 2015; Gorman et al., 2016), V3 high-mannose patch ("N332" supersite)-specific bnAbs (Alam et al., 2017), and MPER-specific bnAbs (Alam et al., 2011; Zhang et al., 2016).

With respect to ongoing CH103 UCA KI priming studies specifically (discussed further below), it is noteworthy that the TF virus-derived priming immunogens *and* the UCA KI model made for evaluating them, have both been engineered based on the B-cell lineage design approach (Haynes, Kelsoe, et al., 2012) of activating and maturing bona fide (time-of-infection) UCAs, which represents an alternative concept to that of the reverse engineering strategy discussed above, for priming VRC01- and PGT121-class bnAbs. Both strategies will be discussed further in Section 6, regarding their translatability and relevance to vaccine design. Also notable is that priming immunogens made by several groups, based on either strategy, and in various forms (soluble or multimeric gp120s, native or nonnative trimers, etc.) are being tested in various new precursor bnAb KI models that are distinct yet related, i.e., expressing either reverted or UCA bnAb rearrangements (or unrearranged segments) of a given bnAb. Additionally, in many cases now, greater than one bnAb KI model is being made for a specific "bnAb class." Thus, the field as a whole is moving toward much more iterative and collaborative immunogen testing in complementary animal

models, which provides considerable hope that several feasible Env priming targets will be identified fairly soon, a key step in developing an effective bnAb-based vaccine strategy.

Thus, while much initial progress has been made in developing priming immunogens, we are still in the early phases of understanding the rules for optimally engaging the spectrum of B-cell lineage precursors with the potential ability to go on and develop neutralization breadth. In this regard, there are at least two key issues we currently must consider in further studies. The first is that despite the demonstration that core proteins synthetically engineered to bind VRC01-class bnAb precursors at high affinity in vitro can also prime these precursors in vivo, the process appears to be highly inefficient, and in particular, also leads to induction of many "off-target" (cross-reactive) non-bnAb responses, especially in studies done in the more physiological KI models (e.g., V_H1–2 mice), and as previously noted in vitro (McGuire et al., 2014). Optimization of bnAb precursor priming/activation relative to these off-target clones, is likely to be a key issue to resolve, since more efficient priming may considerably shorten the prolonged maturation pathways seen during infection, and thus could play a significant role in devising a more feasible vaccine strategy. In this regard, some native-like trimer immunogens already appreciably bind some of the bnAb precursors, e.g., V1V2/glycan class bnAbs (Sliepen et al., 2015), and are now being further optimized for their ability to bind bnAb precursors of various classes at higher affinity (simultaneously in some cases), and/or are also being multimerized (Andrabi et al., 2015; Gorman et al., 2016, Sanders, personal communication). When these immunogens shortly become available, it will be highly relevant to compare these to the bnAb precursor-priming "core protein" antigens noted above, as well as to more "minimal" immunogens (Alam, Dennison, et al., 2013), both in terms of strength of precursor bnAb induction and relative elicitation of "off-target" responses. Thus, assuming concepts of high affinity and/or multimerization can be equally applied to redesign trimer immunogens, an active area of interest will be testing the relative effectiveness of such trimers to *specifically* and *robustly* engage bnAb precursors, relative to other immunogen forms. In this regard, arguments have been made on both sides as to why such trimeric constructs may or not be better: on one hand, there is the compelling case that closed conformations of near-native trimeric proteins can most effectively present the complex quaternary (CD4bs) and/or glycopeptide bnAb epitopes to precursor BCRs, while most efficiently shielding many immunodominant, off-target (nonneutralizing) epitopes that would normally be occluded

(de Taeye et al., 2015; Sanders et al., 2015). On the other hand, such structures (relative to nonstabilized proteins) could lack flexibility sufficient for optimally engaging IgM$^+$ BCRs of naïve (nonactivated) precursors. Therefore, such evaluations of stabilized vs nonstabilized trimers, and other protein forms will be interesting and important issues for the filed, likely best answered via empirical testing in KI models.

The second issue that impacts choice of immunogens at the priming phase is at what stage tolerization occurs in bnAb lineages and more specifically, what is the signaling status of their precursors in the naïve (preimmune) repertoire? As I touched on in Section 4, anergy of naïve precursors appears to be an issue for many, but not all bnAb lineages. In particular, this phenotype is certainly observed in all MPER$^+$ bnAb KI models tested thus far (Chen, Zhang, Hwang, et al., 2013; Doyle-Cooper et al., 2013; Finton et al., 2013; Verkoczy, Chen, et al., 2011), and most likely extends to all MPER$^+$ bnAbs, based on their in vitro self-reactivities (Liu et al., 2015; Verkoczy et al., 2014); whereas for precursors of bnAbs targeting other Env vaccine targets, this may be case-dependent, as seen for the various CD4bs$^+$ bnAb KI models made thus far. Indeed, as discussed earlier, naïve 3BNC60 GLV$_{HL}$ KI mice exhibit anergy among other tolerance controls (McGuire et al., 2016) (Fig. 5C), as does the CH103 UCA dKI (HC + LC) KI model (Verkoczy, L., Williams, W., Haynes, B.F., manuscript submitted) (Fig. 5G), whereas all germline/precursor VRC01 KI models mice exhibit unperturbed B-cell development, even though VRC01-expressing B-cells appear to develop signs of self-reactivity after a certain degree of vaccine-induced maturation has occurred, including binding to the candidate self-antigen UBE3E ligase (Tian et al., 2016; Tian, M., Alt, F.W., & Haynes, B.F., personal communication). In all these examples of preimmune bnAb precursor anergy (excepting VRC01), the issue of "off-target" responses to vaccination may be especially problematic, since nonanergic clones cross-reactive to any of a number of non–bnAb epitopes found in Env immunogens are likely to be preferentially amplified over anergic bnAb precursors, especially if local immunogen concentrations are limiting. Thus, aside from reiterating the importance of defining the preimmune biology (i.e., self-antigen exposure of precursors, prior to immunogen encounter) for each individual bnAb lineage, this also suggests that for those lineages for which B-cell precursors are found to be anergic, issues beyond standard immunogen design (i.e., immunogens needing to bind anergic bnAb-expressing B-cell, due to their lower surface IgM densities, with especially high avidity via multimerization and/or high affinity or

optimization of their delivery/presentation to naïve B-cells) may also be critical. Additionally, as discussed in Section 4, anergic B-cells may have additional signaling requirements that include antigen-independent survival signals, i.e., stronger/more specific CD4 T-cell help and/or TLR signals (Chaturvedi et al., 2008; Cooke et al., 1994; Leadbetter et al., 2002; Marshak-Rothstein & Rifkin, 2007; Sekiguchi et al., 2002; Seo et al., 2002), which may also be necessary to incorporate into vaccine regimens. In the case of primed 3BNC60 GLV$_{HL}$ KI mice, it is likely additional (non-BCR) signals may be lacking, as multimerization of the VRC01-class targeting immunogen 426c can activate and expand 3BNC60$^+$ precursors, yet elicits virtually no SHM (McGuire et al., 2016) relative to other comparable (single) primes in VRC01 or PGT121 KI models. Similar findings have also been observed for anergic 2F5 precursors in 2F5 UA (precursor) dKI (HC + LC) mice, whose priming with an MPER bnAb peptide, when in complex with liposomes (and TLR agonists) can bind the 2F5 UA Ab (but not non-bnAb MPER$^+$ Abs) at high avidity in vitro (Alam et al., 2011; Zhang et al., 2016) but can only partially activate 2F5 lineage precursors in vivo. Specifically, in these mice, KI HC/LC B-cell can be robustly expanded, yet undergo minimal class switch or SHM, even after multiple immunizations (Zhang et al., 2016). This again suggests that not only will avidities of HIV immunogens for bnAb precursor BCRs need to be altered, but other signals, may need to be incorporated into vaccine regimens.

Finally, concepts to fine-tune priming immunogens may not just be restricted to triggering anergic bnAb lineages, but may also apply for bnAb precursors *not* subjected to negative selection. For instance, tweaking timing, amounts, and avidity ranges of priming immunogens may be required to further optimize responses, since too high avidities/concentrations, excessive multimerization, or overly prolonging prime times, could all lead to early exit from GC reactions and/or preferentially induce T-I responses (Benson, Erickson, Gleeson, & Noelle, 2007; Mond, Vos, Lees, & Snapper, 1995). In this regard, extrapolating more narrow, relevant affinity "ranges" from in vitro results may be difficult because precursor-targeting immunogen affinities in vitro are against soluble IgGs and thus do not necessarily reflect interactions with IgM$^+$ BCRs on naïve B-cells in vivo. In such cases, in vitro studies would fail to predict GC recruitment and AM in vivo. Indeed, at least in some cases, while prolonged GC maturation is based on selection for clones with higher acquired affinities (Dal Porto et al., 1998; Schwickert et al., 2011; Shih et al., 2002), lower affinity clones have been found to best initiate GC formation, while high-affinity

naïve B-cells are recruited for plasmacyte differentiation (Benson et al., 2007; Linton, Decker, & Klinman, 1989; Paus et al., 2006; Phan et al., 2006; Raman, Lind, Benson, & Noelle, 2007). In these cases, strategies guiding the bnAb pathways may benefit from high–affinity boosting, but overly strong initial signals may be counterproductive, since activation thresholds would be predicted to be much lower than seen during typical positive selection. The issue of avidity priming ranges could be even more relevant for any bnAb lineages found to be hyperresponsive to BCR ligation, and thus which are not only on the complete opposite end of the spectrum as being negatively selected/anergic, but also having activation requirements substantially differing even from those *of* "typical" naïve B-cells; in such, cases lower affinity signals could actually be beneficial, as such clones may have ultra-low affinity thresholds for activation. For example, B-cells with a propensity to be nonspecifically crossprimed by endogenous or environmental (super) antigens may be hypersensitive to subsequent immunogen priming (Silverman & Goodyear, 2006). Thus overall, the systematic evaluation of precursor-directed immunogens of varying avidities for iterative testing in KI models in which representative bnAb lineages exhibit distinct degrees of selection will likely be critical to optimize bnAb lineage priming across multiple targets.

5.4 Emergence of Sequential Boosting Concepts for Broadening nAb Responses to HIV

While the bnAb precursor-targeting immunogens we discussed above have been/are being designed with the goal of activating naïve B-cells and initiating bnAb lineage AM, repeated immunizations with such priming immunogens alone, would not be anticipated to induce the complete set of somatic mutations required for the development of broad neutralization activity (Burton & Hangartner, 2016; Haynes, Kelsoe, et al., 2012; Klein et al., 2013; Kwong & Mascola, 2012; West et al., 2014). In this regard, the assertion that immunization with two or more heterologous Env immunogens will generate more broadly reactive humoral responses has been a long-standing premise in the field, yet no such approaches had led to measurably better responses (reviewed in Bonsignori, Alam, et al., 2012; Mascola & Haynes, 2013; McElrath & Haynes, 2010). As discussed in the previous section, we now know from recent studies that this has been due, at least in part, to not having employed immunogens with the ability to robustly and/or specifically activate bnAb precursors. Furthermore, in these earlier heterologous prime/boost studies, it was unclear if specific

combinations of immunogens were required for broadening responses, and if so, which ones gave significant, yet incrementally better responses (i.e., not detectable at the serum Ab level), since technology for probing AM at higher resolution (by NGS and/or single-cell memory B-cell sorting) has been only relatively recently developed, as have more practical vaccine testing platforms, i.e., the humanized Ig KI models being discussed in this review (where human repertoire complexity can be simplified, when required). Over the past 4 years, this additional gap in knowledge has been addressed, as significant rationale now has been obtained for testing the concept of serial administration of multiple heterologous envelopes, and this in turn has currently reinvigorated efforts to develop rational heterologous boosting strategies, and now provides a conceptual framework for testing basic sequential (stepwise) protocols in KI models (detailed further below), as starting points for iteratively testing tailored modifications engineered to enhancing nAb response breadth.

While early versions of "sequential-like" strategies had been tried in the past that not exhibit obvious serological signals of enhanced neutralizing Ab breadth (Eda et al., 2006; Klinman, Higgins, & Conover, 1991; Malherbe et al., 2011), but as just mentioned, methodologies needed to probe the vaccine-activated memory B-cell repertoire at a depth where signals of breadth development could be evaluated were not available, nor had relevant Ig locus–humanized animal vaccine models been developed to further increase the resolution of bnAb-relevant readouts. Recent developments, however, have now provided strong rationale to carry out more directed sequential (stepwise) strategies, most notably, recent information from structure–function and longitudinal patient time-of-infection sampling analyses, and both advances have been leveraged to develop two distinct types of sequential immunization strategies.

The first is a structure inference-based "reverse engineering" stepwise vaccination concept (Briney et al., 2016; Burton et al., 2012; Escolano et al., 2016; McGuire et al., 2013; Tian et al., 2016; Zhou et al., 2010). In its most general form, this approach involves first using the type of synthetically engineered immunogens described above for the priming phase, in order to activate naive B-cells to switch and form memory B-cells that have undergone some degree of SHM. The sequential boosting phase that then follows employs a related set of synthetically engineered immunogens, based on introducing structural modifications (e.g., gradually increasing key N-glycosylation sites in the CD4bs region, in order to incrementally resemble native Env). The goal of such "directed" boosting would be to preferentially reactivate memory B-cells expressing Abs that

progressively matured toward recognizing more native forms of Env. The process would be reiterated with more native-like Env antigens, with the goal of eventually using native Envs to select out B-cells expressing matured bnAbs. The overall concept of this immunization scheme is thus to guide Ab maturation in gradual stepwise fashion, which presumably imparts more realistic demands on the SHM required for each boosting step. A key-related consideration with such strategies, in order to ensure proper shepherding of AM, i.e., toward breadth development takes place, is to have overlap in the binding profiles of the immunogen sets/pools used in such stepwise regimens, i.e., boosts must include overlapping administration of "bridging" immunogens, e.g., those that can bind both precursors and more "intermediately native" forms, and then, those which can bind the same intermediate forms, in addition to more (or fully) native Envs. Analogous "reverse engineering" sequential strategies have also been proposed for other highly variable pathogens, and in some cases, such as in efforts to develop a universal flu vaccine, have also begun to produce some successful proof-of-concept results (Corti & Lanzavecchia, 2013; Dormitzer, Grandi, & Rappuoli, 2012; Lanzavecchia, Fruhwirth, Perez, & Corti, 2016), albeit, using regimens not as complicated as are likely to be required in eliciting HIV bnAbs, to deal with greater viral diversity. In particular, sequential immunizations with influenza chimeric immunogens comprised of HA domains derived from various head regions, but the same stalk domains have been demonstrated to induce bnAb responses recognizing the conserved HA stalk while conferring crossprotection to the various head domains (Margine et al., 2013; Nachbagauer et al., 2014).

The second distinct type of sequential immunization concept developed for broadening the HIV neutralizing Ab response is the patient-based strategy of B-cell lineage design (Haynes, Kelsoe, et al., 2012; Haynes et al., 2016; Liao, Lynch, et al., 2013). In particular, the elucidation of virus and Ab coevolutionary molecular pathways from which effective bnAbs evolve during infection, via comprehensive longitudinal sampling of HIV-infected subjects (Bhiman et al., 2015; Bonsignori et al., 2016; Doria-Rose et al., 2014; Gao et al., 2014; Kong et al., 2016; Liao, Lynch, et al., 2013; Moore et al., 2012; Moore & Williamson, 2016; Moore, Williamson, & Morris, 2015; Wu et al., 2015), has not only served as the rationale behind this approach, but has also been a transformative event for highly variable pathogen vaccinology in general. From such virus coevolutionary studies, not only has it possible to decipher the molecular basis of the ontogeny involved in bnAb recognition of progressively more evolved Env trimers, but these studies have also provided a natural model of

breadth development. Although knowing how much of the exceptional degree of AM observed during bnAb evolution is actually required during immunization is obfuscated by other, non-bnAb-related factors arising from the chronic infection milieu, such natural evolutionary pathways of bnAb development nevertheless serve as a starting blueprint, whose primary goal for vaccination is to recapitulate the viral evolutionary process using immunogens selected at key evolutionary branchpoints, in order to enable the gradual accumulation of mutations that can steer AM toward acquiring increased breadth. Longer-term however, the optimization of such strategies would be sought, via further rounds of iterative testing, with the goal of "short-circuiting" the maturation process during natural infection that served as the initial roadmap, in order to achieve a practical boosting regimen, i.e., one refined to only include the minimal boost(s) required to achieve reasonable breadth. The general strategy for the B-cell lineage design vaccine concept is shown, using the well-characterized CH103 bnAb lineage as an example (Fig. 6; Haynes, Kelsoe, et al., 2012; Liao, Lynch, et al., 2013). In this alternative type of sequential vaccination strategy, naïve precursor B-cells expressing the bona fide (time-of-infection) UCA of a particular bnAb lineage's evolutionary pathway, would be activated by using the pathway's original TF virus (instead of priming with a synthetically constructed immunogen optimized to bind a structurally inferred reverted bnAb). Sequential boosts would then be done using Env immunogens generated from the viral isolates that coevolved and were confirmed in vitro to bind at high affinity with its progressively matured Ab intermediates.

Although the general applicability of this B-cell lineage design sequential boosting approach in vivo remains to be validated in experimental immunization models (including KI mice) and requires careful comparative evaluation to the "reverse engineering" type of sequential approaches we described above, the premise behind it may have the greatest potential as part of a relevant general vaccine strategy, for two key reasons. First, it is becoming better appreciated that bnAbs obtained from multiple donors, which target similar Env epitope clusters, including both "HCDR3-binder" and "CD4 mimic" classes of CD4bs[+] bnAbs (Bonsignori et al., 2016; Scharf et al., 2016; Zhou et al., 2015), and also V2/glycan-directed bnAbs (Andrabi et al., 2015; Gorman et al., 2016) share similar structural hallmarks of appropriate "angles of approach" to interact with Env trimers (a key early predictor of having breadth potential), and also use reproducible developmental AM pathways. Thus, such structural and developmental commonalities make such lineage Abs and their coevolved viruses good representative

Fig. 6 Patient-based sequential vaccination for targeting bnAb B-cell lineages. The CH505 "4-valent" vaccine regimen shown here as an example, is based on the B-cell lineage design-based strategy first proposed in Haynes, Kelsoe, et al. (2012) *Nat Biotech*, and is comprised of the HIV-1 Envs from the transmitted founder (TF), week 53, week 78, and week 100 time-of-infection viruses in the CH505 patient from which the CH103 bnAb lineage was elucidated (Liao, Lynch, et al., 2013). These four viruses coevolved with Abs that eventually developed broad neutralization and thus the basic concept is to administer these Envs in the same sequentially, in order to recreate by vaccination, the Ab maturation that occurred during natural infection. *Figure is kindly provided by Kevin O. Saunders and is adapted with permission from Mascola, J. R., & Haynes, B. F. (2013). HIV-1 neutralizing antibodies: Understanding nature's pathways.* Immunological Reviews, 254, 225.

templates for vaccine design. Furthermore, Env viral evolution in the original CH505 HIV-infected individual has recently been found to be recapitulated in strikingly similar fashion during infection of rhesus macaques with SHIV505, a SHIV that has been reengineered to bear the same TF Env sequence isolated from the CH505 individual (Li et al., 2016), suggesting this lineage's coevolutionary Ab–Env pathway trajectories are not only reproducible between individuals but also even across primates, thus further validating B-cell lineage design as a viable strategy to guide vaccine-mediated development of bnAb breadth.

The two sequential approaches we have described above are certainly not mutually exclusive with each other, nor with alternative sequential concepts, such as using a more "iterative"-based boosting approach based on empirical testing after each immunization to inform subsequent boosts,

for instance, screening serum from each immunization step for their ability binding to a panel of progressively of related, but progressively evolved Env boosting immunogens, as has recently been described (and will be further discussed below) for inducing PGT121 nAb responses (Escolano et al., 2016). Ultimately, an overall bnAb–based vaccine approach will likely be a hybrid of several approach, based on building from both sequential results and also incorporating other vaccine concepts, such as ones manipulating GC/Tfh responses to enhance bnAb AM, or adjuvanting modifications aimed at overcoming B–cell tolerance roadblocks at various selection stages of bnAb development, either prior to or during boosts as necessary. Additionally, while the sequential boosting approaches for driving breadth are gaining traction in the field based on the rationale discussed above, it will also be key to comparatively evaluate *related* but distinct boosting approaches proposed for recapitulating diversity, such as concepts that "incremental" boosting, where Env diversity is gradually increased, or "swarm" boosting, where a cocktail of coevolved Envs in a bnAb maturation pathway (or even more generally, from multiple donors, representative of the natural viral diversity seen in several similar lineages) are administered simultaneously (Haynes et al., 2016). The assertion that sequential boosting may be superior (relative to additive or swarm boosting approaches) in guiding bnAb maturation toward breadth is supported by recent bioinformatic modeling studies (Shaffer, Moore, Kardar, & Chakraborty, 2016; Wang et al., 2015). However, it could also be theoretically argued that the antigenic diversity swarm/additive approaches confer is beneficial, rooted on notions extrapolated from both the above viral–Ab coevolution studies and central tenets of B–cell AM studies, namely that: (i) activating B–cells of varying affinities in an oligoclonal family may increase the pool to generate high–affinity memory B–cells and (ii) HIV-1 quasi–species continuously evolve during infection, and as such Env variants may not be generated in a perfectly sequential manner, but as overlapping pools of related Envs. Ultimately, empirical comparisons of these related yet distinct approaches (and combinations therein), enabled by more iterative testing should provide clarity to the issue of if and which approaches are most effective in breadth induction.

Below, we will review results from recent sequential boosting studies in precursor bnAb KI models, which all show promising initial results, and thus provide beachheads to now test what improvements are now needed to drive breadth, relative to (and/or in combination with) other vaccine approaches. In reviewing these studies, the KI strains being used will themselves be discussed, both in terms of how they provide unparalleled iterative

platforms to test such boosting strategies, but also regarding their current limitations for informing the most relevant immunogen design. In subsequent sections, these limitations will themselves be further discussed, as will ongoing efforts to improve KI model design, to allow even more practical and physiological vaccine testing.

5.5 Evaluation of Sequential (Stepwise) Boosting Approaches in bnAb KI Models

Several sequential boosting strategies (both reverse-engineering and patient-based) have either been recently reported or are currently underway for numerous bnAb classes and in various other KI models, including those for studying various V1V2-glycan nAb class boosting regimens, being done as several collaborative efforts between the Scripps/Duke CHAVI-ID consortiums, the NIH-Vaccine Research Center, and Cornell/Amsterdam. In this section, we will review promising initial results from vaccination studies in various KI models in which candidate sequential boosting regimens for broadening bnAb responses have been evaluated. As for the previous sections detailing priming studies in these models, we will primarily focus on studies that have examined the breadth of VRC01-like nAb responses to sequential vaccination, thus far all using synthetically engineered immunogens to boost various V_H1-2 germline precursor KI models. However, some very new findings in PGT121 KI mice, involving a promising sequential boosting strategy to drive breadth of V3 high-mannose patch-directed nAbs will also be reviewed, as will a just-completed study with the "4-valent" CH505 sequential vaccine regimen (Fig. 6), devised to induce "HCDR3-binder" CD4bs-class nAb responses in CH103 UCA KI mice, the first patient-based (B-cell lineage design) concept to be evaluated in vivo.

5.5.1 Sequential-Based Induction of CD4bs nAb Responses in VRC01 and CH103 Class Precursor KI Models

As the priming studies in the VRC01 gH, 3CBN60 GLV$_H$, and V_H1-2 KI models (Fig. 5A, B, and E) have all demonstrated, immunogens targeting VRC01-class precursors can successfully activate and initiate detectable SHM in V_H1-2 KI-expressing naïve B-cells, and elicit VRC01-like Abs to mature enough to attain some neutralization activity (Dosenovic et al., 2015; Jardine et al., 2015; Tian et al., 2016). However, even repeated immunizations with such priming immunogens, alone, fail to induce the complete, substantial set of somatic mutations required by this bnAb class for

their broad neutralization activity. Given the limited SHM and breadth priming elicited in these models, VRC01-like Abs at this stage would be unlikely to effectively recognize, and thus be boosted by, native Env proteins. Indeed, as noted above for the version of the 3BCN60 KI model generated to represent a synthetic 3BNC60 "later intermediate" (Fig. 5D), immunization with either the native Env trimer BG505 SOSIP or the priming immunogen eOD–GT8 60mer could expand and promote further maturation of this intermediate, but of the two immunogens, BG505 SOSIP induced considerably broader neutralization (Dosenovic et al., 2015), suggesting later intermediate Abs, if they can be elicited, can be best driven to complete maturation by native-like Env immunogens. Taken together, these considerations thus prompted the development of "bridging" immunogens for the initial boosting phase, to promote further maturation of VRC01-like primed Abs (Briney et al., 2016). Two such immunogens were produced as initial boosting components of candidate sequential regimens. One construct, BG505 core GT3, was multimerized using the same nanoparticle platform as the precursor-targeting eOD–GT8 immunogen, but unlike eOD–GT8, contained the complete gp120 core of BG505 Env including its inner and outer domains. Additionally, BG505 core GT3 contained fewer mutations than eOD–GT8 to make the CD4bs more "native-like," including retaining three critical N-linked glycosylation sites, resulting in this construct binding mature VRC01-class Abs with >1000-fold higher affinity than their germline-reverted counterparts. As an alternative bridging immunogen, BG505 GT3 was also produced as a native Env trimer, i.e., BG505 GT3 SOSIP.

To test the efficacies of these two bridging immunogens, VRC01gH mice, one of the first generation "reverted" KI models described above under the priming studies (expressing $V_H D J_H$ rearrangements bearing germline $V_H 1$–2 linked to the mature HCDR3 from the original VRC01 bnAb; Fig. 5A), were immunized with two sequential immunization protocols (Briney et al., 2016), differing only in the two bridging immunogens described above. For both sequential schemes, the mice were primed with eOD–GT8 60mer, then boosted once with the bridging immunogen (i.e., BG505 GT3 core multimers or BG505 GT3 SOSIP), and finally boosted twice with BG505 SOSIP N276, a further modified, (even more native) BG505 trimer lacking only the N276 N-linked glycosylation site. Adjuvant (Ribi) was used during the prime, while boosts were either done in its presence or absence. As with the priming studies discussed earlier, both sequential immunization protocols elicited CD4bs[+] Abs comprised of VRC01gH

and mouse LCs bearing 5-aa CDRL3s, with the regimen that included BG505 core GT3 regimen in particular eliciting the highest frequency of activated (IgG-switched) memory B-cells, with substantially more SHM induced (with up to 16% mutation rates in HCs observed) in all animals from this immunization group. Importantly, there was also evidence for sequence convergence of 5-aa CDRL3-containing LCs induced, with some mutations corresponding to those found in VRC01-class bnAbs known to be critical for gp120 binding. Particularly striking was a strong enrichment for a conserved glutamic acid residue at position 96 within the 5-aa CDRL3, with some CDRL3s even having acquired the complete consensus QQYEF motif of VRC01-class bnAbs. IgG Abs purified from serum of mice administered the entire sequential boosting regimen did not neutralize any isolates from a panel of eight WT viruses, but when the critical N276 residues of these viruses were mutated, the sequential immunization–elicited IgG Abs could neutralize multiple tier 2 HIV-1 isolates bearing the N276 mutation. As with those assayed with IgG serum Abs, viral strains were also refractory to neutralization by mAbs cloned from immunized mice, while multiple N276-mutagenized viral strains were not, although interestingly, two mAbs in particular neutralized a tier 2 virus N276 mutant 191084 B7–19, with comparable potency as the mature VRC01 Ab, and could also weakly neutralize the native form of this viral isolate, i.e., bearing the intact N276 glycosylation site. Thus, along with inducing substantial SHM, this boosting regimen matured VRC01-like Abs to an "intermediate" stage, since vaccine-elicited serum nAbs (and most mAbs isolated) could not bypass the glycan 276 "bottleneck."

Sequential vaccination for inducing breadth of CD4bs$^+$ nAb responses was also very recently evaluated in a collaboration between the Alt lab and the NIH-Vaccine Research Center, using the V_H1–2 unrearranged "second generation" KI model (Fig. 5E) described above under the priming studies. Owing to the diverse Ab repertoire in this model, VRC01-like precursors were highly infrequent, making the AM studies impractical. To facilitate such studies, a model, V_H1–2/LC was generated via introduction of a rearranged gl–VRC01 LC integrated into the Jκ locus of the V_H1–2 model (Fig. 5F) so that the higher frequencies of precursors could be generated. A similar but somewhat more complex sequential immunization strategy was used to vaccinate the V_H1–2/LC model. eOD-GT6 60mer (an earlier version of eOD-GT8 with lower binding affinities to the germline-reverted VRC01 Abs) was administered to selectively activate B-cells expressing VRC01-like precursor Abs. The first set of boosting

immunogens was based on the Env protein of 426c virus, with the use of Env antigens from a different viral strain used for this boost protocol (than from which the priming immunogen eOD was derived from) added as a consideration, with the intent of helping to focus immune responses to CD4bs. The 426c gp120 core (a similar concept to the "BG505 GT3 core" described above for the Scripps study), with mutations at three key N-glycosylation sites (N276, N60, and N463) was then used as a bridging immunogen in initial boosts. At this early stage of immunization, the precursor Ab would be expected to have insufficiently progressed through AM, since the triple glycosylation mutation in this immunogen was intended to facilitate interaction with early intermediates. In particular, and analogous to the strategy used with BG505 GT3 core, the 426c core immunogen contains both the outer and inner domains of gp120, whereas eOD-GT6 consists primarily of a minimal outer domain, thus the 426 core bridging immunogen was intended to serve as a first step in shepherding Abs toward interacting with the CD4bs in a more native context. Subsequent boosts, devised to gradually select for B-cells expressing nAbs capable of accommodating CD4bs-proximal glycans, were then carried out by stepwise administration of 426c core derivatives engineered to have either two, one, or none of the three key N-linked glycosylation site mutations. The final boost then employed the native trimeric form of 426c Env protein.

As with the sequential studies in the VRC01 gH model, this more complex (six step) sequential protocol elicited CD4bs-specific VRC01-like Abs, which in this case were composed of KI V_H1-2 HCs and gl-VRC01 LCs. This stepwise regimen also successfully induced Abs that accumulated substantial levels of SHM throughout the course of immunizations, including developing some mutations which mimicked those in matured VRC01-class Abs. Interestingly, LC mutations were heavily focused on the CDRL1, a region critical for avoiding steric clashes with carbohydrates at the loop D N276 glycosylation site. Notably, serum VRC01-like Abs from mice receiving the full stepwise vaccine regimen exhibited neutralization activities against various autologous 426c viruses lacking one or more of the various N-glycosylation sites, as well as a heterologous virus lacking N276, but not against the WT (fully glycosylated) tier 2 426c virus. The mAbs cloned from these immunized animals largely recapitulated the serum binding data, with 12/15 Abs isolated exhibiting neutralization activities against the autologous 426c virus with N276 mutation, some with potencies comparable to that of the mature VRC01 bnAb, and 4/15 Abs neutralized a heterologous virus that lacks N276 glycosylation. Additionally, 1/15 mAbs also bound

(albeit weakly) to the heterologous native BG505 Env trimer, similar to potentially promising preliminary results seen in the other sequential study, again suggesting in rare cases (below detection limits in serum assays), some clones could circumvent the carbohydrate-related issues at N276. Thus, as with the above sequential vaccination study by the Scripps group in the VRC01-gH mice, along with inducing substantial SHM, this boosting regimen matured VRC01-like Abs to an "intermediate" stage, at which point vaccine-elicited serum nAbs (and most mAbs isolated) could not bypass a key glycan bottleneck. Nevertheless, more generally, these two initial studies provide validation for both the strategy of sequential boosting (as part of a heterologous immunization concept) and the KI mouse model for evaluating maturation of VRC01-like Abs, as viable approaches for studying vaccine-guided breadth development and provide beachheads for iterative optimization of this strategy.

Even more recently, a sequential vaccine regimen targeting the "HCDR3 class" CD4bs[+] bnAb lineage, CH103 has been evaluated in both rhesus macaques and in CH103 UCA het dKI mice (Fig. 5G), a model that heterozygously expresses the HC + LC rearrangements of the bona fide (time-of-infection) CH103 UCA Ab (Williams, W., Verkoczy, L., & Haynes, B., manuscript submitted), and also only replaces a portion of the Jκ cluster, to allow for additional secondary LC events to occur. Combined, these features were intended to decrease precursor frequencies, so that AM to this vaccine regimen could be studied in a highly competitive setting. As noted in Section 4.3, very low (<1%) frequencies of HC + LC KI CH103 clones were found in the naïve mature B-cell repertoire, due to extensive LC editing. As in the 3BNC60 GLV$_{HL}$ KI model, multimerization of the TF Env priming immunogen could activate the minor residual anergic B-cell subset ex vivo, and also expand and induce class switching memory B-cells. However, using the "4-valent" B-cell lineage sequential strategy (Fig. 6) elicited significantly higher numbers of lineage-specific (non-LC edited) memory clones, relative to repeated priming with TF Env. Re-activated memory clones also had selectively been induced to undergo affinity maturation, relative to Env$^-$, LC-edited-clones. However, while activation and bnAb lineage initiation with sequential immunization was better than with priming alone, in this setting AM was highly limited, and sequential immunization and lineage-specific responses became diverted very early in this regimen (after two boosts), indicating either better T-cell help and or adjuvanting to promote bnAb GC responses and/or increasing precursor frequencies is needed.

Thus, several types of CD4bs-targeting sequential immunization studies, now done in five types of mouse models, have thus far provided several important insights and pointed directions for future studies aimed at optimizing sequential strategies to enhance breadth of CD4bs + nAb responses. Most generally, three concepts have come to light: (1) activation of precursors require higher affinity immunogens, as had been predicted, (2) several sequential administrations with progressively more native-like Env immunogens are required to mature precursor VRC01-like Abs toward nAbs, since repeated immunizations are ineffective at inducing AM, and (3) "off-target" (non-CD4bs bnAb) responses also occur, but become more prevalent as system polyclonality is increased (for example, the $V_H1–2$ KI model, relative to the VRC01 gH model), indicating either priming immunogens are not that highly selective for bnAb precursors, or bnAb precursors eventually get outcompeted by some cross-reactive clones over time. With respect to the CH103 UCA dKI model specifically, like the $V_H1–2$ KI model, it also represents a "quasi-polyclonal system," and like all other four studies in VRC01-like KI models, sequential immunization also induced qualitatively better responses than did repeated immunization with the priming immunogen. However, in this case, off-target responses began to predominate in even more pronounced fashion than the $V_H1–2$ model, i.e., after two immunizations, and regardless of vaccine strategy. Also, since the CH103 UCA dKI model was not like the VRC01 models (which exhibited normal B-cell development), and more analogous to the 3BNC60 GL_HL KI model, in that preimmunization, a minor (nonedited) subset in the periphery of lineage-specific anergic clones existed, the earlier termination of sequential-driven bnAb lineage development in this model most likely reflects more stringent out-competition of anergic bnAb clones, by nonanergic Env cross-reactive clones. This suggests sequential immunization for bnAb precursors like CH103 (and 3BNC60) while required, is not sufficient to drive proper maturation of bnAb precursors, and additional signals that increase B-cell survival and/or T-cell help will likely need to be incorporated into such regimens.

With respect to inducing VRC01 class bnAbs specifically, the additional, common theme from the studies done in all four KI models is that accommodation of N276 glycosylation appears to be a bottleneck for VRC01-like Ab development. In mature VRC01 Abs, CDRL1 truncation or mutation helps to accommodate the N276 glycan, as some of the elicited Abs from the immunized VRC01 mouse models utilized mouse LCs with short CDRL1s (Briney et al., 2016; Dosenovic et al., 2015; Jardine et al., 2015;

Tian et al., 2016), but this was not enough to overcome this bottleneck that arises after partial completion of maturation.

5.5.2 Sequential Vaccine Broadening of V3-Glycan "N332 Supersite" nAb Responses in PGT121 KI Models

In addition to the sequential immunization strategies like those described above for CD4bs$^+$ bnAbs, which are based on either structural and/or patient-based information regarding how bnAbs interact with conserved viral epitopes, other, more iterative "empirical" strategies have also been applied as rationale for guiding maturation of precursors toward breadth. One such case is a strategy that Escalano et al. have recently devised for the "N332 supersite" class of PGT121-type Abs (Escolano et al., 2016). In this study, the efficacy of such an alternative "iterative" stepwise boosting regimen was evaluated for its ability to generate breadth development of PGT121-type Abs, in the same two KI models, $GL_{HL}121$ and Mut_HGL_L121, which have already been described in Section 5.3. The overall strategy of this iterative approach was to screen serum from immunized animals after each step in this sequential regimen, for their reactivity against gradually less-mutated Env variants and lower affinities for gl-PGT121 (i.e., 7MUT, 5MUT, 3MUT, etc.) which are derivatives of the near-native WT BG505 SOSIP trimer, T332 that represents progressively more "native-like" AM intermediates between the 10MUT priming immunogen, and BG505 Env (Steichen et al., 2016). Essentially, the least modified Env variants that exhibited the highest serum binding affinity after each round of vaccination was then used in the subsequent boost.

Thus, after successfully engaging and inducing initial maturation of PGT121-like Abs with the synthetically engineered priming immunogen 10MUT, as noted above (in Section 5.3), the serum acquired binding affinity for an engineered version of BG505 Env (7MUT) with fewer mutations, and thus closer to native Env, than 10MUT. Accordingly, trimeric 7MUT SOSIP was then used for the second immunization to guide AM toward recognition of more native Env forms. After second immunizations, serum Abs gained detectable affinity toward an even less-mutated forms of BG505 Env, 5MUT, which was then chosen as the third boost. After third immunizations, binding activity for the autologous WT BG505 SOSIP T332 Env trimer as well as various other heterologous native Env trimers became detectable in serum, leading to the use of the native Env trimer as the fourth boost. Finally, with the intent of further broadening serum Ab responses, a

"cocktail" of heterologous native-like WT BG505 Env trimers with diverse variable loop sequences was used as the final two boosts.

Importantly, at the end of this iterative series of sequential vaccinations, impressive cross-clade viral neutralization activities were detectable in serum IgGs from 3/7 $GL_{HL}121$ and 7/7 Mut_HGL_L121 mice. To more comprehensively evaluate the degree of neutralization breadth the elicited Abs exhibited, 40 mAbs were isolated and assessed on a panel of 54 tier 2 viruses and 2 tier 1B viruses, compared side-by-side with the original (fully matured) PGT121 bnAb. mAbs from $GL_{HL}121$ and Mut_HGL_L121 mice were able to neutralize 12 and 23 viruses in the test panel, respectively; whereas in comparison, the original PGT121 bnAb could neutralize 50 viral isolates. Also notably, the neutralizing activities of the cloned mAbs correlated along with the development of neutralization activities, the elicited Abs accumulated substantial levels of SHM, some of which mimicked those in PGT121-class Abs. Furthermore, either repeated immunization with the 10MUT immunogen, or a simple heterologous prime/boost, i.e., 10MUT prime, followed by a boost with WT BG505 SOSIPs, both failed to elicit serum neutralizing Abs or yield cloned mAbs having any significant neutralizing activity, thus validating the specific effect of this particular sequential regimen in inducing the breadth of nAb responses observed.

Despite the caveats with this particular animal model (further detailed in the next paragraph), this is nevertheless the first proof-of-concept study that shows development of broadly neutralizing responses, from a less mature point in an evolutionary pathway, can be elicited by vaccination. Additionally, together with the studies for eliciting VRC01-class nAb, it also further highlights the general requirement for a directed heterologous prime/ boosting approach to guide relevant bnAb maturation, and more specifically, further validates the "sequential" immunization concept, as a strategy to induce bnAb responses. However, going forward, the induction of PGT121-like Abs not only faces some immunological challenges in common with those for VRC01-targeting bnAbs and other bnAb classes, but also has its own technical issues regarding the particular KI models in these initial studies, that also cannot be overlooked.

Regarding the common issues first, such sequential immunization strategies will need to be able to elicit bnAbs in a complex unrearranged Ab repertoire, where the bona fide PGT121 (UCA) precursor Ab frequencies after undergoing preantigenic V(D)J recombination and HC/LC pairing in a fully polyclonal setting would normally result in extremely low frequencies. This problem would be predicted to be more acute for PGT121-class Abs

and other long HCDR3-expressing bnAbs, than for VRC01. PGT121-like HCDR3s play a critical role in this bnAb class' interactions with Env; and for this reason, PGT–121 like Abs have stringent requirements for both HCDR3 sequence and length. By comparison, VRC01-class Abs are more flexible with respect to HCDR3 characteristics, and their more typical HCDR3 length and composition are not normally associated with negative selection–mediated culling that long HCDR3-expressing B-cells often face early in B-cell ontogeny both prior to BCR expression likely (at least partly) due to both preantigenic HC/surrogate LC and HC/LC pairing issues (Ivanov et al., 2005; Martin et al., 2003; Vettermann & Jack, 2010; von Boehmer & Melchers, 2010) and/or due to potential self-reactivity due to their surface expression at the pre–BCR stage (Keenan et al., 2008; Minegishi & Conley, 2001) and the first tolerance checkpoint upon their expression as IgM$^+$ BCRs (Meffre et al., 2001; Shiokawa et al., 1999). Thus, the frequency of bona fide precursors of PGT121-like bnAbs would be anticipated to be even lower than those that have been found for VRC01-class Abs (Jardine, Kulp, et al., 2016; Sok et al., 2016).

Immunization in a fully polyclonal B-cell repertoire poses yet another difficulty: the induction of multiple "off-target" Ab responses by irrelevant (nonneutralizing) epitopes to more complex, multiepitope immunogens such as Env. In the case of VRC01, the problem can be ameliorated at least in part by using a minimal outer domain where the antigenic variable loops are trimmed away. This solution may not apply to PGT121 immunogens, since V1 and V3 are part of the bnAb epitope. Furthermore, V1–V3 loops mediate protomer association (Julien et al., 2013; Pancera et al., 2013), and as shown by immunization studies in the PGT121 KI models, trimeric but not monomeric immunogens are necessary to elicit adequate immune response (Escolano et al., 2016). Thus, despite the fact that such native trimeric immunogens may better occlude many normally hidden immunogenic epitopes than monomeric gp120 Env immunogens (de Taeye et al., 2016; Sliepen & Sanders, 2016), even these will present immunogenic non-neutralizing epitopes. For example, V1–V3 loops need to be preserved in the trimeric PGT121 immunogens, but the presence of these variable and potentially antigenic loops may increase the chance of diverting immune responses. In this regard, the presence of multiple "off-target" competing clones in the setting of a polyclonal repertoire means that what are anticipated to be very rare PGT121 precursor clones will need optimization of priming immunogens for their ability to bind these precursors at much high affinities than 10MUT currently binds gl–reverted PGT 121 KI cells; indeed,

despite successfully triggering PGT121 Ab responses in vivo in the setting of the $GL_{HL}121$ model, the fact $GL_{HL}121$ KI B-cells could not be activated ex vivo (Escolano et al., 2016) lend support to this notion.

Third, while these initial studies in the PGT121 KI model, along with the other ones discussed in this section, are still very much at the proof-of-concept stage, longer term, it will likely be key to learn if and how to "short-circuit" such maturation pathways, as reducing the number of sequential boosting steps required will be critical for devising a more practical and truly feasible global vaccine concept. In this regard, what is clearly the "common theme" in all sequential studies done in KI models thus far (VRC01, CH103, and PGT121 class) is that repeated immunization with the same priming immunogen clearly fails to produce any significant nAb responses or SHM, and heterologous prime/boosting with additional Env variants is needed. However, what minimum number of related Envs is needed for guiding such responses appropriately (and if having a limited set is even possible for certain bnAb lineages/classes with substantial SHM accumulated during infection), are key open questions for the vaccine field. The studies thus far suggest multiple Env variants will needed, at least with current iterations of the sequential concepts, and especially for driving *complete* bnAb evolutionary pathways, in *more physiological* settings. For instance, the sequential study in the VRC01 gH model that went to an intermediate stage (Briney et al., 2016) required less boosts (three boosts over four immunizations), but this model was also more enriched for VRC01-like precursors and did not have to deal with the issue of large numbers of competing "off-target" clones, whereas in the more physiological $V_H1–2$ model, where there were considerably more off-target responses, a more complex reverse-engineering sequential approach that required seven steps achieved similar "intermediate" maturation pathways having limited neutralization breadth (Tian et al., 2016). Also, of the two PGT121 KI models more representative of the PGT121 precursor ($GL_{HL}121$), the iterative sequential approach just discussed required five steps (six immunizations) to achieve a heterogeneous and partial degree of breadth, and even in this more "precursor-like" version of PGT121, it is not clear if and at what maturation stage of the evolutionary clade derived from a bona fide PGT 121 UCA these germline-reverted precursors truly represent in the priming/boosting process (see below for further discussion). Finally, the "4-valent" patient-based B-cell lineage design approach in CH103 UCA dKI mice could select for and induce limited maturation of the CH103 UCA (above and beyond repeated immunization with the priming immunogen), but will likely require further immunogens

and/or adjuvanting to overcome this block in early maturation. Thus, while the PGT sequential strategy (and the others discussed in this section) represent promising early leads and the most direct evidence that reverted bnAbs can be activated and matured by vaccination, in more physiological settings, where complete maturation pathways need to be induced, such approaches would appear to require considerably more immunization-guided AM, and thus barring more straightforward ways to bypass developmental bottlenecks or short-circuit pathways to relevant breath, it is anticipated much more iterative optimization will be necessary.

With respect to the partial breadth induced by iterative sequential boosting in the GL_{HL} 121 KI model in particular, there are also three substantial caveats with this particular model, which give pause to drawing any general, physiological conclusions yet, but definitely warrants further investigation of this promising approach. First, as already mentioned in the priming section, GL_{HL} 121 mice use a "least-mutated" member structural inference with key HCDR3 mutations remaining, which represents a "quasi-intermediate" Ab that may or may not normally be induced by AM of the available human repertoire (either in response to infection or vaccination). Thus, it remains to be seen if bona fide PGT121 precursors can be found in all healthy humans and activated in Kymab mice by "N332 supersite" Ab–priming immunogens like 10MUT. Second, in addition to the point mentioned above (that PGT 121 Abs, when knocked-in as both HC + LC KI rearrangements likely bypassed negative selection prior to self-antigen encounter that HCDR3 issues impart on HC/LC pairing; Vettermann & Jack, 2010; von Boehmer & Melchers, 2010), by also having mutations in the HCDR3, this least-mutated PGT121 precursor, relative to a bona fide unmutated HCDR3-expressing PGT121 UCA precursor, may also have avoided initial BCR encounter with self-antigen. Thus, immunizations could be done instead in Kymab mice or either newer unrearranged models, either ones based on the "V_H1–2-like" KI concept, but which has a human D also knocked-in and thus does not rely on shorter mouse D segments to generate longer HCDR3s in PGT121-like bnAbs (for which it is near-impossible to deconvolute SHM vs VDJ recombination contributions), or prearranged V(D)J UCA KI models like the CH103 UCA dKI platform, constructed from bona fide time-of-infection patient samples that can allow higher-probability inferences of such long HCDR3 junctions to be made. In the next section, we will discuss such newer models being planned in further detail, both in terms of their importance for further bridging the gap between physiological relevance and practicality of the KI platforms we

described here (Fig. 3). Finally, it is also important to point out that only some of the sequentially immunized GL_{HL} 121 mice (3/7) developed cross-clade neutralization, showing this strategy not only induced partial breadth (12/50 isolates neutralized by mAbs from these mice, relative to 50/50 by the original PGT121 bnAb) but also exhibited variability in developing such breadth, despite the inbred genetic backgrounds of the mice. Thus, these results also suggest immunogens cannot (yet) guide the responses of this partial maturation pathway in highly reproducible fashion, and thus has to be further optimized and/or combined with emerging patient-based lineage concepts, assuming data becomes available that potentially could demonstrate reproducible natural infection maturation pathways and coevolved viral isolates that could be used as immunogen templates. One current example of this possibility, as discussed earlier, is new data from an NHP study demonstrating striking resemblance in virus–Ab evolution upon infection with a SHIV, engineered to express the same TF Env as the original CH505 patient (Li et al., 2016).

6. IG KI-RELATED METHODOLOGICAL ADVANCES RELEVANT FOR STUDYING bnAb DEVELOPMENT

The various methodological advances in bnAb discovery, cloning, and characterization, as well as the initial vaccine strategies in various precursor bnAb KI models noted above that have shown promising beachheads (both for priming and inducing a degree of maturation toward breadth), all represent significant steps forward for bnAb-based vaccinology. However, fundamental gaps in knowledge and technical aspects of learning how to induce protective HIV Ab responses remain, both of which can benefit tremendously from further improvements in existing human Ig KI methodologies. Below, we will briefly discuss some of these murine gene-targeting methodologies, both established and new alike, that could be applied specifically for this key goal. We will focus on advances that will enhance throughput for generating HIV Ab KI models, further balance their practicality and physiological relevance, and manipulate timing or frequency of bnAb expression or general B-cell selection pressure and SHM levels, which collectively should allow more iterative and practical evaluation of new HIV vaccine candidates for their ability to induce protective Ab responses, as well as more precise and systematic identification of what the minimal requirements for (and limitations to) developing more durable, robust, and rapid bnAb responses. Collectively, these enhancements to KI methodologies should

thus ultimately enable relevant refinements to be made for improving protective humoral responses by candidate vaccine regimens.

6.1 Technologies for High-Throughput Production of bnAb KI Models

Technical advances for generating relevant humanized Ig KI models in a less cost prohibitive and rapid fashion would have the obvious benefit of providing a larger spectrum of models in which protective responses to different Env targets could be more conveniently tested. As a result, increasing the capacity to produce HIV Ab KI models would have major ramifications from both a technical vantage–point and more fundamentally, for testing hypotheses relevant to understanding limitations to bnAb induction that exist for vaccination. From the more pragmatic aspect of HIV vaccine testing specifically, as greater numbers of bnAb lineages now begin to be deciphered with time-of-infection sampling, and particularly if similar, reproducible bnAb/viral coevolutionary intermediates exist as has recently been reported for CH103 coevolved quasi-species (Li et al., 2016) and could thus be used as templates to shepherd bnAb maturation during vaccination, increased numbers of such KI models will be needed. This expansion of KI models made for relevant bnAb lineages, in turn would make it more feasible for multiple immunogens and/or adjuvant modifications targeting individual bnAb lineages to be evaluated for their ability to reproduce, and possibly even short-circuit such pathways. For example, more practical and efficient initial readouts like serum neutralization analysis, rather than mAb generation/characterization could be done in such models, and also in more standardized fashion, since direct comparisons to each would be possible. Additionally, because many novel vaccine concepts will mandate some degree of empiricism (for example, in testing multiple timing permutations of when adjuvants/SMIs would be best incorporated into regimens to enhance B–cell survival, enhance T_{FH} function, or prolong GC reactions, or for determining the most effective orders of sequentially administered immunogens during boosting regimens), a much larger array of vaccine regimens targeting individual bnAb lineages could be evaluated at much higher resolution, which collectively would allow more systematic stratification of which new strategies could potentially best elicit candidate protective humoral responses to HIV.

From the basic science side, as noted earlier in this review, a fundamental question for HIV vaccinology is whether certain Env targets are more tractable for vaccination to elicit bnAbs against (or "later intermediates" of bnAb

lineages), either due to requiring lower amounts of AM and/or not being under tolerance controls. As for the practical issue we discussed above, this question will also require generating significantly larger volumes of gene-targeted animal models, to enable systematic, high-resolution identification of which particular impediments are common or unique at distinct Env targets, and then, devising strategies with modified or specifically tailored immunogens adjuvants, SMIs, or T–cell primes, in order to test how to overcome them safely. Thus, determining relative tractability of such targets for vaccine candidates will require comprehensive testing of tolerance prevalence and minimal SHM requirements of bnAbs across all Env targets, which in turn will necessitate use of higher-throughput KI-producing methodologies. Given both these practical and basic challenges mandate increased numbers of studies aimed at learning how to induce bnAb lineage development, what methods could increase the capacity to make platforms expressing bnAb lineage members in vivo?

One key technological advance with respect to increasing capacity of generating HIV Ab KI models comes from the Alt lab, who applied a methodology they pioneered over 20 years ago, termed RDBC (RAG2-deficient blastocyst complementation) (Chen, Lansford, Stewart, Young, & Alt, 1993) originally employed to evaluate the impact any given gene (lymphocyte-specific or generally expressed) had on lymphocyte function and/or differentiation (Chen, 1996; Chen, Shinkai, Young, & Alt, 1994). As proof-of-concept, they recently applied this technology to generate the V_H1–2 series of models (Tian et al., 2016) that was discussed in the previous section. As was the case for generating these KI models (Fig. 7), recombinant ES cells are microinjected into RAG2-deficient blastocysts. As RAG2 is critical for V(D)J recombination, all the B and T lymphocytes in the resultant chimeric mice will originate from the injected ES cells. For this reason, the chimeric mice can be directly used for immunization experiments, thus obviating the need for lengthy and costly mouse breeding during germline transmission. The RDBC approach is particularly advantageous for mouse Ig KI models originating from ES cells contain multiple genetic modifications on different chromosomes, which would normally segregate during mouse breeding, such as in the case of bnAb precursor[+] KI ES cells in which both HC and LC rearrangements have been knocked–in.

Construction of higher numbers of bnAb lineage (and other protective HIV Ab) KI mouse models could also be further aided by technologies that increase gene-targeting efficiency, and thus expedite genetic manipulations

Fig. 7 High-throughput in vivo expression of bnAbs in chimeric mice using RDBC. Shown are the two major steps in the RAG-dependent blastocyst complementation (RDBC) approach (Chen et al., 1993, 1994; Tian et al., 2016) for generating bnAb KI chimeric mice. In the first step (A) blastocyst chimeras are generated by microinjection of bnAb KI ES cells. Then, in the second step (B), blastocyst are implanted into pseudopregnant RAG2$^{-/-}$ foster mothers, resulting in chimeric offspring, whose lymphocytes all express the knocked-in bnAb specificity and can be directly utilized for immunization. Shown as an optional step (C) is germline transmission of bnAb KI allele to generate a standard KI model, which can be pursued if more in-depth studies with a particular model are desired. *Reproduced with permission from Verkoczy, L., Alt, F.W., Tian, M. (2017). Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.* Immunological Reviews, 275, 89.

in ES cells, such as the relatively nascent "genome-editing"–based Cas9/ CRISPR technology (Ran et al., 2013). This methodology allows for considerably more rapid and efficient gene-targeted replacement than conventional (homologous recombination-based) gene targeting. Since many/most of the new KI mouse models the HIV field will use as immunization platforms are likely be made via similar (if not identical) Ig locus–targeting strategies (in order to allow direct head-to-head comparisons of immunogen efficacy and bnAb class/Env target feasibility to be made) they will differ only in bnAb VDJ exon specificities, or even more specifically in some cases, among a related series variant Abs (for example, progressively matured intermediate Ab members of a given bnAb lineage), differ at only a single key mutation (representing a potential selection bottleneck in bnAb development). Thus, to replace specific Ig locus V, D, or J segments (or V(D)J exons), Ig mini–gene or rearrangement "swapping" of ES cells with such highly similar targetable sequences could be performed using Cas9/CRISP target sites. Another process that could be used for the same purpose would be to perform such site-specific targeted replacement via use of a recombinase-based cassette exchange system (Turan, Zehe, Kuehle, Qiao, & Bode, 2013).

Thus, with the combined application of RDBC and CRISPR for generating bnAb precursor KI models, it will now be feasible to accelerate the production bnAb KI models (from years to months, and by a degree of magnitude or even less in terms of cost), thus making it more feasible to analyze

bnAb development across multiple lineages, targeting multiple Env regions. Furthermore, by using the combination of these two technologies, it will not only enable study of multiple individual bnAb lineages, but even an array of related variants, for example in addition to UCAs and matured bnAbs of key lineages, selected intermediate members (at key developmental branch points), thus making it possible to study critical maturation bottlenecks unique to particular lineages. This may be critical, since extensive SHM can either remove or introduce self-reactive residues (Haynes, Verkoczy, et al., 2014; Mietzner et al., 2008; Sabouri et al., 2014; Shlomchik et al., 1990; Tiller et al., 2007; Verkoczy et al., 2013), and matured bnAbs can have less tolerizing self-reactivity than their precursors (Zhang et al., 2016), or potentially more, as could be the case in the CH103 lineage, based on reported in vitro poly-/autoreactivity profiles (Liao, Lynch, et al., 2013). Thus, critical lineage-specific selection bottlenecks can occur at distinct stages of maturation, and the ability to rapidly produce, and have in hand, KI models expressing intermediates will allow testing of lineage-specific vaccine regimens for their ability to overcome unique bottlenecks, at an unparalleled level of resolution.

6.2 Further Bridging the Gap Between Practicality and Translatability of Ig KI Models

### 6.2.1 Conventional "Germline-Reverted" and UCA Precursor bnAb KI Models

As noted earlier in Section 3, Ig KI models, due to their unique ability to balance physiological relevance and practicality, have various advantages over other, nongenetically manipulated experimental animal models for the purpose of evaluating humoral responses to HIV vaccines, and more specifically, in understanding specific limitations and requirements for bnAb induction. In this section, we will overview various types of newer humanized Ig models, either unpublished or at the planning phases (Fig. 8), in relation to those already published, with respect to their potential to further bridge this gap, and thus convert such systems from being strictly lead-generating platforms to more translational, or potentially even bona fide preclinical, models for testing HIV vaccine candidates.

In identifying gaps in physiological relevance that still remain in such models, one must ponder which critical questions remain for the field, that cannot be satisfactorily be answered by existing versions of bnAb KI models. An example of such a question is what the most effective stimulating antigens are to initiate development of bnAb lineages. A major consideration in

Fig. 8 See legend on next page.

properly designing such studies, for their being relevant to more general vaccination approaches, will be for candidate immunogens, to reproducibly bind precursor naïve B-cells bearing bona fide "gl (germline)-derived" rearrangements, i.e., direct products of V(D)J recombination originating from *unmutated* human variable region exons (of any particular bnAb of interest they originate from), that are present in the repertoire of most healthy individuals. Thus, of all human Ig KI models potentially available to test this question (Fig. 8), only those capable of generating such validated "unmutated" gl-derived rearrangements, can be considered physiologically relevant. In particular, of the gl-reverted models discussed in this review, those like the VRC01gH, gl-3CN60, and gl-PGT121 models, have been made akin to conventional Ig KI models previously made in the B-cell tolerance field, i.e., with prerearranged V(D)Js. However, these particular models specifically use gl V_H segments but either retain mature HCDR3s (Dosenovic et al., 2015; Jardine et al., 2015) or "least-mutated" members of structurally inferred (rather than time-of-infection) lineages (Escolano et al., 2016) (Fig. 8, Model "1A"). Thus, it is impossible from such starting rearrangement inferences to know if certain key mutations have already been introduced that would bypass purifying selection bottlenecks during AM, nor is it possible to ascertain if clones expressing such rearrangements could be made during AM. Thus, while possibly informative as proof-of-

Fig. 8 Types of Ig-humanized mouse models to study vaccine-guided bnAb development. Pictorial representation of the structural organization of targeted alleles from various kinds of current or planned Ig-humanized models is shown, relative to the WT murine allele. For simplicity, only HC loci are depicted, at only one allele, and the mouse IgH locus, which spans 3 mb, is not drawn to scale, in order to emphasize the key genetic elements. Models that have been published (with corresponding references to the right), or models which are being generated, are denoted in *black text* (Models 1, 2, and 5), while theoretical germline/unrearranged models (that could be made or are being planned, to further bridge the current gap between physiological relevance and practicality to study bnAb specificities with long HCDR3s and thus are difficult to infer; Models 4 and 5), are annotated in *blue text*. Mouse and human germline-derived sequences/segments are depicted in *red* and *blue*, respectively. Denoted as a *green* segment in the 1A type of models are "mutated" HCDR3s from the human bnAbs VRC01 and PGT121, i.e., from either the original/mature VRC01 bnAb, but with a single mutation to remove an unpaired cysteine (Jardine et al., 2015), or for PGT121, from the least-mutated lineage member (Escolano et al., 2016). The intergenic control region 1 (IGCR1) normally found in WT HC loci is denoted by a *large circle*, which has been removed in models 2–4, to further facilitate rearrangement of D-proximal (V_H81X positioned) V_H segment(s) of interest. p = promoter region; L = leader sequence. *Adapted with permission from Verkoczy, L., Alt, F.W., Tian, M. (2017). Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.* Immunological Reviews, 275, 89.

concept for developing boosting regimen concepts and/or priming *potential* early intermediates of maturation pathways (assuming vaccine-induced pathways would reproducibly form similar partially matured HCDR3 junctions), they cannot reliably inform true priming phases of full maturation pathways.

In certain instances, such as when the bona fide UCA of a given bnAb lineage has been deciphered, and/or a bnAb lineage has the potential to be reproducibly driven in multiple individuals, then using conventional KI models, in which such bnAbs' UCA V(D)J rearrangements have been knocked-in (Fig. 8, Model "1B") may be warranted, since these can predict (or at least approximate) starting rearrangements of lineages with reasonable certainty. In particular, if complete virus and Ab coevolutionary pathways from which a given bnAb develops has been elucidated via comprehensive longitudinal (time-of-infection) sampling, including a higher-probability inference of its UCA, then the "B-cell lineage immunogen design" vaccine strategy (Haynes, Kelsoe, et al., 2012) noted in the previous section, to recapitulate (and potentially short-circuit), maturation seen during infection, can be rigorously tested in such models. As an example, bnAb KI mice bearing the CH103 lineage UCA rearrangements would hold particular promise for evaluating this type of sequential vaccine approach, since the CH103 lineage's coevolutionary trajectory has been extensively sampled (Liao, Lynch, et al., 2013) and includes molecular elucidation of time-of-infection samples acquired near to, or at, the TF virus and UCA interaction step occurring in acute infection. Furthermore, the viral evolution of this lineage in the CH505 patient has recently been found to be faithfully recapitulated in a CH505 redesigned SHIV in macaques (Li et al., 2016), suggesting its coevolved bnAb lineage maturation trajectories may not only be reproducible across various individuals, but potentially primate species.

6.2.2 KI Models Expressing Unrearranged Minigenes From Individual bnAbs

Unfortunately, the use of conventional KI models expressing prerearranged V(D)J exons are likely not to be ideal for studying vaccine-mediated maturation pathways of most currently identified bnAbs, in at least two instances. First, for many (if not most) current bnAbs identified, time-of-infection samples are either not available or limited, thus restricting information regarding their molecular evolution, resulting in moderate to lower probability inferences. Thus, KI models that could address this issue, particularly for bnAbs with typical length HCDR3s, such as many of the "CD4

mimic" class of CD4bs$^+$ bnAbs, would be those engineered like the Alt lab's V_H1–2 KI model (Tian et al., 2016) (Fig. 8, Model "2A"), but in addition to expressing an unrearranged V_H, will also express the given bnAb's human J_H segments (Fig. 8, Model "2B"), to further ensure the relevant repertoire of V(D)J rearrangements is formed, since these minigenes are considerably less diverse and homologous between mouse and man, than are the array of potential D segments capable of forming typical length HCDR3s (Ichihara, Hayashida, Miyazawa, & Kurosawa, 1989). Additionally, like in the V_H1–2 model, such models will insert relevant V_H segments at the V_H81X site, which due to at least in part to their proximity to D segments, when positioned at this site will be the most frequently utilized V_H segment during HC rearrangement (Alt et al., 2013). Also like the V_H1–2 model, this bias for rearrangement at the V_H81X site can be made even more pronounced, by deletion of a regulatory element at the intergenic region between V_H and D segments: the intergenic control region 1 (IGCRI), which negatively regulates V_H81X rearrangement (Guo et al., 2011). Thus, with this additional modification, such models can express a repertoire highly enriched for bnAb lineages comprised of rearrangements made from the given knocked-in V_H and J_H segments. Importantly, this feature distinguishes such models from "fully" Ig-humanized models expressing completely polyclonal, human V(D)J-derived repertoires, i.e., Kymab$^®$ (Lee et al., 2014; Sok et al., 2016) or Regeneron VelocImmune$^®$ mice (Macdonald et al., 2014; Murphy et al., 2014) (Fig. 8, Model "5"), which rarely express such bnAb rearrangements, and thus are likely to make (at least initial phases of) iterative vaccination studies aimed at inducing development of specific bnAb lineages, highly impractical.

A second instance of where conventional KI models expressing prerearranged V(D)J exons, including those expressing bona fide UCAs (regardless of time-of-infection information available) are *not ideal* to test prime-boost regimens for inducing bnAb maturation pathways, is for bnAbs with exceptionally long HCDR3 regions. It is estimated that ~2/3 of all bnAbs isolated thus far have long HCDR3s (≥20-aa), and those targeting the V3 or V1/V2 in particular have exceptionally long (often >25-aa) HCDR3 regions. Thus, for any bnAbs in these latter classes especially, even for which maturation trajectories have been deciphered by longitudinal sampling, it may still be challenging to correctly deduce their UCA rearrangements, since attributing nucleotides originating from SHM rather than N-addition at V(D)J junctions becomes increasingly difficult, the longer the HCDR3 (Kepler, 2013). In such cases, the current

"second generation" Ig bnAb KI hypothetical model we just described, expressing unrearranged V_H and J_H (Fig. 8, Model "2B") would also fall short, but could be modified to deal with this issue, by the further alterations to accommodate the longer human D regions (relative to those in WT mouse IgH loci), required to produce elongated HCDR3s (Briney, Willis, & Crowe, 2012). Such additional modifications could involve either removing the entire murine D cluster as has been done before by loxP site-mediated deletion (Nitschke, Kestler, Tallone, Pelkonen, & Pelkonen, 2001; Schelonka et al., 2005), and replacing it with a relevant long human D segment (Fig. 8, Model "3") such as D3-3, a minigene used by many long HCDR3-containing bnAbs (Briney et al., 2012; Willis et al., 2016), or alternatively, replacing the murine J_H cluster with a human DJ_H containing a long DJ_H junction.

6.2.3 Limited Repertoire Models and Other Systems to Increase Polyclonality and bnAb Response Diversity

Longer-term, models that could provide some degree of polyclonality and also generate multiple bnAb specificities, would obviously further balance the aspects of practicality with and physiological relevance for studying development of protective HIV/bnAb responses. One such model in the planning phases is the LGR; "Limited Germline Repertoire" HIV Ab/bnAb KI model, which would preferentially express rearrangements derived from a limited set of V, D, and J segments, common to bnAbs with long HCDR3s (Fig. 8, Model "4"). This latter model, representing a "hybrid" KI model between fully Ig-humanized KI mice (Fig. 8, Model "5") and the second generation (unrearranged) individual bnAb KI models (Fig. 8, Model "3") would be intended to provide the best balance of convenience and relevance, and thus the greatest degree of translatability (Table 2), by retaining advantages of both generating a more diverse polyclonal system, yet still allowing a restricted number of specific bnAb-specific rearrangements to predominate, relative to the much larger set of non-bnAb specificities. One major advantage with such a model is that testing of combined "bnAb lineage-targeting strategies," or more universal immunogen/vaccine approaches would be possible to evaluate at higher resolution, for their relative abilities to induce multiple bnAbs. Assuming more than one bnAb class/Env target is in fact tractable to elicit, the concept of achieving more modest breadth with such approaches, as apart of a "cumulative breath" strategy, could thus be more directly tested, and thus more rapidly translated to other preclinical (or even directly into clinical) trials. Shorter term, one existing model that could have the potential to serve as such

a "hybrid model," at least in some instances, could be a rat "human IgH/κ/λ minilocus" transgenic model (Ma et al., 2013; Osborn et al., 2013), which is similar to the "fully Ig-humanized" Kymab/Regeneron models (Fig. 8, Model "5"), except that it expresses a more restricted set of human V_H families, but many that are utilized by long HCDR3 bnAbs, giving it the potential to provide more convenient bnAb–specific readouts than the fully Ig-humanized mouse platforms. However, because this model does not have the relevant bnAb genes positioned proximally, nor in the presence of the IgCR1 deletion, as the LGR model would be proposed to, nor is not clear from published reports how frequently various V_H family rearrangements are found in this model's repertoire, it would need validation in the setting of HIV vaccination studies.

Other, more immediate ways to increase polyclonality of bnAb KI models for immunization studies would be adoptive transfers of either donor splenic KI$^+$ B-cells into uMT recipient mice (Kitamura, Roes, Kuhn, & Rajewsky, 1991) or donor KI bone marrow cells into irradiated F1 allotype WT recipient mice, in order to generate mixed BM chimeras. In such models, the critical point is that frequencies of bnAb precursors and their repertoire can be manipulated: while the starting point will be homozygous mice to ensure bnAb precursor enrichment, degree of clonal competition can be controlled by adoptive cotransfers with varying ratios of donor wild-type and/or KI B-cells. Additionally, depending on the particular

Table 2 Comparison of Conventional bnAb Precursor KI, Complete Human Ig Loci, and "Hybrid" bnAb KI Models

Potential Limiting Issue	Individual bnAb Reverted/UCA KIs	Regeneron/ Kymab	bnAb LGR "Hybrid" KI
Infrequent "long HCDR3" bnAb precursors?	No (but monospecificity can be manipulated)	Yes	Enriched for bnAb precursors
Breeding to other KI/KO models possible?	Yes	No (proprietary)	Yes
Is inference for true (unmutated) V(D)J rearrangement possible?	No (for most, without complete time-of-infection information)	Not required	Not required
Is simultaneous evaluation of responses to vaccines possible at multiple Env regions (bnAb targets)?	No	Yes	Yes

experimental system and/or design used for reconstitution, two (or potentially more) HIV Ab/bnAb precursors can be evaluated head–to–head, in a setting where they are at limiting amounts, yet can be conveniently tracked by flow–based demarcations, either using the combination of CD45 allotypic and/or with appropriate fluorometric markers, the latter which can be achieved by deriving donor precursor KI+ B-cells from bnAb UCA models crossed to eGFP or eCFP transgenic mice. One instance where this type of in vivo system could be particularly informative is to test responses of candidate protective Ab lineages with overlapping, yet distinct Env epitopes to common immunogens. As a specific example (Fig. 9), the activation and maturation of donor KI B-cell precursors from two models under


Fig. 9 Dual adoptive transfer strategy to study simultaneous in vivo priming and/or maturation of dKI B-cells expressing precursors of V2+ CH58 and CH01 lineages. Given the possibility of clonal competition impacting vaccination outcomes in dKI models, the degree of competition can be manipulated via coadoptive transfers strategies in which distinct bnAb UCA+ B-cells and WT donor B-cells can be used to reconstitute recipients. Thus, the immunization outcomes of bnAb lineage precursors with overlapping Env epitopes (in this case CH58 and CH01), can be compared in a polyclonal in vivo setting, in response to common (A244△11 gp120 and V2man$_5$ glycopeptide) immunogens.

development (Verkoczy, L. & Haynes, B.F., unpublished), either eGFP[+] clones expressing the UCA of CH01, a V2/glycan-specific bnAb (Bonsignori et al., 2011), or CFP[+] clones expressing the UCA of CH58, a V2-specific ADCC mediating, but minimally neutralizing (tier 1) candidate protective Ab from the RV144 trial (Liao, Bonsignori, et al., 2013), could be evaluated in such chimera systems, in response to A244△11 gp120, an immunogen that binds both these lineage's UCAs at relatively high affinity (Alam, Liao, et al., 2013). Importantly, while similar competition studies between precursors of CD4bs[+] bnAb and neutralizing Abs have been reported using transformed B-cell lines (McGuire et al., 2014), and thus may be a useful starting point for studying clonal competition dynamics in the context of priming specifically, i.e., evaluating relative BCR engagement/activation of such clones, only similar in vivo studies like the ones noted above can examine GC selection and AM in such competing lineages. Another instance where such in vivo mixed chimera systems could be useful immunization platforms are studies to understand the impact of two cooperating lineages on each others' development, in the setting of immunization. For example, coadoptively transferring B-cells from KI mice expressing the UCA rearrangements of the CH103 and CH235 cooperating lineages (Bonsignori et al., 2016; Gao et al., 2014; Liao, Lynch, et al., 2013), both KI models which are also under construction (Alt, F.W. & Tian, M., unpublished; Verkoczy, L. & Haynes, B.F., unpublished), may be highly informative for understanding the dynamics of coevolving lineages in the setting of vaccination.

Longer-term, other approaches that could also further increase translatability of such models, especially "hybrid" humanized bnAb/HIV Ab platforms like the proposed LGR strain (Fig. 8, Model "4") are ones that provide increased relevance for testing vaccine strategies in preclinical and/or clinical settings. For example, one key issue that may impact studying T-dependent Ab responses in highly inbred mouse strains, regardless of the degree to which models on such backgrounds have their Ig loci optimally humanized, is MHC dependence of CD4 T-cell responses. Precedent for the issue of response variability among inbred strains exists for T-dependent anti-HIV Ab responses, at least for certain bnAb targets like the MPER (Zhang et al., 2014). In this regard, backcrossing relevant bnAb KI strains like the LGR model not just into F1 backgrounds, but speed-crossing and/or reengineering their ES cells by Cas9/CRISPR into the collaborative cross (CC-RIX) mouse background (Aylor et al., 2011; Churchill et al., 2004; Phillippi et al., 2014), a strain specifically outbred to mimic human population diversity, would thus be highly beneficial for the more general purpose

of conferring increased class II haplotype diversity. Another example of where a further layer of translatability could potentially be added in LGR models or any such "hybrid" humanized Ig KI models having more limited (practical yet still physiologically represented) bnAb repertoires, would be to breed them to so-called human CD4/human CCR5 HIV-1 "infectable" transgenic models (Gruell et al., 2013; Seay et al., 2013). Such manipulations could in theory convert bnAb precursor KI repertoire platforms into direct go-to humanized vaccination/challenge protection models, which if successfully validated, would not only provide the benefit of significantly reducing costs relative to existing preclinical studies (i.e., using NHP models), but may also bring to the table various other built-in benefits, such as allowing more convenient and robust determinations of any potential Ab-mediated protection correlates.

6.3 Other Gene-Targeting Manipulations Beneficial for Basic bnAb B-Cell Research and HIV Vaccine Testing

Finally, in addition to the advent of higher-throughput techniques to produce KI models, other novel approaches that may further facilitate study of bnAb development will include those in which stage-specific expression is manipulated. An instance where this could be particularly useful to study responses of bnAb$^+$ B-cells that normally are not permitted by host tolerance to progress into mature B-cell compartments, a potentially significant technical hurdle, given the large number of second generation bnAbs that also exhibit features predicted to predispose them to near-complete deletion in bone marrow, for example bnAbs like VRC26, whose unusually long HCDR3s (Doria-Rose et al., 2014) would normally subject B-cells expressing them to negative selection during early B-cell development (Meffre et al., 2001). One specific example of such an approach would be employing a Cre-loxP inversional recombination system under the control of a B-cell stage-specific marker's promoter such as CD21 (Maruyama, Lam, & Rajewsky, 2000), to conditionally express a "passenger" bnAb specificity in the periphery, analogous to strategies previously used to modify B-cell specificities in memory B-cells (Kraus, Alimzhanov, Rajewsky, & Rajewsky, 2004).

Another area where further refinements to bnAb KI models could open the door to a wider range of experimental possibilities are those providing increased flexibility for studying various mechanistic aspects of priming, maturation, and clonal competition for a various bnAb lineages. With respect to perhaps the single most critical issue, the ability to drive adequate bnAb AM, such refinements would provide greater opportunities for

obtaining a deeper knowledge of whether high SHM levels are inherent to and/or generally required (or perhaps in some cases even detrimental) for bnAb development, and if so, whether inducing such high levels, or unusual, insertion/deletion events associated with such high SHM rates, and also key for function of many bnAbs (Kepler et al., 2014), are feasible for vaccines to elicit. In this regard, one example of bnAb KI models that could be generated to facilitate such questions are those coexpressing passenger KI alleles, which should allow a more robust ability to dissect the intrinsic mutability component of bnAb responses (Yeap et al., 2015).

Finally, one other major category of modified bnAb KI models that would benefit basic HIV B-cell research are those bred to other genetically modified KI/KO lines with either altered SHM and/or GC B-cell selection, survival, or homing. One particularly attractive, existing candidate to which bnAb KI lines could be cross-bred, are $Rev3_{L->F}$ mice, a KI line expressing a dominantly active form of polymerase-ζ (Daly et al., 2012), a key molecular component of the SHM machinery (Diaz, Verkoczy, Flajnik, & Klinman, 2001; Zan et al., 2001). In this KI strain, SHM rates are significantly accelerated, and thus SHM levels during immunization-guided bnAb lineage development in compound "bnAb × rev3 KI" lines would be expected to approach those typically seen during bnAb development during chronic infection. Additionally, $Rev3_{L->F}$ KI-enhanced SHM impacts all base pairs (Daly et al., 2012), in contrast to mice overexpressing activation induced deaminase (AID), the B-cell-specific (predominantly GC-restricted) enzyme required for SHM, that targets G:C bases (Okazaki et al., 2003). This is critical, since affinity-enhancing mutations are required at A:T base pairs in bnAb KI models and for protective HIV Ab responses in general. Finally, a nonmutually exclusive set of "compound" bnAb KI lines (in addition to bnAb x rev3 KI lines) that could be generated to study if enhanced GC reaction dynamics and AM potentiates development of neutralizing breadth for various bnAb lineages, are those enhancing survival of B-cells entering, or already in, GCs. Examples of such strains would be bnAb precursor/UCA KI models cross-bred to mice overexpressing either the prosurvival gene Bcl-2, specifically in the B-cell lineage, i.e., Eμ-Bcl-2 transgenic mice (Smith et al., 2000; Strasser et al., 1991) or the related protein Bcl-xL (Fang et al., 1996, 1998; Takahashi et al., 1999), or alternatively, to mice that are deficient in bcl2 family/pathway-associated, proapoptotic genes such as Bim (Bouillet et al., 1999; Fischer et al., 2007; Oliver, Vass, Kappler, & Marrack, 2006).

7. PERSPECTIVES

Since 2009, the HIV-1 bnAb field has undergone an emphatic revival, with immense progress made on several fronts, including (a) comprehensive longitudinal sampling of multiple cohorts of HIV-1–infected subjects and elucidation of their bnAb lineage evolutionary pathways, (b) the isolation and extensive molecular/structural characterization of numerous potent/broad monoclonal bnAbs from these infected subjects, (c) development of novel series of immunogens and vaccine concepts that have been selected and/or engineered based on high-resolution descriptions of bnAbs' paratopes, epitopes, and maturation pathways, all the result of the multiple technical advances in patient-based profiling, Ab cloning, and structural and protein modeling, and (d) the generation of new animal models (as extensively discussed in this review), namely, various humanized Ig-humanized KI systems and most notably, bnAb KI mice, which have been particularly powerful in obtaining a more fundamental understanding of the fate of bnAb lineages before and during immunization, and which have now also emerged as robust lead translational models for vaccine studies. The availability of novel immunogens, more powerful adjuvants, and the emergence of clinically validated immune checkpoint and/or SMIs, combined with a better immunological understanding of roadblocks and approaches with how to overcome them, are collectively providing an unprecedented environment for basic HIV vaccine testing.

Despite this impressive level of progress, much still remains to be done toward achieving vaccine-guided bnAb induction. By all standard measures of vaccinology, we are still in the infancy of testing those critical HIV immunogens and regimens required to elicit rapid and robust bnAb responses (likely required to block HIV-1 transmission). The assertion that we are still at the "training wheels" phase of this process is perhaps truer now that ever, as it is clear, despite our best efforts to design immunogens bearing highly antigenic vaccine epitopes, that such reagents can still only elicit immunogenically suboptimal protective Ab responses. Although selection of the correct Env combination and sequence of Envs, as well as their optimal form, will likely be critical for optimal bnAb induction, even the most arguably "bnAb" specific Env conformations, i.e., closed (stabilized), near-native trimeric Envs, and Env immunogens designed to target bnAbs precursors at more than adequate affinity to activate them, when used as prime components in sequential boosts, thus far do activate and guide AM in bnAb KI

models (unlike repeated immunization with regular native recombinant Envs), but nevertheless still only induce development that falls short of breadth development. Furthermore, such Env immunogens, thus far, are not nearly as selective as had been hoped for, since they still predominantly induce "off-target" responses in more physiologically relevant settings, such as KI models with increased Ab repertoire diversity. In the lone case (thus far) where some breadth can develop, this is driven from a synthetically derived precursor bnAb, and thus remains to be shown if (and what) portion of a comparable, complete evolutionary pathway in humans this maturation trajectory represents. Thus, it will be important to formally evaluate if further iterations of regimens with near-native Env trimers (currently being optimized to more avidly and specifically engage bnAb precursors) alone, can drive "full" bnAb maturation pathways, i.e., from bona fide bnAb UCA to mature bnAb. However, data both from more comprehensive in vitro host protein screening methods, and from emerging bnAb UCA KI models, suggest that most bnAbs will be impeded from progressing to full breadth/potency by immune tolerance checkpoints, at some point in their maturation. These studies, and those in patient cohorts thus indicate that in addition to "correct" selection of immunogens, a suitable environment, namely, one that can promote Tfh/GC interactions relevant to prolonging bnAb development, will also have to be recapitulated by incorporating suitable adjuvants or other transient modulators into vaccine regimens, as discussed throughout this review.

Thus, the field of HIV vaccine development is at an interesting and critical crossroads. On one side, there is strong impetus to build on results of the promising RV144 trial, including efforts to increase durability of candidate protective Ab responses to vaccines having nonneutralizing activities. In this regard, results from key follow-up trials are set to be reported starting late 2017, and analyses of these studies should thus help further inform this area. At the same time, the bnAb field is now more poised than ever to immerse itself into the HIV vaccine arena with unprecedented fervor, now given the virtual treasure-trove of information regarding bnAb ontogeny and structure, more powerful animal models, higher-throughput (and resolution) technologies to probe the Ab repertoire, and more rational vaccine concepts, based on the combination of iterative screening, patient-based design, and reverse-engineering immunogen design approaches. There is little doubt an impressive toolbox is thus now available to fully probe the immune system before and during vaccination, at a level of resolution impossible even just a few years ago. Overall, there is therefore a high degree of

optimism that developing an effective preventative HIV vaccine, which includes a robust bnAb-based component, once considered an unattainable "holy grail," will come to fruition, sooner rather than later.

Finally, I point out that this review has focused exclusively on use of humanized Ig KI models for bnAb-based HIV vaccine testing, due to the wealth of information and immunogens now available for targeting these types of responses, and also because all "single Ab" versions of such models, thus far, have only knocked-in bnAb specificities. However, such models could be equally beneficial for other HIV vaccine research, for example efforts to iteratively test formulations that seek to build on optimizing other (nonneutralizing) candidate protective responses, like those elicited in the initial RV144 trial results, especially ones aimed at optimizing durability of such responses. More generally, such models could also be employed as an approach to improve therapeutic HIV Abs (including bnAbs), via immunization-mediated AM of existing mAbs used clinically. Furthermore, and beyond the HIV vaccine field altogether, analogous bnAb KI models could also have tremendously benefit for studies seeking to better understand the regulation and induction of protective Ab responses to other highly variable viral infections, such as hepatitis C or influenza, both, which like HIV-1, require bnAb responses and are problematic vaccine targets.

ACKNOWLEDGMENTS

REFERENCES

Alam, S. M., Aussedat, B., Vohra, Y., Meyerhoff, R. R., Cale, E. M., Walcowitz, W. E., et al. (2017). Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. *Science Translational Medicine,* in press.

Alam, S. M., Dennison, S. M., Aussedat, B., Vohra, Y., Park, P. K., Fernandez-Tejada, A., et al. (2013). Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. *Proceedings of the National Academy of Sciences of the United States of America, 110,* 18214.

Alam, S. M., Liao, H. X., Dennison, S. M., Jaeger, F., Parks, R., Anasti, K., et al. (2011). Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. *Journal of Virology, 85,* 11725.

Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., et al. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade

E envelope immunogen is enhanced by a gp120 N-terminal deletion. *Journal of Virology*, *87*, 1554.

Alam, S. M., Morelli, M., Dennison, S. M., Liao, H. X., Zhang, R., Xia, S. M., et al. (2009). Role of HIV membrane in neutralization by two broadly neutralizing antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, *106*, 20234.

Allegrucci, M., Young-Cooper, G. O., Alexander, C. B., Newman, B. A., & Mage, R. G. (1991). Preferential rearrangement in normal rabbits of the 3' VHa allotype gene that is deleted in Alicia mutants; somatic hypermutation/conversion may play a major role in generating the heterogeneity of rabbit heavy chain variable region sequences. *European Journal of Immunology*, *21*, 411.

Alt, F. W., Zhang, Y., Meng, F. L., Guo, C., & Schwer, B. (2013). Mechanisms of programmed DNA lesions and genomic instability in the immune system. *Cell*, *152*, 417.

Amin, R. H., & Schlissel, M. S. (2008). Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. *Nature Immunology*, *9*, 613.

Andrabi, R., Voss, J. E., Liang, C. H., Briney, B., McCoy, L. E., Wu, C. Y., et al. (2015). Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. *Immunity*, *43*, 959.

Aplin, B. D., Keech, C. L., de Kauwe, A. L., Gordon, T. P., Cavill, D., & McCluskey, J. (2003). Tolerance through indifference: Autoreactive B cells to the nuclear antigen La show no evidence of tolerance in a transgenic model. *The Journal of Immunology*, *171*, 5890.

Appelmelk, B. J., Simoons-Smit, I., Negrini, R., Moran, A. P., Aspinall, G. O., Forte, J. G., et al. (1996). Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. *Infection and Immunity*, *64*, 2031.

Arnaout, R., Lee, W., Cahill, P., Honan, T., Sparrow, T., Weiand, M., et al. (2011). High-resolution description of antibody heavy-chain repertoires in humans. *PLoS One*, *6*. e22365.

Aylor, D. L., Valdar, W., Foulds-Mathes, W., Buus, R. J., Verdugo, R. A., Baric, R. S., et al. (2011). Genetic analysis of complex traits in the emerging collaborative cross. *Genome Research*, *21*, 1213.

Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012). Antibody-based protection against HIV infection by vectored immunoprophylaxis. *Nature*, *481*, 81.

Barthel, H. R., & Wallace, D. J. (1993). False-positive human immunodeficiency virus testing in patients with lupus erythematosus. *Seminars in Arthritis and Rheumatism*, *23*, 1.

Batista, F. D., & Neuberger, M. S. (1998). Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. *Immunity*, *8*, 751.

Belkaid, Y., & Tarbell, K. (2009). Regulatory T cells in the control of host–microorganism interactions. *Annual Review of Immunology*, *27*, 551.

Benhamou, D., Labi, V., Novak, R., Dai, I., Shafir-Alon, S., Weiss, A., et al. (2016). A c-Myc/miR17-92/Pten axis controls PI3K–mediated positive and negative selection in B cell development and reconstitutes CD19 deficiency. *Cell Reports*, *16*, 419.

Benschop, R. J., Brandl, E., Chan, A. C., & Cambier, J. C. (2001). Unique signaling properties of B cell antigen receptor in mature and immature B cells: Implications for tolerance and activation. *The Journal of Immunology*, *167*, 4172.

Benson, M. J., Erickson, L. D., Gleeson, M. W., & Noelle, R. J. (2007). Affinity of antigen encounter and other early B-cell signals determine B-cell fate. *Current Opinion in Immunology*, *19*, 275.

Bhiman, J. N., Anthony, C., Doria-Rose, N. A., Karimanzira, O., Schramm, C. A., Khoza, T., et al. (2015). Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. *Nature Medicine*, *21*, 1332.

Bonsignori, M., Alam, S. M., Liao, H. X., Verkoczy, L., Tomaras, G. D., Haynes, B. F., et al. (2012). HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design. *Trends in Microbiology*, *20*, 532.

Bonsignori, M., Hwang, K. K., Chen, X., Tsao, C. Y., Morris, L., Gray, E., et al. (2011). Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. *Journal of Virology*, *85*, 9998.

Bonsignori M., Kreider E.F., Fera D., Meyerhoff R.R., Bradley T., Wiehe K., et al., (2017). Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies, *Science Translational Medicine*, in press.

Bonsignori, M., Montefiori, D. C., Wu, X., Chen, X., Hwang, K. K., Tsao, C. Y., et al. (2012). Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: Implications for vaccine design. *Journal of Virology*, *86*, 4688.

Bonsignori, M., Wiehe, K., Grimm, S. K., Lynch, R., Yang, G., Kozink, D. M., et al. (2014). An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. *The Journal of Clinical Investigation*, *124*, 1835.

Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M. G., et al. (2016). Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. *Cell*, *165*, 449.

Bouillet, P., Metcalf, D., Huang, D. C., Tarlinton, D. M., Kay, T. W., Kontgen, F., et al. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. *Science*, *286*, 1735.

Bowes, T., Wagner, E. R., Boffey, J., Nicholl, D., Cochrane, L., Benboubetra, M., et al. (2002). Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain–Barre syndrome. *Infection and Immunity*, *70*, 5008.

Bradley, T., Yang, G., Ilkayeva, O., Holl, T. M., Zhang, R., Zhang, J., et al. (2016). HIV-1 envelope mimicry of host enzyme kynureninase does not disrupt tryptophan metabolism. *The Journal of Immunology*, *197*, 4663.

Braun, U., Rajewsky, K., & Pelanda, R. (2000). Different sensitivity to receptor editing of B cells from mice hemizygous or homozygous for targeted Ig transgenes. *Proceedings of the National Academy of Sciences of the United States of America*, *97*, 7429.

Briney, B., Sok, D., Jardine, J., Kulp, D. W., Skog, P., Menis, S., et al. (2016). Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. *Cell*, *166*, 1459.

Briney, B. S., Willis, J. R., & Crowe, J. E., Jr. (2012). Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. *PLoS One*, *7*. e36750.

Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., et al. (2012). A blueprint for HIV vaccine discovery. *Cell Host & Microbe*, *12*, 396.

Burton, D. R., & Hangartner, L. (2016). Broadly neutralizing antibodies to HIV and their role in vaccine design. *Annual Review of Immunology*, *34*, 635.

Burton, D. R., & Mascola, J. R. (2015). Antibody responses to envelope glycoproteins in HIV-1 infection. *Nature Immunology*, *16*, 571.

Calza, L., Manfredi, R., Colangeli, V., D'Antuono, A., Passarini, B., & Chiodo, F. (2003). Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. *International Journal of STD and AIDS*, *14*, 356.

Cambier, J. C., Gauld, S. B., Merrell, K. T., & Vilen, B. J. (2007). B-cell anergy: From transgenic models to naturally occurring anergic B cells? *Nature Reviews. Immunology*, 7, 633.

Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001). CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. *Annual Review of Immunology*, *19*, 565.

Chaturvedi, A., Dorward, D., & Pierce, S. K. (2008). The B cell receptor governs the sub-cellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. *Immunity*, *28*, 799.

Chen, J. (1996). Analysis of gene function in lymphocytes by RAG-2-deficient blastocyst complementation. *Advances in Immunology*, *62*, 31.

Chen, J., Lansford, R., Stewart, V., Young, F., & Alt, F. W. (1993). RAG-2-deficient blastocyst complementation: An assay of gene function in lymphocyte development. *Proceedings of the National Academy of Sciences of the United States of America*, *90*, 4528.

Chen, C., Nagy, Z., Prak, E. L., & Weigert, M. (1995a). Immunoglobulin heavy chain gene replacement: A mechanism of receptor editing. *Immunity*, *3*, 747.

Chen, C., Nagy, Z., Radic, M. Z., Hardy, R. R., Huszar, D., Camper, S. A., et al. (1995b). The site and stage of anti-DNA B-cell deletion. *Nature*, *373*, 252.

Chen, J., Shinkai, Y., Young, F., & Alt, F. W. (1994). Probing immune functions in RAG-deficient mice. *Current Opinion in Immunology*, *6*, 313.

Chen, Y., Zhang, J., Bouton-Verville, H., Newman, A., Xia, S.-M., Liao, H. X., et al. (2013a). Lipid components in MPER-based immunization regimens are critical for inducing broadly neutralizing antibody responses in 2F5 and 4E10 knock-in mice. *AIDS Research and Human Retroviruses*, *29*, 20.

Chen, Y., Zhang, J., Hwang, K. K., Bouton-Verville, H., Xia, S. M., Newman, A., et al. (2013b). Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. *The Journal of Immunology*, *191*, 1260.

Chow, K. T., Timblin, G. A., McWhirter, S. M., & Schlissel, M. S. (2013). MK5 activates Rag transcription via Foxo1 in developing B cells. *The Journal of Experimental Medicine*, *210*, 1621.

Churchill, G. A., Airey, D. C., Allayee, H., Angel, J. M., Attie, A. D., Beatty, J., et al. (2004). The collaborative cross, a community resource for the genetic analysis of complex traits. *Nature Genetics*, *36*, 1133.

Clark, B. E., Auyeung, K., Fregolino, E., Parrilli, M., Lanzetta, R., De Castro, C., et al. (2012). A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. *Chemistry & Biology*, *19*, 254.

Coffre, M., Benhamou, D., Riess, D., Blumenberg, L., Snetkova, V., Hines, M. J., et al. (2016). miRNAs are essential for the regulation of the PI3K/AKT/FOXO pathway and receptor editing during B cell maturation. *Cell Reports*, *17*, 2271.

Cooke, M. P., Heath, A. W., Shokat, K. M., Zeng, Y., Finkelman, F. D., Linsley, P. S., et al. (1994). Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. *The Journal of Experimental Medicine*, *179*, 425.

Corti, D., & Lanzavecchia, A. (2013). Broadly neutralizing antiviral antibodies. *Annual Review of Immunology*, *31*, 705.

Cusick, M. F., Libbey, J. E., & Fujinami, R. S. (2012). Molecular mimicry as a mechanism of autoimmune disease. *Clinical Reviews in Allergy and Immunology*, *42*, 102.

Cyster, J. G., Hartley, S. B., & Goodnow, C. C. (1994). Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. *Nature*, *371*, 389.

Dal Porto, J. M., Haberman, A. M., Kelsoe, G., & Shlomchik, M. J. (2002). Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. *The Journal of Experimental Medicine*, *195*, 1215.

Dal Porto, J. M., Haberman, A. M., Shlomchik, M. J., & Kelsoe, G. (1998). Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. *Journal of Immunology*, *161*, 5373.

Daly, J., Bebenek, K., Watt, D. L., Richter, K., Jiang, C., Zhao, M. L., et al. (2012). Altered Ig hypermutation pattern and frequency in complementary mouse models of DNA polymerase zeta activity. *The Journal of Immunology*, *188*, 5528.

de Taeye, S. W., Moore, J. P., & Sanders, R. W. (2016). HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. *Trends in Immunology*, *37*, 221.

de Taeye, S. W., Ozorowski, G., Torrents de la Pena, A., Guttman, M., Julien, J. P., van den Kerkhof, T. L., et al. (2015). Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. *Cell*, *163*, 1702.

DeKosky, B. J., Kojima, T., Rodin, A., Charab, W., Ippolito, G. C., Ellington, A. D., et al. (2015). In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. *Nature Medicine*, *21*, 86.

Diaz, M., & Klinman, N. R. (2000). Relative roles of somatic and Darwinian evolution in shaping the antibody response. *Immunologic Research*, *21*, 89.

Diaz, M., Verkoczy, L. K., Flajnik, M. F., & Klinman, N. R. (2001). Decreased frequency of somatic hypermutation and impaired affinity maturation but intact germinal center formation in mice expressing antisense RNA to DNA polymerase zeta. *The Journal of Immunology*, *167*, 327.

Doores, K. J., Kong, L., Krumm, S. A., Le, K. M., Sok, D., Laserson, U., et al. (2015). Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. *Journal of Virology*, *89*, 1105.

Doria-Rose, N. A., Louder, M. K., Yang, Z., O'Dell, S., Nason, M., Schmidt, S. D., et al. (2012). HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. *Journal of Virology*, *86*, 3393.

Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., Dekosky, B. J., et al. (2014). Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. *Nature*, *509*, 55.

Dormitzer, P. R., Grandi, G., & Rappuoli, R. (2012). Structural vaccinology starts to deliver. *Nature Reviews. Microbiology*, *10*, 807.

Dosenovic, P., Soldemo, M., Scholz, J. L., O'Dell, S., Grasset, E. K., Pelletier, N., et al. (2012). BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. *The Journal of Immunology*, *188*, 6018.

Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N. T., Gitlin, A. D., et al. (2015). Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. *Cell*, *161*, 1505.

Doyle-Cooper, C., Hudson, K. E., Cooper, A. B., Ota, T., Skog, P., Dawson, P. E., et al. (2013). Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. *The Journal of Immunology*, *191*, 3186.

Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., et al. (2006). Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. *Journal of Virology*, *80*, 5552.

Eisen, H. N., & Siskind, G. W. (1964). Variations in affinities of antibodies during the immune response. *Biochemistry*, *3*, 996.

Erikson, J., Radic, M. Z., Camper, S. A., Hardy, R. R., Carmack, C., & Weigert, M. (1991). Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. *Nature*, *349*, 331.

Escolano, A., Steichen, J. M., Dosenovic, P., Kulp, D. W., Golijanin, J., Sok, D., et al. (2016). Sequential immunization elicits broadly neutralizing anti-HIV antibodies in Ig knock-in mice. *Cell*, *166*, 1445.

Excler, J. L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014). Nonneutralizing functional antibodies: A new "old" paradigm for HIV vaccines. *Clinical and Vaccine Immunology*, *21*, 1023.

Fang, W., Mueller, D. L., Pennell, C. A., Rivard, J. J., Li, Y. S., Hardy, R. R., et al. (1996). Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. *Immunity*, *4*, 291.

Fang, W., Weintraub, B. C., Dunlap, B., Garside, P., Pape, K. A., Jenkins, M. K., et al. (1998). Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. *Immunity*, *9*, 35.

Finton, K. A., Larimore, K., Larman, H. B., Friend, D., Correnti, C., Rupert, P. B., et al. (2013). Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. *PLoS Pathogens*, *9*. e1003639.

Fischer, S. F., Bouillet, P., O'Donnell, K., Light, A., Tarlinton, D. M., & Strasser, A. (2007). Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. *Blood*, *110*, 3978.

Gao, F., Bonsignori, M., Liao, H. X., Kumar, A., Xia, S. M., Lu, X., et al. (2014). Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. *Cell*, *158*, 481.

Garces, F., Lee, J. H., de Val, N., de la Pena, A. T., Kong, L., Puchades, C., et al. (2015). Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. *Immunity*, *43*, 1053.

Garces, F., Sok, D., Kong, L., McBride, R., Kim, H. J., Saye-Francisco, K. F., et al. (2014). Structural evolution of glycan recognition by a family of potent HIV antibodies. *Cell*, *159*, 69.

Gautam, R., Nishimura, Y., Pegu, A., Nason, M. C., Klein, F., Gazumyan, A., et al. (2016). A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. *Nature*, *533*, 105.

Gay, D., Saunders, T., Camper, S., & Weigert, M. (1993). Receptor editing: An approach by autoreactive B cells to escape tolerance. *The Journal of Experimental Medicine*, *177*, 999.

Georgiev, I. S., Rudicell, R. S., Saunders, K. O., Shi, W., Kirys, T., McKee, K., et al. (2014). Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. *The Journal of Immunology*, *192*, 1100.

Goepfert, P. A., Elizaga, M. L., Sato, A., Qin, L., Cardinali, M., Hay, C. M., et al. (2011). Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. *The Journal of Infectious Diseases*, *203*, 610.

Gonzalez-Martin, A., Adams, B. D., Lai, M., Shepherd, J., Salvador-Bernaldez, M., Salvador, J. M., et al. (2016). The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. *Nature Immunology*, *17*, 433.

Goodnow, C. C. (1992). Transgenic mice and analysis of B-cell tolerance. *Annual Review of Immunology*, *10*, 489.

Goodnow, C. C. (2007). Multistep pathogenesis of autoimmune disease. *Cell*, *130*, 25.

Goodnow, C. C., Brink, R., & Adams, E. (1991). Breakdown of self-tolerance in anergic B lymphocytes. *Nature*, *352*, 532.

Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., et al. (1988). Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. *Nature*, *334*, 676.

Goodnow, C. C., Crosbie, J., Jorgensen, H., Brink, R. A., & Basten, A. (1989). Induction of self-tolerance in mature peripheral B lymphocytes. *Nature*, *342*, 385.

Goodnow, C. C., Vinuesa, C. G., Randall, K. L., Mackay, F., & Brink, R. (2010). Control systems and decision making for antibody production. *Nature Immunology*, *11*, 681.

Gorman, J., Soto, C., Yang, M. M., Davenport, T. M., Guttman, M., Bailer, R. T., et al. (2016). Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. *Nature Structural and Molecular Biology*, *23*, 81.

Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., et al. (2011). The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 + T cell decline and high viral load during acute infection. *Journal of Virology*, *85*, 4828.

Gruell, H., Bournazos, S., Ravetch, J. V., Ploss, A., Nussenzweig, M. C., & Pietzsch, J. (2013). Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. *Journal of Virology*, *87*, 8535.

Guo, C., Yoon, H. S., Franklin, A., Jain, S., Ebert, A., Cheng, H. L., et al. (2011). CTCF-binding elements mediate control of V(D)J recombination. *Nature*, *477*, 424.

Gupta, S., Clark, E. S., Termini, J. M., Boucher, J., Kanagavelu, S., LeBranche, C. C., et al. (2015). DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. *Journal of Virology*, *89*, 4158.

Han, S., Zheng, B., Dal Porto, J., & Kelsoe, G. (1995). In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. *The Journal of Experimental Medicine*, *182*, 1635.

Hansen, S. G., Piatak, M., Jr., Ventura, A. B., Hughes, C. M., Gilbride, R. M., Ford, J. C., et al. (2013). Immune clearance of highly pathogenic SIV infection. *Nature*, *502*, 100.

Hansen, S. G., Sacha, J. B., Hughes, C. M., Ford, J. C., Burwitz, B. J., Scholz, I., et al. (2013). Cytomegalovirus vectors violate CD8 + T cell epitope recognition paradigms. *Science*, *340*, 1237874.

Hardy, R. R. (2006). B-1 B cells: Development, selection, natural autoantibody and leukemia. *Current Opinion in Immunology*, *18*, 547.

Hartley, S. B., Crosbie, J., Brink, R., Kantor, A. B., Basten, A., & Goodnow, C. C. (1991). Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. *Nature*, *353*, 765.

Hayakawa, K., Asano, M., Shinton, S. A., Gui, M., Wen, L. J., Dashoff, J., et al. (2003). Positive selection of anti-thy-1 autoreactive B-1 cells and natural serum autoantibody production independent from bone marrow B cell development. *The Journal of Experimental Medicine*, *197*, 87.

Haynes, B. F. (2015). New approaches to HIV vaccine development. *Current Opinion in Immunology*, *35*, 39.

Haynes, B. F., Fleming, J., St Clair, E. W., Katinger, H., Stiegler, G., Kunert, R., et al. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. *Science*, *308*, 1906.

Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., et al. (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *The New England Journal of Medicine*, *366*, 1275.

Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012). B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. *Nature Biotechnology*, *30*, 423.

Haynes, B. F., Moody, M. A., Alam, M., Bonsignori, M., Verkoczy, L., Ferrari, G., et al. (2014). Progress in HIV-1 vaccine development. *The Journal of Allergy and Clinical Immunology*, *134*, 3.

Haynes, B. F., Moody, M. A., Liao, H. X., Verkoczy, L., & Tomaras, G. D. (2011). B cell responses to HIV-1 infection and vaccination: Pathways to preventing infection. *Trends in Molecular Medicine*, *17*, 108.

Haynes, B. F., Moody, M. A., Verkoczy, L., Kelsoe, G., & Alam, S. M. (2005). Antibody polyspecificity and neutralization of HIV-1: A hypothesis. *Human Antibodies*, *14*, 59.

Haynes, B. F., Shaw, G. M., Korber, B., Kelsoe, G., Sodroski, J., Hahn, B. H., et al. (2016). HIV–host interactions: Implications for vaccine design. *Cell Host & Microbe*, *19*, 292.

Haynes, B. F., & Verkoczy, L. (2014). AIDS/HIV. Host controls of HIV neutralizing antibodies. *Science*, *344*, 588.

Haynes, B. F., Verkoczy, L., & Kelsoe, G. (2014). Redemption of autoreactive B cells. *Proceedings of the National Academy of Sciences of the United States of America*, *111*, 9022.

Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., et al. (2009). Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. *Nature Medicine*, *15*, 951.

Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., et al. (2009). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. *PLoS Pathogens*, *5*. e1000433.

Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., et al. (2013). Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. *PLoS Pathogens*, *9*. e1003106.

Hraber, P., Seaman, M. S., Bailer, R. T., Mascola, J. R., Montefiori, D. C., & Korber, B. T. (2014). Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. *AIDS*, *28*, 163.

Huang, Y., DiazGranados, C., Janes, H., Huang, Y., deCamp, A. C., Metch, B., et al. (2016). Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. *Current Opinion in Virology*, *17*, 57.

Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., et al. (2012). Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. *Nature*, *491*, 406.

Ichihara, Y., Hayashida, H., Miyazawa, S., & Kurosawa, Y. (1989). Only DFL16, DSP2, and DQ52 gene families exist in mouse immunoglobulin heavy chain diversity gene loci, of which DFL16 and DSP2 originate from the same primordial DH gene. *European Journal of Immunology*, *19*, 1849.

Ivanov, I. I., Schelonka, R. L., Zhuang, Y., Gartland, G. L., Zemlin, M., & Schroeder, H. W., Jr. (2005). Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. *The Journal of Immunology*, *174*, 7773.

Jardine, J., Julien, J. P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., et al. (2013). Rational HIV immunogen design to target specific germline B cell receptors. *Science*, *340*, 711.

Jardine, J. G., Kulp, D. W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., et al. (2016). HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. *Science*, *351*, 1458.

Jardine, J. G., Ota, T., Sok, D., Pauthner, M., Kulp, D. W., Kalyuzhniy, O., et al. (2015). HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. *Science*, *349*, 156.

Jardine, J. G., Sok, D., Julien, J. P., Briney, B., Sarkar, A., Liang, C. H., et al. (2016). Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. *PLoS Pathogens*, *12*. e1005815.

Julien, J. P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffenberg, S., et al. (2013). Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. *Proceedings of the National Academy of Sciences of the United States of America*, *110*, 4351.

Kain, R., Exner, M., Brandes, R., Ziebermayr, R., Cunningham, D., Alderson, C. A., et al. (2008). Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. *Nature Medicine*, *14*, 1088.

Kaye, B. R. (1989). Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). *Annals of Internal Medicine*, *111*, 158.

Keenan, R. A., De Riva, A., Corleis, B., Hepburn, L., Licence, S., Winkler, T. H., et al. (2008). Censoring of autoreactive B cell development by the pre-B cell receptor. *Science*, *321*, 696.

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. *Annual Review of Immunology*, *26*, 677.

Kelsoe, G., Verkoczy, L., & Haynes, B. F. (2014). Immune system regulation in the induction of broadly neutralizing HIV-1 antibodies. *Vaccines (Basel)*, *2*, 1.

Kepler, T. B. (2013). Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. *F1000Research*, *2*, 103.

Kepler, T. B., Liao, H. X., Alam, S. M., Bhaskarabhatla, R., Zhang, R., Yandava, C., et al. (2014). Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. *Cell Host & Microbe*, *16*, 304.

Kepler, T. B., & Perelson, A. S. (1993). Somatic hypermutation in B cells: An optimal control treatment. *Journal of Theoretical Biology*, *164*, 37.

Kepler, T. B., & Perelson, A. S. (1995). Modeling and optimization of populations subject to time-dependent mutation. *Proceedings of the National Academy of Sciences of the United States of America*, *92*, 8219.

Kitamura, D., Roes, J., Kuhn, R., & Rajewsky, K. (1991). A B cell–deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. *Nature*, *350*, 423.

Klein, U., Casola, S., Cattoretti, G., Shen, Q., Lia, M., Mo, T., et al. (2006). Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. *Nature Immunology*, *7*, 773.

Klein, F., Diskin, R., Scheid, J. F., Gaebler, C., Mouquet, H., Georgiev, I. S., et al. (2013). Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell*, *153*, 126.

Klinman, D. M., Higgins, K. W., & Conover, J. (1991). Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells. *The Journal of Experimental Medicine*, *173*, 881.

Knight, K. L. (1992). Restricted VH gene usage and generation of antibody diversity in rabbit. *Annual Review of Immunology*, *10*, 593.

Kong, L., Ju, B., Chen, Y., He, L., Ren, L., Liu, J., et al. (2016). Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor. *Immunity*, *44*, 939.

Kraus, M., Alimzhanov, M. B., Rajewsky, N., & Rajewsky, K. (2004). Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. *Cell*, *117*, 787.

Kumar, K. R., & Mohan, C. (2008). Understanding B-cell tolerance through the use of immunoglobulin transgenic models. *Immunologic Research*, *40*, 208.

Kuraoka, M., Snowden, P. B., Nojima, T., Verkoczy, L., Haynes, B. F., Kitamura, D., et al. (2017). BCR and endosomal TLR signals synergize to increase AID expression and establish central B cell tolerance. *Cell Reports*, *18*, 1627.

Kuwahara, K., Fujimura, S., Takahashi, Y., Nakagata, N., Takemori, T., Aizawa, S., et al. (2004). Germinal center-associated nuclear protein contributes to affinity maturation of B cell antigen receptor in T cell-dependent responses. *Proceedings of the National Academy of Sciences of the United States of America*, *101*, 1010.

Kuwahara, K., Tomiyasu, S., Fujimura, S., Nomura, K., Xing, Y., Nishiyama, N., et al. (2001). Germinal center-associated nuclear protein (GANP) has a phosphorylation-dependent DNA-primase activity that is up-regulated in germinal center regions. *Proceedings of the National Academy of Sciences of the United States of America*, *98*, 10279.

Kwon, Y. D., Pancera, M., Acharya, P., Georgiev, I. S., Crooks, E. T., Gorman, J., et al. (2015). Crystal structure, conformational fixation, and entry-related interactions of mature ligand-free HIV-1 Env. *Nature Structural and Molecular Biology*, *22*, 522.

Kwong, P. D., & Mascola, J. R. (2012). Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. *Immunity*, *37*, 412.

Lai, M., Gonzalez-Martin, A., Cooper, A. B., Oda, H., Jin, H. Y., Shepherd, J., et al. (2016). Regulation of B-cell development and tolerance by different members of the miR-17 approximately 92 family microRNAs. *Nature Communications*, 7, 12207.

Lang, J., Jackson, M., Teyton, L., Brunmark, A., Kane, K., & Nemazee, D. (1996). B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. *The Journal of Experimental Medicine*, *184*, 1685.

Lanzavecchia, A., Fruhwirth, A., Perez, L., & Corti, D. (2016). Antibody-guided vaccine design: Identification of protective epitopes. *Current Opinion in Immunology*, *41*, 62.

Larman, H. B., Zhao, Z., Laserson, U., Li, M. Z., Ciccia, A., Gakidis, M. A., et al. (2011). Autoantigen discovery with a synthetic human peptidome. *Nature Biotechnology*, *29*, 535.

Lau, C. M., Broughton, C., Tabor, A. S., Akira, S., Flavell, R. A., Mamula, M. J., et al. (2005). RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. *The Journal of Experimental Medicine*, *202*, 1171.

Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002). Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. *Nature*, *416*, 603.

Lee, E. C., Liang, Q., Ali, H., Bayliss, L., Beasley, A., Bloomfield-Gerdes, T., et al. (2014). Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. *Nature Biotechnology*, *32*, 356.

Lee, C. H., Melchers, M., Wang, H., Torrey, T. A., Slota, R., Qi, C. F., et al. (2006). Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. *The Journal of Experimental Medicine*, *203*, 63.

Levesque, M. C., Moody, M. A., Hwang, K. K., Marshall, D. J., Whitesides, J. F., Amos, J. D., et al. (2009). Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. *PLoS Medicine*, *6*. e1000107.

Li, H., Jiang, Y., Prak, E. L., Radic, M., & Weigert, M. (2001). Editors and editing of anti-DNA receptors. *Immunity*, *15*, 947.

Li, Y., Li, H., & Weigert, M. (2002). Autoreactive B cells in the marginal zone that express dual receptors. *The Journal of Experimental Medicine*, *195*, 181.

Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., et al. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. *Journal of Virology*, *85*, 8954.

Li, H., Wang, S., Kong, R., Ding, W., Lee, F. H., Parker, Z., et al. (2016). Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, *113*, E3413.

Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., et al. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. *Immunity*, *38*, 176.

Liao, H. X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., et al. (2013). Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature*, *496*, 469.

Lifson, J. D., Piatak, M., Jr., Rossio, J. L., Bess, J., Jr., Chertova, E., Schneider, D., et al. (2002). Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge. *Journal of Medical Primatology*, *31*, 205.

Linton, P. L., Decker, D. J., & Klinman, N. R. (1989). Primary antibody-forming cells and secondary B cells are generated from separate precursor cell subpopulations. *Cell*, *59*, 1049.

Liu, M., Yang, G., Wiehe, K., Nicely, N. I., Vandergrift, N. A., Rountree, W., et al. (2015). Polyreactivity and autoreactivity among HIV-1 antibodies. *Journal of Virology*, *89*, 784.

Llorian, M., Stamataki, Z., Hill, S., Turner, M., & Martensson, I. L. (2007). The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. *The Journal of Immunology*, *178*, 1981.

Locci, M., Wu, J. E., Arumemi, F., Mikulski, Z., Dahlberg, C., Miller, A. T., et al. (2016). Activin A programs the differentiation of human TFH cells. *Nature Immunology*, *17*, 976.

Ma, B. J., Alam, S. M., Go, E. P., Lu, X., Desaire, H., Tomaras, G. D., et al. (2011). Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. *PLoS Pathogens*, *7*. e1002200.

Ma, B., Osborn, M. J., Avis, S., Ouisse, L. H., Menoret, S., Anegon, I., et al. (2013). Human antibody expression in transgenic rats: Comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions. *Journal of Immunological Methods*, *400–401*, 78.

Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., et al. (2014). Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proceedings of the National Academy of Sciences of the United States of America*, *111*, 5147.

Malherbe, D. C., Doria-Rose, N. A., Misher, L., Beckett, T., Puryear, W. B., Schuman, J. T., et al. (2011). Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. *Journal of Virology*, *85*, 5262.

Margine, I., Krammer, F., Hai, R., Heaton, N. S., Tan, G. S., Andrews, S. A., et al. (2013). Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. *Journal of Virology*, *87*, 10435.

Marshak-Rothstein, A., & Rifkin, I. R. (2007). Immunologically active autoantigens: The role of toll-like receptors in the development of chronic inflammatory disease. *Annual Review of Immunology*, *25*, 419.

Martin, D. A., Bradl, H., Collins, T. J., Roth, E., Jack, H. M., & Wu, G. E. (2003). Selection of Ig mu heavy chains by complementarity-determining region 3 length and amino acid composition. *The Journal of Immunology*, *171*, 4663.

Martin, F., & Kearney, J. F. (2002). Marginal-zone B cells. *Nature Reviews. Immunology*, *2*, 323.

Maruyama, M., Lam, K. P., & Rajewsky, K. (2000). Memory B-cell persistence is independent of persisting immunizing antigen. *Nature*, *407*, 636.

Mascola, J. R., & Haynes, B. F. (2013). HIV-1 neutralizing antibodies: Understanding nature's pathways. *Immunological Reviews*, *254*, 225.

McElrath, M. J., & Haynes, B. F. (2010). Induction of immunity to human immunodeficiency virus type-1 by vaccination. *Immunity*, *33*, 542.

McGuire, A. T., Dreyer, A. M., Carbonetti, S., Lippy, A., Glenn, J., Scheid, J. F., et al. (2014). HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. *Science*, *346*, 1380.

McGuire, A. T., Gray, M. D., Dosenovic, P., Gitlin, A. D., Freund, N. T., Petersen, J., et al. (2016). Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. *Nature Communications*, *7*, 10618.

McGuire, A. T., Hoot, S., Dreyer, A. M., Lippy, A., Stuart, A., Cohen, K. W., et al. (2013). Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. *The Journal of Experimental Medicine*, *210*, 655.

McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N., & Haynes, B. F. (2010). The immune response during acute HIV-1 infection: Clues for vaccine development. *Nature Reviews. Immunology*, *10*, 11.

Meffre, E., Milili, M., Blanco-Betancourt, C., Antunes, H., Nussenzweig, M. C., & Schiff, C. (2001). Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. *The Journal of Clinical Investigation*, *108*, 879.

Melkus, M. W., Estes, J. D., Padgett-Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., et al. (2006). Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. *Nature Medicine*, *12*, 1316.

Mietzner, B., Tsuiji, M., Scheid, J., Velinzon, K., Tiller, T., Abraham, K., et al. (2008). Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. *Proceedings of the National Academy of Sciences of the United States of America*, *105*, 9727.

Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G., & Stamatatos, L. (2011). Characteristics of the earliest cross-neutralizing antibody response to HIV-1. *PLoS Pathogens*, *7*. e1001251.

Minegishi, Y., & Conley, M. E. (2001). Negative selection at the pre-BCR checkpoint elicited by human mu heavy chains with unusual CDR3 regions. *Immunity*, *14*, 631.

Moir, S., & Fauci, A. S. (2013). Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. *Immunological Reviews*, *254*, 207.

Mond, J. J., Vos, Q., Lees, A., & Snapper, C. M. (1995). T cell independent antigens. *Current Opinion in Immunology*, *7*, 349.

Moody, M. A., Pedroza-Pacheco, I., Vandergrift, N. A., Chui, C., Lloyd, K. E., Parks, R., et al. (2016). Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. *Science Immunology*, *1*, aag0851.

Moore, P. L., Gray, E. S., Wibmer, C. K., Bhiman, J. N., Nonyane, M., Sheward, D. J., et al. (2012). Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. *Nature Medicine*, *18*, 1688.

Moore, P. L., & Williamson, C. (2016). Approaches to the induction of HIV broadly neutralizing antibodies. *Current Opinion in HIV and AIDS*, *11*, 569.

Moore, P. L., Williamson, C., & Morris, L. (2015). Virological features associated with the development of broadly neutralizing antibodies to HIV-1. *Trends in Microbiology*, *23*, 204.

Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J. F., et al. (2012). Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, *109*, E3268.

Mouquet, H., Scheid, J. F., Zoller, M. J., Krogsgaard, M., Ott, R. G., Shukair, S., et al. (2010). Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. *Nature*, *467*, 591.

Murakami, M., Tsubata, T., Okamoto, M., Shimizu, A., Kumagai, S., Imura, H., et al. (1992). Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. *Nature*, *357*, 77.

Murphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., et al. (2014). Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. *Proceedings of the National Academy of Sciences of the United States of America*, *111*, 5153.

Mylonakis, E., Paliou, M., Greenbough, T. C., Flaningan, T. P., Letvin, N. L., & Rich, J. D. (2000). Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. *Archives of Internal Medicine*, *160*, 2386.

Nachbagauer, R., Wohlbold, T. J., Hirsh, A., Hai, R., Sjursen, H., Palese, P., et al. (2014). Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. *Journal of Virology*, *88*, 13260.

Nemazee, D. A., & Burki, K. (1989). Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. *Nature*, *337*, 562.

Nitschke, L., Kestler, J., Tallone, T., Pelkonen, S., & Pelkonen, J. (2001). Deletion of the DQ52 element within the Ig heavy chain locus leads to a selective reduction in VDJ recombination and altered D gene usage. *The Journal of Immunology*, *166*, 2540.

Okamoto, M., Murakami, M., Shimizu, A., Ozaki, S., Tsubata, T., Kumagai, S., et al. (1992). A transgenic model of autoimmune hemolytic anemia. *The Journal of Experimental Medicine*, *175*, 71.

Okazaki, I., Yoshikawa, K., Kinoshita, K., Muramatsu, M., Nagaoka, H., & Honjo, T. (2003). Activation-induced cytidine deaminase links class switch recombination and somatic hypermutation. *The Annals of the New York Academy of Sciences*, *987*, 1.

Oliver, P. M., Vass, T., Kappler, J., & Marrack, P. (2006). Loss of the proapoptotic protein, Bim, breaks B cell anergy. *The Journal of Experimental Medicine*, *203*, 731.

Osborn, M. J., Ma, B., Avis, S., Binnie, A., Dilley, J., Yang, X., et al. (2013). High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/ Igkappa/Iglambda loci bearing the rat CH region. *The Journal of Immunology*, *190*, 1481.

Ota, T., Aoki-Ota, M., Tsunoda, K., Simoda, K., Nishikawa, T., Amagai, M., et al. (2004). Auto-reactive B cells against peripheral antigen, desmoglein 3, escape from tolerance mechanism. *International Immunology*, *16*, 1487.

Ota, T., Doyle-Cooper, C., Cooper, A. B., Doores, K. J., Aoki-Ota, M., Le, K., et al. (2013). B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. *The Journal of Immunology*, *191*, 3179.

Ota, T., Doyle-Cooper, C., Cooper, A. B., Huber, M., Falkowska, E., Doores, K. J., et al. (2012). Anti-HIV B cell lines as candidate vaccine biosensors. *The Journal of Immunology*, *189*, 4816.

Palacios, R., Santos, J., Valdivielso, P., & Marquez, M. (2002). Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. *Lupus*, *11*, 60.

Pancera, M., Shahzad-Ul-Hussan, S., Doria-Rose, N. A., McLellan, J. S., Bailer, R. T., Dai, K., et al. (2013). Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. *Nature Structural and Molecular Biology*, *20*, 804.

Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., et al. (2014). Structure and immune recognition of trimeric pre-fusion HIV-1 Env. *Nature*, *514*, 455.

Pantophlet, R., & Burton, D. R. (2006). GP120: Target for neutralizing HIV-1 antibodies. *Annual Review of Immunology*, *24*, 739.

Patel, P., & Kearney, J. F. (2016). Immunological outcomes of antibody binding to glycans shared between microorganisms and mammals. *The Journal of Immunology*, *197*, 4201.

Paus, D., Phan, T. G., Chan, T. D., Gardam, S., Basten, A., & Brink, R. (2006). Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. *The Journal of Experimental Medicine*, *203*, 1081.

Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P. S., Wang, S. K., et al. (2011). A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. *Science*, *334*, 1097.

Pejchal, R., Walker, L. M., Stanfield, R. L., Phogat, S. K., Koff, W. C., Poignard, P., et al. (2010). Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, *107*, 11483.

Phan, T. G., Paus, D., Chan, T. D., Turner, M. L., Nutt, S. L., Basten, A., et al. (2006). High affinity germinal center B cells are actively selected into the plasma cell compartment. *The Journal of Experimental Medicine*, *203*, 2419.

Phillippi, J., Xie, Y., Miller, D. R., Bell, T. A., Zhang, Z., Lenarcic, A. B., et al. (2014). Using the emerging collaborative cross to probe the immune system. *Genes and Immunity*, *15*, 38.

Plotkin, S. A. (2010). Correlates of protection induced by vaccination. *Clinical and Vaccine Immunology*, *17*, 1055.

Pujanauski, L. M., Janoff, E. N., McCarter, M. D., Pelanda, R., & Torres, R. M. (2013). Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, *110*, 1422.

Pulendran, B., Kannourakis, G., Nouri, S., Smith, K. G., & Nossal, G. J. (1995). Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. *Nature*, *375*, 331.

Raman, V. S., Lind, E. F., Benson, M. J., & Noelle, R. J. (2007). Strategies for selective priming of memory B cells. *Immunology Letters*, *109*, 93.

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nature Protocols*, *8*, 2281.

Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., et al. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *The New England Journal of Medicine*, *361*, 2209.

Richter, K., Brar, S., Ray, M., Pisitkun, P., Bolland, S., Verkoczy, L., et al. (2009). Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. *The Journal of Biological Chemistry*, *284*, 30652.

Richter, K., Burch, L., Chao, F., Henke, D., Jiang, C., Daly, J., et al. (2012). Altered pattern of immunoglobulin hypermutation in mice deficient in Slip-GC protein. *The Journal of Biological Chemistry*, *287*, 31856.

Rojas, M., Hulbert, C., & Thomas, J. W. (2001). Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen. *The Journal of Immunology*, *166*, 3194.

Russell, D. M., Dembic, Z., Morahan, G., Miller, J. F., Burki, K., & Nemazee, D. (1991). Peripheral deletion of self-reactive B cells. *Nature*, *354*, 308.

Sabouri, Z., Schofield, P., Horikawa, K., Spierings, E., Kipling, D., Randall, K. L., et al. (2014). Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. *Proceedings of the National Academy of Sciences of the United States of America*, *111*, E2567.

Sakaguchi, N., Kimura, T., Matsushita, S., Fujimura, S., Shibata, J., Araki, M., et al. (2005). Generation of high-affinity antibody against T cell-dependent antigen in the Ganp gene-transgenic mouse. *The Journal of Immunology*, *174*, 4485.

Sanders, R. W., van Gils, M. J., Derking, R., Sok, D., Ketas, T. J., Burger, J. A., et al. (2015). HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. *Science*, *349*, aac4223.

Scharf, L., West, A. P., Sievers, S. A., Chen, C., Jiang, S., Gao, H., et al. (2016). Structural basis for germline antibody recognition of HIV-1 immunogens. *eLife*, *5*, e13783.

Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y., et al. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science*, *333*, 1633.

Schelonka, R. L., Ivanov, I. I., Jung, D. H., Ippolito, G. C., Nitschke, L., Zhuang, Y., et al. (2005). A single DH gene segment creates its own unique CDR-H3 repertoire and is sufficient for B cell development and immune function. *The Journal of Immunology*, *175*, 6624.

Schroeder, H. W., Jr. (2006). Similarity and divergence in the development and expression of the mouse and human antibody repertoires. *Developmental and Comparative Immunology*, *30*, 119.

Schwickert, T. A., Victora, G. D., Fooksman, D. R., Kamphorst, A. O., Mugnier, M. R., Gitlin, A. D., et al. (2011). A dynamic T cell–limited checkpoint regulates affinity-dependent B cell entry into the germinal center. *The Journal of Experimental Medicine*, *208*, 1243.

Sciammas, R., Shaffer, A. L., Schatz, J. H., Zhao, H., Staudt, L. M., & Singh, H. (2006). Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. *Immunity*, *25*, 225.

Seay, K., Qi, X., Zheng, J. H., Zhang, C., Chen, K., Dutta, M., et al. (2013). Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: A new model for investigating HIV-1 transmission and treatment efficacy. *PLoS One*, *8*. e63537.

Sekiguchi, D. R., Jainandunsing, S. M., Fields, M. L., Maldonado, M. A., Madaio, M. P., Erikson, J., et al. (2002). Chronic graft–versus–host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells. *The Journal of Immunology*, *168*, 4142.

Seo, S. J., Fields, M. L., Buckler, J. L., Reed, A. J., Mandik–Nayak, L., Nish, S. A., et al. (2002). The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. *Immunity*, *16*, 535.

Shaffer, J. S., Moore, P. L., Kardar, M., & Chakraborty, A. K. (2016). Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens. *Proceedings of the National Academy of Sciences of the United States of America*, *113*(45), E7039–E7048.

Sharma, P., & Allison, J. P. (2015a). The future of immune checkpoint therapy. *Science*, *348*, 56.

Sharma, P., & Allison, J. P. (2015b). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. *Cell*, *161*, 205.

Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007). The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nature Immunology*, *8*, 239.

Shih, T. A., Meffre, E., Roederer, M., & Nussenzweig, M. C. (2002). Role of BCR affinity in T cell dependent antibody responses in vivo. *Nature Immunology*, *3*, 570.

Shiokawa, S., Mortari, F., Lima, J. O., Nunez, C., Bertrand, F. E., 3rd, Kirkham, P. M., et al. (1999). IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. *The Journal of Immunology*, *162*, 6060.

Shlomchik, M. J. (2008). Sites and stages of autoreactive B cell activation and regulation. *Immunity*, *28*, 18.

Shlomchik, M., Mascelli, M., Shan, H., Radic, M. Z., Pisetsky, D., Marshak-Rothstein, A., et al. (1990). Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. *The Journal of Experimental Medicine*, *171*, 265.

Shokat, K. M., & Goodnow, C. C. (1995). Antigen-induced B-cell death and elimination during germinal-centre immune responses. *Nature*, *375*, 334.

Silverman, G. J., & Goodyear, C. S. (2006). Confounding B-cell defences: Lessons from a staphylococcal superantigen. *Nature Reviews. Immunology*, *6*, 465.

Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., et al. (2009). Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. *Journal of Virology*, *83*, 7337.

Singh, S. K., Maeda, K., Eid, M. M., Almofty, S. A., Ono, M., Pham, P., et al. (2013). GANP regulates recruitment of AID to immunoglobulin variable regions by modulating transcription and nucleosome occupancy. *Nature Communications*, *4*, 1830.

Sliepen, K., Medina-Ramirez, M., Yasmeen, A., Moore, J. P., Klasse, P. J., & Sanders, R. W. (2015). Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. *Virology*, *486*, 116.

Sliepen, K., & Sanders, R. W. (2016). HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. *Expert Review of Vaccines*, *15*, 349.

Smith, K. G., Light, A., O'Reilly, L. A., Ang, S. M., Strasser, A., & Tarlinton, D. (2000). bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. *The Journal of Experimental Medicine*, *191*, 475.

Sok, D., Briney, B., Jardine, J. G., Kulp, D. W., Menis, S., Pauthner, M., et al. (2016). Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. *Science*, *353*, 1557–1560.

Sok, D., Laserson, U., Laserson, J., Liu, Y., Vigneault, F., Julien, J. P., et al. (2013). The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. *PLoS Pathogens*, *9*. e1003754.

Stanfield, R. L., De Castro, C., Marzaioli, A. M., Wilson, I. A., & Pantophlet, R. (2015). Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. *Glycobiology*, *25*, 412.

Steichen, J. M., Kulp, D. W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R. L., et al. (2016). HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. *Immunity*, *166*, 1445.

Strasser, A., Whittingham, S., Vaux, D. L., Bath, M. L., Adams, J. M., Cory, S., et al. (1991). Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. *Proceedings of the National Academy of Sciences of the United States of America*, *88*, 8661.

Takahashi, Y., Cerasoli, D. M., Dal Porto, J. M., Shimoda, M., Freund, R., Fang, W., et al. (1999). Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice. *The Journal of Experimental Medicine*, *190*, 399.

Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2006). A molecular perspective of CTLA-4 function. *Annual Review of Immunology*, *24*, 65.

Tian, M., Cheng, C., Chen, X., Duan, H., Cheng, H.-L., Dao, M., et al. (2016). Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. *Cell*, *166*, 1471.

Tiegs, S. L., Russell, D. M., & Nemazee, D. (1993). Receptor editing in self-reactive bone marrow B cells. *The Journal of Experimental Medicine*, *177*, 1009.

Tiller, T., Tsuiji, M., Yurasov, S., Velinzon, K., Nussenzweig, M. C., & Wardemann, H. (2007). Autoreactivity in human IgG+ memory B cells. *Immunity*, *26*, 205.

Tomaras, G. D., Binley, J. M., Gray, E. S., Crooks, E. T., Osawa, K., Moore, P. L., et al. (2011). Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. *Journal of Virology*, *85*, 11502.

Tomaras, G. D., Ferrari, G., Shen, X., Alam, S. M., Liao, H. X., Pollara, J., et al. (2013). Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. *Proceedings of the National Academy of Sciences of the United States of America*, *110*, 9019.

Tong, T., Crooks, E. T., Osawa, K., & Binley, J. M. (2012). HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. *Journal of Virology*, *86*, 3574.

Turan, S., Zehe, C., Kuehle, J., Qiao, J., & Bode, J. (2013). Recombinase-mediated cassette exchange (RMCE)—A rapidly-expanding toolbox for targeted genomic modifications. *Gene*, *515*, 1.

Vcelar, B., Stiegler, G., Wolf, H. M., Muntean, W., Leschnik, B., Mehandru, S., et al. (2007). Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. *AIDS*, *21*, 2161.

Verkoczy, L., Chen, Y., Bouton-Verville, H., Zhang, J., Diaz, M., Hutchinson, J., et al. (2011). Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. *The Journal of Immunology*, *187*, 3785.

Verkoczy, L., Chen, Y., Zhang, J., Bouton-Verville, H., Newman, A., Lockwood, B., et al. (2013). Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: Selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. *The Journal of Immunology*, *191*, 2538.

Verkoczy, L., & Diaz, M. (2014). Autoreactivity in HIV-1 broadly neutralizing antibodies: Implications for their function and induction by vaccination. *Current Opinion in HIV and AIDS*, *9*, 224.

Verkoczy, L., Diaz, M., Holl, T. M., Ouyang, Y. B., Bouton-Verville, H., Alam, S. M., et al. (2010). Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. *Proceedings of the National Academy of Sciences of the United States of America*, *107*, 181.

Verkoczy, L., Duong, B., Skog, P., Ait-Azzouzene, D., Puri, K., Vela, J. L., et al. (2007). Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell–positive selection. *The Journal of Immunology*, *178*, 6332.

Verkoczy, L., Kelsoe, G., & Haynes, B. F. (2014). HIV-1 envelope gp41 broadly neutralizing antibodies: Hurdles for vaccine development. *PLoS Pathogens*, *10*. e1004073.

Verkoczy, L., Kelsoe, G., Moody, M. A., & Haynes, B. F. (2011). Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. *Current Opinion in Immunology*, *23*, 383.

Vettermann, C., & Jack, H. M. (2010). The pre-B cell receptor: Turning autoreactivity into self-defense. *Trends in Immunology*, *31*, 176.

Victor Garcia, J. (2016). Humanized mice for HIV and AIDS research. *Current Opinion in Virology*, *19*, 56.

von Boehmer, H., & Melchers, F. (2010). Checkpoints in lymphocyte development and autoimmune disease. *Nature Immunology*, *11*, 14.

Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J. P., et al. (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature*, *477*, 466.

Wang, S., Mata-Fink, J., Kriegsman, B., Hanson, M., Irvine, D. J., Eisen, H. N., et al. (2015). Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. *Cell*, *160*, 785.

Wang, H., & Shlomchik, M. J. (1997). High affinity rheumatoid factor transgenic B cells are eliminated in normal mice. *The Journal of Immunology*, *159*, 1125.

Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003). Predominant autoantibody production by early human B cell precursors. *Science*, *301*, 1374.

Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., et al. (2003). Antibody neutralization and escape by HIV-1. *Nature*, *422*, 307.

West, A. P., Jr., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014). Structural insights on the role of antibodies in HIV-1 vaccine and therapy. *Cell*, *156*, 633.

Willis, J. R., Finn, J. A., Briney, B., Sapparapu, G., Singh, V., King, H., et al. (2016). Long antibody HCDR3s from HIV-naive donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. *Proceedings of the National Academy of Sciences of the United States of America*, *113*, 4446.

Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., et al. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science*, *329*, 856.

Wu, X., Zhang, Z., Schramm, C. A., Joyce, M. G., Kwon, Y. D., Zhou, T., et al. (2015). Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. *Cell*, *161*, 470.

Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., et al. (2011). Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. *Science*, *333*, 1593.

Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., et al. (2009). Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. *Biochemical and Biophysical Research Communications*, *390*, 404.

Yang, G., Holl, T. M., Liu, Y., Li, Y., Lu, X., Nicely, N. I., et al. (2013). Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. *The Journal of Experimental Medicine*, *210*, 241.

Yeap, L. S., Hwang, J. K., Du, Z., Meyers, R. M., Meng, F. L., Jakubauskaite, A., et al. (2015). Sequence-intrinsic mechanisms that target AID mutational outcomes on antibody genes. *Cell*, *163*, 1124.

Yu, R. K., Ariga, T., Usuki, S., & Kaida, K. (2011). Pathological roles of ganglioside mimicry in Guillain–Barre syndrome and related neuropathies. *Advances in Experimental Medicine and Biology*, *705*, 349.

Zan, H., Komori, A., Li, Z., Cerutti, A., Schaffer, A., Flajnik, M. F., et al. (2001). The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. *Immunity*, *14*, 643.

Zemlin, M., Klinger, M., Link, J., Zemlin, C., Bauer, K., Engler, J. A., et al. (2003). Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. *Journal of Molecular Biology*, *334*, 733.

Zhang, J., Alam, S. M., Bouton-Verville, H., Chen, Y., Newman, A., Stewart, S., et al. (2014). Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies. *The Journal of Immunology*, *192*, 1693.

Zhang, J., & Shakhnovich, E. I. (2010). Optimality of mutation and selection in germinal centers. *PLoS Computational Biology*, *6*. e1000800.

Zhang, Y., Su, S. C., Hecox, D. B., Brady, G. F., Mackin, K. M., Clark, A. G., et al. (2008). Central tolerance regulates B cells reactive with Goodpasture antigen alpha3(IV)NC1 collagen. *The Journal of Immunology*, *181*, 6092.

Zhang, R., Verkoczy, L., Wiehe, K., Munir Alam, S., Nicely, N. I., Santra, S., et al. (2016). Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. *Science Translational Medicine*, *8*, 336ra62.

Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., et al. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. *Science*, *329*, 811.

Zhou, T., Lynch, R. M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N. A., et al. (2015). Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. *Cell*, *161*, 1280.

Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., et al. (2013). Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. *Immunity*, *39*, 245.